

0001493152-24-03161010-Q Glucotrack, Inc. 2024081320240813160600160600160600 0 0001493152-24-031610 10-Q 42 20240630 20240813 20240813 Glucotrack, Inc. 0001506983 3841 980668934 DE 1231 10-Q 34 001-41141 241201381 301 RT 17 NORTH SUITE 800 RUTHERFORD NJ 07070 972 (8) 675-7878 301 RT 17 NORTH SUITE 800 RUTHERFORD NJ 07070

Glucotrack, Inc. 20220328 Integrity Applications, Inc. 20101203 10-Q 1 form10-q.htm false Q2 -12-31 0001506983 PSY 0001506983 2024-01-01 2024-06-30 0001506983 2024-08-09

0001506983 2024-06-30 0001506983 2023-12-31 0001506983 2023-01-01 2023-06-30 0001506983 2024-04-01 2024-06-30 0001506983 2023-04-01 2023-06-30 0001506983 us-gaap:CommonStockMember 2022-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001506983 us-gaap:RetainedEarningsMember 2022-12-31 0001506983 2022-12-31 0001506983 us-gaap:CommonStockMember 2023-03-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-03-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001506983 us-gaap:RetainedEarningsMember 2023-03-31 0001506983 2023-03-31 0001506983 us-gaap:CommonStockMember 2023-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001506983 us-gaap:RetainedEarningsMember 2023-12-31 0001506983 us-gaap:CommonStockMember 2024-03-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-03-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001506983 us-gaap:RetainedEarningsMember 2024-03-31 0001506983 2024-03-31 0001506983 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-01-01 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001506983 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001506983 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-04-01 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001506983 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001506983 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001506983 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001506983 us-gaap:CommonStockMember 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001506983 us-gaap:RetainedEarningsMember 2023-06-30 0001506983 2023-06-30 0001506983 us-gaap:CommonStockMember 2024-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-06-30 0001506983 us-gaap:SubsequentEventMember 2024-08-14 0001506983 us-gaap:IPOMember 2023-01-01 2023-12-31 0001506983 us-gaap:PrivatePlacementMember 2024-01-01 2024-06-30 0001506983 GCTK:NoteAndWarrantMember 2024-01-01 2024-06-30 0001506983 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2024-07-18 0001506983 us-gaap:SubsequentEventMember GCTK:ConvertiblePromissoryNotesMember GCTK:WarrantsAgreementMember 2024-07-30 0001506983 GCTK:PrefundedWarrantsMember 2024-01-01 2024-06-30 0001506983 GCTK:PrefundedWarrantsMember 2023-01-01 2023-06-30 0001506983 GCTK:PrefundedWarrantsMember 2024-04-01 2024-06-30 0001506983 GCTK:PrefundedWarrantsMember 2023-04-01 2023-06-30 0001506983 GCTK:PerformanceMilestoneMember 2024-01-01 2024-06-30 0001506983 GCTK:PerformanceMilestoneMember 2023-01-01 2023-06-30 0001506983 GCTK:PerformanceMilestoneMember 2024-04-01 2024-06-30 0001506983 GCTK:PerformanceMilestoneMember 2023-04-01 2023-06-30 0001506983 GCTK:PrefundedWarrantsMember 2024-01-03 2024-01-03 0001506983 GCTK:ExchangeAgreementMember us-gaap:CommonStockMember 2024-02-13 2024-02-13 0001506983 GCTK:ExchangeAgreementMember us-gaap:WarrantMember 2024-02-13 2024-02-13 0001506983 GCTK:ExchangeAgreementMember 2024-02-13 2024-02-13 0001506983 GCTK:ExchangeAgreementMember 2024-02-13 0001506983 us-gaap:LeaseAgreementsMember 2024-02-19 2024-02-19 0001506983 us-gaap:LeaseAgreementsMember 2024-02-19 0001506983 us-gaap:PrivatePlacementMember 2024-04-22 2024-04-22 0001506983 us-gaap:PrivatePlacementMember 2024-04-22 0001506983 2024-04-30 0001506983 GCTK:UnsecuredPromissoryNotesMember 2024-06-27 0001506983 2024-06-27 0001506983 2024-06-27 0001506983 GCTK:NoteAndWarrantMember 2024-06-27 2024-06-27 0001506983 GCTK:LessThanOneYearMember 2024-06-27 0001506983 GCTK:BetweenOneYearToTwoYearsMember 2024-06-30 0001506983 GCTK:MoreThanTwoYearsMember 2024-06-30 0001506983 GCTK:NotesMember 2024-06-27 0001506983 GCTK:WarrantsMember 2024-06-27 0001506983 GCTK:IsraelInnovationAuthorityMember 2024-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember srt:MinimumMember 2004-03-03 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember srt:MaximumMember 2004-03-03 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember 2024-06-30 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember us-gaap:CommonStockMember 2022-10-07 2022-10-07 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember us-gaap:CommonStockMember srt:MinimumMember 2022-10-07 2022-10-07 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember us-gaap:CommonStockMember srt:MinimumMember GCTK:TrueupSharesMember 2022-10-07 0001506983 2023-06-01 2023-06-20 0001506983 2024-05-01 2024-05-31 0001506983 us-gaap:SubsequentEventMember GCTK:ConvertiblePromissoryNotesMember GCTK:WarrantsAgreementMember 2024-07-30 2024-07-30 0001506983 us-gaap:SubsequentEventMember G

[illegible]

consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not recorded.

Â C. Lease Agreement Â A On February 19, 2024, the Company entered into Lease Agreement (the "Lease Agreement") with Tapsac Enterprises LLC dba Virginia Analytical (the "Landlord") under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of \$2.5 over a period of 3-years commencing March 1, 2024 through February 28, 2027 (the "Initial Lease Period"). Security deposit of \$2.5 which represents payment of one month is held by the Landlord which will be return to the Company at the end of the Initial Lease Period. Â A In addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the Initial Lease Period (the "Option Term"), following advanced notice as defined in the Agreement. The monthly rental fee over the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area. Â 12 Â A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) Â C. Lease Agreement (Cont.) Â A In accordance with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to usage asset equals to lease liability in total amount of \$79. The lease liability was measured at the present value of the future lease payments, which are discounted based on an estimate of the additional interest rate that the Company would be required to pay in order to borrow a similar amount for a similar period in order to obtain a similar amount on the date of first recognition of the lease. Â A As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option to extend the period was not considered as reasonably certain. Â Operating lease: Â SCHEDULE OF OPERATING LEASE Â A June 30, 2024 Â A Â A Operating right of use asset Â 71 Â Current operating lease liability Â 25 Â Non-Current operating lease liability Â 46 Â A Maturity analysis of the Company's lease liability: Â SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY Â A June 30, 2024 Â A Â A Less than one year Â 30 Â Between 1-2 years Â 30 Â More than 2 years Â 20 Â A Â A Total operating lease payments Â 80 Â A Â A Less: imputed interest Â (9) Â A Â A Present value of lease liabilities Â 71 Â A Additional information on lease Â The following is a summary of weighted average remaining lease terms and discount rate for Company's leases: Â SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE Â A June 30, 2024 Lease term (years) Â 2.92 Â Weighted average discount rate Â 9.03 Â D. Private Placement Agreement Â A On April 22, 2024, the Company entered into a private placement agreement under which the Company issued 79,366 shares of its common stock at a price of \$6.3 per share for aggregate gross proceeds of \$500 (the "Offering"). The Offering included participation of certain members of the Company's executive management, Board of Directors and existing shareholders. Â 13 Â A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) Â E. Adoption of 2024 Equity Incentive Plan and Reverse Share Split Â A On April 26, 2024, the Company held its Annual Meeting of Shareholders (the "Annual Meeting") under which the Company's stockholders approved, inter alia, the following proposals: (i) adoption of the Company's 2024 Equity Incentive Plan and (ii) an amendment to Article IV of the Company's Certificate of Incorporation, to effect a reverse stock split of the Company's Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company's Board of Directors approved a one-for-five reverse stock split of the Company's issued and outstanding shares of common stock (the "Reverse Stock Split"). On May 17, 2024, the Company filed a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. Â For accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements. Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share. Â F. Note and Warrant Purchase Agreements Â A On June 27, 2024, the Board of Directors approved the Company to enter into note and warrant purchase agreements with certain officers, directors and existing investors, providing for the private placement of unsecured promissory notes in the aggregate principal amount of \$100 (the "Notes") and warrants to purchase up to an aggregate of 300,000 shares of the Company's Common Stock (the "Warrants"). Â The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of: (i) twelve months from the date of the Note; or (ii) the date the Company raises third-party equity capital in an amount equal to or in excess of \$1,000 (the "Maturity Date"). The Company may prepay the Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. Â Each Warrant has an exercise price of \$4.95 per share and immediately exercisable and have a five-year term. Such Warrant was determined as eligible for equity classification. Â At the initial date, the total proceeds received of \$80 were allocated to the Notes and the Warrants based on their relative fair value of the identified components (i.e. Notes and Warrants) as determined by the Company's management as follows: Â SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS Â A Fair value at Closing Date Â A Notes (1) Â 12 Â Warrants (2) Â 68 Â Fair value at Closing Date Â 80 Â A (1) The fair value of the Notes was determined based on rating model using a discount rate of 12% which represented the Company's applicable rate of risk, as determined by management. Â A (2) The fair value of the Warrants determined by management based on Black-Scholes pricing model taking into account expected stock price volatility of 245% and risk-free interest rate of 4.52%. Â The Note is accounted for as a financial liability measured at amortized cost. At subsequent dates, the Company recognized a discount expense over the economic life of the Notes based on the effective interest rate method. However, during the period of six month, discount expense were de minimis. Â 14 Â A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES Â A On March 4, 2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately \$93 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the "Development Plan"). Integrity Israel is required to pay royalties to the IIA at a rate ranging between 3-5% of the proceeds from the sale of the Company's products arising from the Development Plan up to an amount equal to \$93, plus interest at LIBOR from the date of grant. As to the replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of June 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately \$73, excluding interest. Such contingent obligation has no expiration date. Â B On October 7, 2022 (the "Closing Date"), the Company entered into Intellectual Property Purchase Agreement (the "Agreement") with Paul Goode, which is the Company's Chief Executive Officer (the "Seller"), under which it was agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller shall sell, assign, transfer, convey and deliver to the Company, all of Seller's right, title and interest in and to the following assets, properties and rights (collectively, the "Purchased Assets"): Â A (a) All rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the "Conveyed Intellectual Property"); and Â A (b) All the goodwill relating to the Purchased Assets. Â In consideration for the sale by Seller of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated to issue up to 200,000 shares of Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the "Purchase Price"). In addition, if upon the final issuance, the aggregate 200,000 shares represent less than 1.5% of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5% of the outstanding shares (the "True-Up Shares"). All shares of Common Stock of the company that will be issued under this agreement shall be (i) restricted over a limited period as defined in the Agreement and issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and (ii) subject to the lockup provisions. Â When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (the "IPR&D") to be used in research and development projects which have been determined not to have alternative future use at the acquisition date, is expensed immediately. Â At the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&D with no alternative future use. However, the achievement of each of the performance milestones is considered as contingent event outside the Company's control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date will be recognized when it becomes probable that each target will be achieved within the reasonable period of time. Such additional contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is resolved. Â In June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfillment of the first performance milestone the Company was committed to issue 20,000 restricted shares to the Seller. Accordingly, the Company recorded an amount of \$131 as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance milestone shares were issued on February 6, 2024. Â 15 Â A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES (Cont.) Â B. (Cont.) Â In May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue 30,000 restricted shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to \$192 which representing the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate of 30 % over the applicable restriction period. As of June 30, 2024, the second performance milestone shares were not yet issued. Â As of June 30, 2024, achievement of all other remaining performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof. Â NOTE 5 - SUBSEQUENT EVENTS Â A On July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the Company's executive management, providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of \$360 (the "Notes") and each a "Qualified Financing (as defined below) (the "Maturity Date"). Â Except regarding conversion of the Notes as discussed below, the Company may not prepay the Notes without the written consent of the holder. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Notes (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least \$500 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than \$1.56. Â A Upon the occurrence of an Event of Default (as defined below), a holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the Note Balance. An "Event of Default" means (i) failure by the Company to pay the Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note Balance shall automatically and immediately become due and payable, in all cases without any action on the part of the holder. Â 16 Â A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â NOTE 5 - SUBSEQUENT EVENTS (Cont.) Â B. On July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the "Warrants") with an existing investor (the "Holder"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of \$4,000 (the "Note"). The Note is not convertible until and unless approved at a meeting of the Company's stockholders (the "Stockholder Approval"). The Company has agreed to hold such a meeting to seek Stockholder Approval within 90 days. Â The Note bears simple interest at the rate of 8% per annum and is due and payable in cash on the earlier of: (i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (defined below) (the "Maturity Date"). The Note is secured by a first-priority security interest on all Company assets. Â Except with regard to conversion of the Note or a Sale Transaction as discussed below, the Company may not prepay the Note without the written consent of the Holder. If Stockholder Approval is obtained, the Note (i) is convertible at the discretion of the Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price (the "VWAP") of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction). Â In the event of a Sale Transaction on or prior to the Maturity Date, the Company will repay the Holder, at the Holder's election, as follows: (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the Note was converted pursuant to an optional conversion. Â Sale Transaction means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the assets of the Company, or any other transaction or series of related transactions in which the Company's stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent. Â Upon the occurrence of an Event of Default (defined below), a Holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the Note balance. An "Event of Default" means (i) failure by the Company to pay the Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the Holder. Â Each Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The Warrants are exercisable for cash only and have no price-based antidilution. The first Warrant is for 2,133,334 shares at \$1.875 per share. The second Warrant is for 1,523,810 shares at \$2.625 per share. The third Warrant is for 1,185,186 shares at \$3.375 per share. Â 17 Â A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. Â A Cautionary Note Regarding Forward-Looking Statements Â This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies and prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, capital raising and financing, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words "believe," "expect," "anticipate," "intend," "estimate," "plan," "may," "will," "could," "would," "should" and other similar words and phrases, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified under the caption "Risk Factors" included in our annual report on Form 10-K for the year ended December 31, 2023. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item 1 of this Quarterly Report on Form 10-Q. Â Overview Â We are a medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes. We are currently developing an Implantable CBGM for those with Type 1 diabetes and insulin-dependent Type 2 diabetes. Â The Company

was founded with a mission to develop GlucoTrack®®, a noninvasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation GlucoTrack, which successfully received CE Mark approval, obtained glucose measurements via a small sensor clipped onto one®™'s earlobe. A limited release beta test in Europe and the Middle East demonstrated the need for an updated product with improved accuracy and human factors. As the glucose monitoring landscape rapidly moved away from point-in-time measurement to continuous measurement since then, the Company recently determined that it would focus its efforts on developing its Implantable CBGM. As such, we have since withdrawn our CE Mark for GlucoTrack and are no longer pursuing commercialization of this product or development of any further iterations. A The Company is currently developing an Implantable CBGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. Implant longevity is key to the success of such a device. We have continued to evolve our sensor chemistry following our successful in-vitro feasibility study demonstrating that a minimum two-year implant life is highly probable with the current sensor design. Recently we announced a 3-year longevity is feasible leveraging both in-vitro and in-silico test results. We have also completed our animal study with an initial prototype system which demonstrated a simple implant procedure and good functionality. The results of both were recently presented in poster form at the American Diabetes Association annual conference. The Company has also initiated a longer-term animal trial (to support projected longevity studies) as well as development of its commercial device. A regulatory submission has been made for a first in human study, expected to initiate in Q3 2024. Further to the above progress on our CBGM product, we have also successfully demonstrated continuous glucose sensing in the epidural space. This latter approach is of importance for patients with painful diabetic neuropathy contemplating spinal cord stimulation therapy for their condition. We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development. A 18 A A Our Senior Management team includes; CEO and President, Paul V. Goode PhD, who has a decorated career developing innovative medical technologies, including at Dexcom and MiniMed, CFO, James Cardwell, CPA who has over 16 years of experience as a Chief Financial Officer and Chief Operating Officer with a concentration in both SEC financial reporting and tax compliance, James P. Thrower PhD, Vice President of Engineering, a seasoned executive formerly of Sterling Medical Devices, Mindray DS USA and Dexcom, Inc., Mark Tapsak PhD, Vice President of Sensor Technology, a medical research scientist who brings over 25 years of experience in the diabetes industry, including previous senior roles at Dexcom and Medtronic, and Drinda Benjamin, Vice President of Marketing, a medical device professional with over 20 years of experience in the medical device and diabetes industry with senior roles at Intuity Medical, Senseonics, Abbott Diabetes, and Medtronic Diabetes. Erin Carter, formerly of Medtronic and Boston Scientific, has joined as an independent board member. Several highly talented and accomplished executives joined the Company as senior advisors to the Board. These include Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert formerly at Samsung Health and Dexcom, Inc., and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought leader. We intend to continue to invest in our talent and to expand and strengthen all areas within the Company. A Recent Events A On April 22, 2024, we entered into a private placement agreement under which we issued 79,366 shares of our common stock at a price of \$6.3 per share for aggregate gross proceeds of \$500,000 to certain members of our executive management, Board of Directors and existing shareholders. A On April 26, 2024, we held our Annual Meeting of Shareholders (the Annual Meeting) under which our stockholders approved, inter alia, the following proposals: (i) adoption of our 2024 Equity Incentive Plan; (ii) approval of an amendment to Article IV of our Certificate of Incorporation, as amended, to effect a reverse stock split of the Companys Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Board of Directors approved a one-for-five reverse split of our issued and outstanding shares of Common Stock (the Reverse Stock Split). On May 17, 2024, we filed a Certificate of Amendment to the Companys Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. A On June 27, 2024, the Board of Directors approved us to enter into note and warrant purchase agreements with certain investors, providing for the private placement of unsecured promissory notes in the aggregate principal amount of \$100,000 (the Notes) and warrants (the Warrants) to purchase up to an aggregate of 300,000 shares of our Common Stock. The closing of the private placement occurred on July 1, 2024. The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of: (a) twelve months from the date of the Note; or (b) the date we raise third-party equity capital in an amount equal to or in excess of \$1,000,000 (the Maturity Date). We may prepay the Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. Each Warrant has an exercise price of \$4.95 per share. The Warrants are immediately exercisable and have a five-year term. A On July 18, 2024, we entered into a series of convertible promissory notes with certain investors, providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of \$360,000 (the Notes and each a Note). The Notes bear simple interest at the rate of 8% per annum and are due and payable in cash on the earlier of: (a) the twelve month anniversary of Note; or (b) the date of closing of a Qualified Financing (as defined above). Interest will be computed on the basis of a 365-day year. On July 30, 2024, we entered into a convertible promissory note and three warrant agreements (the Warrants) with an existing investor (the Holder), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of \$4,000,000 (the Note). The Note is not convertible until and unless approved at a meeting of our stockholders. We have agreed to hold such a meeting to seek stockholder approval within 90 days. The Note bears simple interest at the rate of 8% per annum and is due and payable in cash on the earlier of: (i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (as defined above) (the Maturity Date). The Note is secured by a first-priority security interest on all our assets. Each Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The Warrants are exercisable for cash only and have no price-based antidilution. The first Warrant is for 2,133,334 shares at \$1.875 per share. The second Warrant is for 1,523,810 shares at \$2.625 per share. The third Warrant is for 1,185,186 shares at \$3.375 per share. The summary of our significant accounting policies is included under Item 7 - Managements Discussion and Analysis of Financial Condition and Results of Operations of our fiscal 2023 Form 10-K. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There have been no material changes to the critical accounting policies and estimates as filed in such report. A 19 A A Liquidity and Capital Resources A To date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities. A Since our incorporation, we have devoted substantially all our resources to research and product development and providing general and administrative support for these activities. Since our incorporation, we have incurred significant losses and negative cash flows from operations. During the six months ended June 30, 2024, we incurred a net loss of approximately \$7.5 million and used \$4.8 million of cash in our operations. As of June 30, 2024, we had an accumulated deficit of approximately \$117.3 million. We expect to continue to incur significant and increasing losses and do not expect positive cash flows from operations for the foreseeable future, and our net losses may fluctuate significantly from period to period depending on the timing of and expenditures on our research and development activities. A As of June 30, 2024, the balance of cash and cash equivalents of approximately \$159,000 is insufficient for the Company to realize its business plans for the twelve-month period subsequent to the reporting period. A Results of Operations A The following discussion of our operating results explains material changes in our results of operations for the three and six months ended June 30, 2024 compared with the same periods ended June 30, 2023. The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this report. A Consolidated Results of Operations for the Three Months Ended June 30, 2024 and 2023 A Research and development expenses A Research and development expenses were approximately \$3.6 million for the three-month period ended June 30, 2024, as compared to approximately \$627,000 for the prior-year period. The increase is attributable to ramping up product development activities. A Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials, production labor and other expenses. We expect research and development expenses to marginally increase in 2025 and beyond, primarily due to hiring additional personnel, as well clinical trials for the GlucoTrack CBGM; however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of new GlucoTrack CBGM models and others. A Marketing expenses A Marketing expenses were approximately \$100,000 for the three-month period ended June 30, 2024, as compared to \$0 for the prior-year period. This increase is primarily attributable to business development personnel and professional marketing services. A General and administrative expenses A General and administrative expenses were approximately \$802,000 for the three-month period ended June 30, 2024, as compared to approximately \$552,000 for the prior-year period. The increase is attributable to professional fees we accrued during the period. A General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services. A 20 A A Financing income, net A Financing income, net was approximately \$2,000 for the three-month period ended June 30, 2024, as compared to financing income of approximately \$3,000 for the prior-year period. The change is immaterial. A Net Loss A Net loss was approximately \$4.5 million for the three-month period ended June 30, 2024, as compared to approximately \$1.2 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above. A Consolidated Results of Operations for the Six Months Ended June 30, 2024 and 2023 A Research and development expenses A Research and development expenses were approximately \$5.7 million for the six-month period ended June 30, 2024, as compared to approximately \$1.3 for the prior-year period. The increase is attributable to professional fees we accrued during the period. A Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials and other expenses. We expect research and development expenses to marginally increase in 2025 and beyond, primarily due to hiring additional personnel, as clinical trials for the GlucoTrack CBGM; however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of new GlucoTrack CBGM models and others. A Marketing expenses A Marketing expenses were approximately \$170,000 for the six-month period ended June 30, 2024, as compared to \$0 for the prior-year period. This increase is primarily attributable to business development personnel and professional marketing services. A General and administrative expenses A General and administrative expenses were approximately \$1.5 million for the six-month period ended June 30, 2024, as compared to approximately \$1.2 million for the prior-year period. The increase is attributable to professional fees we accrued during the period. A General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services. A Financing income, net A Financing income, net was approximately \$26,000 for the six-month period ended June 30, 2024, as compared to financing income of approximately \$1,000 for the prior-year period. The increase is attributable to interest income received during the period. A Net Loss A Net loss was approximately \$7.4 million for the six-month period ended June 30, 2024, as compared to approximately \$2.5 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above. A 21 A A Cash Flows for the Six Months Ended June 30, 2024 and 2023 A Operating Activities A Net cash used in operating activities was approximately \$4.8 million and approximately \$2.3 million for the six-month periods ended June 30, 2024 and 2023, respectively. Net cash used in operating activities primarily reflects the net loss for those periods of approximately \$7.4 million and approximately \$2.5 million, respectively. A Investing Activities A Net cash used in investing activities was \$71,000 and \$0 for the six-month periods ended June 30, 2024 and 2023, respectively. Net cash used in investing activities primarily reflects the purchasing of fixed assets. A Financing Activities A Net cash provided by financing activities was approximately \$580,000 and \$8.7 million for the six-month periods ended June 30, 2024 and 2023, respectively. Net cash provided by financing activities primarily reflects the proceeds received from private placement transaction in 2024 versus net proceeds received upon completion of public offering. A Off-Balance Sheet Arrangements A As of June 30, 2024, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K. A Critical Accounting Policies A This Managements Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our condensed consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. A Going Concern Uncertainty A The development of the implantable continuous glucose sensor product is expected to require substantial further expenditures. We remain dependent upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses and negative operating cash flow and have a significant accumulated deficit. We do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, government funding, strategic alliances, licensing arrangements, and other marketing or distribution arrangements, any of which may include terms that may adversely affect our stockholders rights. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may have to significantly delay, scale back or discontinue our development or commercialization initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. As of June 30, 2024, we believe that our cash on hand will not provide sufficient working capital to fund its current operations and animal trial program for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period. A Item 3. Quantitative and Qualitative Disclosures About Market Risk. A Not required for smaller reporting companies. A 22 A A Item 4. Controls and Procedures. A Evaluation of Disclosure Controls and Procedures A Our management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2024 (the Evaluation Date). Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management, including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure, due to the material weaknesses in internal control over financial reporting related to lack of sufficient internal accounting personnel, segregation of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole with respect to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions and adequate financial reporting. A Management has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees and engaging in external financial reporting consultants. Management intends to implement procedures to remediate such material weaknesses during the fiscal year 2024; however, the implementation of these initiatives may not fully address any material weaknesses that we may have in our internal control over financial reporting. A Changes in Internal Control over Financial Reporting A There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A 23 A A PART II - OTHER INFORMATION A Item 1. Legal Proceedings A From time to time in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. At June 30, 2024, except as described in the preceding paragraph, the Company did not have any pending claims, charges or litigation that were expected to have a material adverse impact on its financial position, results of operations or cash flows. A Item 1A. Risk Factors. A You should carefully consider the factors discussed in Part I, Item 1A, Risk Factors in our Annual Report for the fiscal year ended December 31, 2023, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report for the fiscal year ended December 31, 2023, are not the only risks we face. Additional risks and

uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. The risk factor set forth below supplements and updates the risk factors previously disclosed and should be read together with the risk factors described in our Annual Report for the fiscal year ended December 31, 2023 and with any risk factors we may include in subsequent periodic filings with the SEC. Á We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Á Given the current momentum for continuous glucose monitoring (á€œCGMá€œ) in the diabetes market, we have announced our decision to reset our priorities, improve our commercial outlook and refine our business strategy to focus on our implantable CGM technology. Should our efforts to focus on CGM not be successful, we will need to further evaluate our business strategy and, as a result, our Board of Directors may decide that it is in the best interest of our stockholders to dissolve our Company and liquidate our assets or otherwise modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons. As a result of changes in our strategy, we have and may in the future change or refocus our existing product development, commercialization and manufacturing activities. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Our decisions to allocate our research and development, management and financial resources toward particular product candidates may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities. Á 24 Á Á Our failure to maintain compliance with Nasdaqá€™s continued listing requirements could result in the delisting of our Common Stock. Á Our common stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our common stock on The Nasdaq Stock Market LLC. Á On May 26, 2023, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not currently in compliance with the requirement to maintain a minimum bid price of \$1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the á€œBid Price Ruleá€œ). We had 180 days from May 26, 2023, or through November 22, 2023, to regain compliance with the Bid Price Rule. Á On November 24, 2023, we received a second letter from Nasdaq notifying the Company that it had been granted an additional 180 calendar days, or until May 20, 2024 (the á€œExtended Compliance Periodá€œ), to regain compliance with the Minimum Bid Price Requirement in accordance with Nasdaq Listing Rule 5810(c)(3)(A). Á On May 21, 2024, we received a third letter from Nasdaq (the á€œLetterá€œ) notifying us that it had not regained compliance with the Minimum Bid Price Requirement during the Extended Compliance Period. The Letter also notified us that our Form 10-Q for the period ended March 31, 2024, indicates that we no longer meet the \$2,500,000 minimum stockholdersá€™ equity requirement for continued listing set forth under Listing Rule 5550(b)(1) (the á€œMinimum Stockholdersá€™ Equity Requirementá€œ). Pursuant to Listing Rule 5810(d)(2), the failure to comply with the Minimum Stockholdersá€™ Equity Requirement has become an additional and separate basis for delisting. Á Because we were under review for failure to meet the Minimum Bid Price Requirement, we were not eligible to submit a plan to regain compliance. Accordingly, unless we would request an appeal of this determination by May 28, 2024, trading of our common stock would be suspended at the opening of business on May 30, 2024, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the á€œSECá€œ). We timely requested a hearing before a Nasdaq Hearings Panel (the á€œPanelá€œ). The hearing request would result in a stay of any suspension or delisting action pending the hearing. On August 5, 2024, we received the decision of the Panel, and they granted us an extension to November 18, 2024 to regain compliance with the Minimum Stockholdersá€™ Equity Requirement. On May 17, 2024, in order to regain compliance with the Minimum Bid Price Requirement, we filed a Certificate of Amendment to the Companyá€™s Certificate of Incorporation with the Secretary of State of the State of Delaware which effected, as of 4:30 p.m. Eastern Time, on May 17, 2024, a one-for-five Reverse Stock Split of our issued and outstanding shares of Common Stock. Á In the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our Common Stock may be delisted from Nasdaq. If our Common Stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a á€œpenny stock,á€œ which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital. Á Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Á None. Á Item 3. Defaults Upon Senior Securities Á None. Á Item 4. Mine Safety Disclosures Á None. Á Item 5. Other Information Á None. Á 25 Á Á Item 6. Exhibits. Á Exhibit No. Á Description Á Á 3.1 Á Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.1 to the Companyá€™s Registration Statement on Form S-1 filed with the SEC on August 22, 2011) 3.2 Á Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.2 to the Companyá€™s Registration Statement on Form S-1 filed with the SEC on August 22, 2011) 3.3 Á Bylaws of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.3 to the Companyá€™s Registration Statement on Form S-1 filed with the SEC on August 22, 2011) 3.4 Á Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 99.1 to the Companyá€™s Current Report on Form 8-K filed with the SEC on April 23, 2020) 3.5 Á Amendments to The Companyá€™s Certificate of Incorporation (incorporated by reference to Exhibit 3.7 to the Companyá€™s Annual Report on Form 10-K, filed with the SEC on March 31, 2022) 3.6 Á Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on May 17, 2024 (incorporated by reference to Exhibit 3.1 to the Companyá€™s Current Report on Form 8-K filed with SEC on May 20, 2024) 3.7 Á First Amendment to Bylaws (incorporated by reference to Exhibit 3.1 to the Companyá€™s Current Report on Form 8-K filed with the SEC on June 20, 2024) 4.1 Á Form of Warrant (incorporated by reference to Exhibit 4.1 to the Companyá€™s Current Report on Form 8-K filed with SEC on July 1, 2024) 4.2 Á Form of Warrant (incorporated by reference to Exhibit 10.2 to the Companyá€™s Current Report on Form 8-K filed with SEC on July 31, 2024) 10.1 Á Form of Note and Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Companyá€™s Current Report on Form 8-K filed with SEC on July 1, 2024) 10.2 Á Form of Promissory Note (incorporated by reference to Exhibit 10.2 to the Companyá€™s Current Report on Form 8-K filed with SEC on July 1, 2024) 10.3 Á Form of Promissory Note (incorporated by reference to Exhibit 10.1 to the Companyá€™s Current Report on Form 8-K filed with SEC on July 22, 2024) 10.4 Á Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Companyá€™s Current Report on Form 8-K filed with SEC on July 31, 2024) 31.1* Á Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Á Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Á Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.1** Á Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Á Inline XBRL Instance Document 101.SCH Á Inline XBRL Schema Document 101.CAL Á Inline XBRL Calculation Linkbase Document 101.LAB Á Inline XBRL Label Linkbase Document 101.PRE Á Inline XBRL Presentation Linkbase Document 101.DEF Á Inline XBRL Definition Linkbase Document 104 Á Cover Page Interactive Data File (embedded within the Inline XBRL document) Á * Filed herewith. ** Furnished herewith. Á 26 Á Á SIGNATURES Á Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Á Dated: August 13, 2024 Á Á GLUCOTRACK, INC. Á Á Á Á By: /s/ James Cardwell Á Name: James Cardwell Á Title Chief Financial Officer Á Á (Principal Financial Officer) Á 27 Á EX-31.1 2 ex31-1.htm Á Exhibit 31.1 Á CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Á I, Paul Goode, certify that: Á 1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2024 of Glucotrack, Inc.; Á Á 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Á Á 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Á Á 4. The registrantá€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Á Á (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Á Á Á (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Á Á Á (c) evaluated the effectiveness of the registrantá€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Á Á Á (d) disclosed in this report any change in the registrantá€™s internal control over financial reporting that occurred during the registrantá€™s most recent fiscal quarter (the registrantá€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantá€™s internal control over financial reporting; and Á 5. The registrantá€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantá€™s auditors and the audit committee of the registrantá€™s board of directors (or persons performing the equivalent functions): Á Á (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantá€™s ability to record, process, summarize and report financial information; and Á Á Á (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantá€™s internal control over financial reporting. Á Date: August 13, 2024 By: /s/ Paul Goode Á Á Paul Goode Á Á Principal Executive Officer Á Á EX-31.2 3 ex31-2.htm Á Exhibit 31.2 Á CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Á I, James Cardwell, certify that: Á 1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2024 of Glucotrack, Inc.; Á Á 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Á Á 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Á Á 4. The registrantá€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Á Á (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Á Á Á (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Á Á Á (c) evaluated the effectiveness of the registrantá€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Á Á Á (d) disclosed in this report any change in the registrantá€™s internal control over financial reporting that occurred during the registrantá€™s most recent fiscal quarter (the registrantá€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantá€™s internal control over financial reporting; and Á 5. The registrantá€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantá€™s auditors and the audit committee of the registrantá€™s board of directors (or persons performing the equivalent functions): Á Á (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantá€™s ability to record, process, summarize and report financial information; and Á Á Á (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantá€™s internal control over financial reporting. Á Date: August 13, 2024 By: /s/ James Cardwell Á Á James Cardwell Á Á Principal Financial Officer Á Á EX-32.1 4 ex32-1.htm Á Exhibit 32.1 Á CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Á In connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the á€œCompanyá€œ) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the á€œReportá€œ), I, Paul Goode, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: Á (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Á (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Á Á By: /s/ Paul Goode Á Á Paul Goode Á Á Principal Executive Officer Á Á Á Dated: August 13, 2024 Á Á EX-32.2 5 ex32-2.htm Á Exhibit 32.2 Á CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Á In connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the á€œCompanyá€œ) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the á€œReportá€œ), I, James Cardwell, Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: Á (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Á (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Á Á By: /s/ James Cardwell Á Á James Cardwell Á Á Principal Financial Officer Á Á Á Dated: August 13, 2024 Á Á Á Á EX-101.SCH 6 gctk-20240630.xsd XBRL SCHEMA FILE 000000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000000007 - Disclosure - GENERAL link:presentationLink link:calculationLink link:definitionLink 000000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000000009 - Disclosure - SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000000011 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000000014 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000000015 - Disclosure - GENERAL (Details Narrative) link:presentationLink

link:calculationLink link:definitionLink 00000016 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SCHEDULE OF OPERATING LEASE (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) (parentheticals) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gctk-2024040630 cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gctk-2024040630 def.xml XBRL DEFINITION FILE EX-101.LAB 9 gctk-2024040630 lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Receipts on Account of Shares [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Sale of Stock [Axis] IPO [Member] Private Placement [Member] Note And Warrant [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] Convertible Promissory Notes [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Warrants Agreement [Member] Prefunded Warrants [Member] Performance Milestone [Member] Exchange Agreement [Member] Warrant [Member] Lease Agreements [Member] Debt Instrument [Axis] Unsecured Promissory Notes [Member] Lease Contractual Term [Axis] Less Than One Year [Member] Between 1 - 2 Years [Member] More Than 2 Years [Member] Financial Instrument [Axis] Notes [Member] Warrants [Member] Legal Entity of Counterparty, Type [Axis] Israeli Innovation Authority [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Legal Entity [Axis] Intellectual Property Purchase Agreement [Member] Class of Stock [Axis] Trueup Shares [Member] First Warrant [Member] Second Warrant [Member] Third Warrant [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Other current assets Total current assets Operating lease right-of-use asset, net (Note 3C) Property and equipment, net Restricted cash TOTAL ASSETS LIABILITIES AND STOCKHOLDERSâ€™ EQUITY (DEFICIT) Current liabilities Accounts payable Notes payable (Note 3F) Operating lease liability, current (Note 3F) Other current liabilities Total current liabilities Non-current liabilities Loans from stockholders Operating lease liability, non-current (Note 3F) Total liabilities Commitments and contingent liabilities (Note 4) Stockholdersâ€™ equity Common Stock of \$ 0.001 par value (â‚¬Common Stockâ‚¬): 100,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 5,501,164 and 4,178,438 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Additional paid-in capital Receipts on account of shares Accumulated other comprehensive income Accumulated deficit Total stockholdersâ€™ equity (deficit) TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY (DEFICIT) Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Research and development expenses Marketing expenses General and administrative expenses Total operating expenses Operating loss Finance income, net Net Loss Other comprehensive income: Foreign currency translation adjustment Comprehensive loss for the period Basic net loss per common stock Diluted net loss per common stock Weighted average number of common stock outstanding used in computing basic net loss per share Weighted average number of common stock outstanding used in computing diluted net loss per share Statement [Table] Statement [Line Items] Balance Balance, shares Loss for the period Other comprehensive income Stock-based compensation Deemed dividend resulted from trigger of down round protection feature of certain warrants granted Issuance of Common Stock upon private placement transaction (Note 3D) Issuance of common stock upon private placement transactions , shares Issuance of restricted shares as compensation towards directors Issuance of shares as compensation to the board of directors , shares Issuance of restricted shares as compensation towards directors Issuance of restricted shares as compensation towards directors, shares Restricted shares to be issued as compensation towards directors Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B) Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement, shares Exercise of prefunded warrants into shares (Note 3A) Exercise of prefunded warrants into shares, shares Exchange of warrants into shares (Note 3B) Exchange of warrants into shares, shares Issuance of warrants through private placement transaction (Note 3F) Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock-based compensation Issuance of restricted shares as compensation towards directors Linkage difference on principal of loans from stockholders Changes in assets and liabilities: Other current assets Accounts payable Other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Issuance of notes and warrants through private placement transaction (Note 3F) Net proceeds received from underwritten U.S. public offering Proceeds received from private placement transaction (Note 3D) Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents, and restricted cash Change in cash and cash equivalents, and restricted cash Cash and cash equivalents, and restricted cash at beginning of the period Cash and cash equivalents, and restricted cash, end of period Supplemental disclosure of cash flow activities: (a) Net cash paid during the year for: Interest (b) Non-cash investment and financing activities: Deemed dividend upon trigger of down round protection Recognition of right for usage asset against a lease liability (Note 3C) Organization, Consolidation and Presentation of Financial Statements [Abstract] GENERAL Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Transactions SIGNIFICANT TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENT LIABILITIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates in the Preparation of Financial Statements Principles of Consolidation Cash and Cash Equivalents Modification of equity-classified contracts Warrants Leases Basic and diluted loss per share SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE SCHEDULE OF OPERATING LEASE SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accumulated deficit Net proceeds Debt instrument face amount Net loss Deemed dividend related to trigger of down round protection feature Net loss attributable to common stockholders Weighted average number of Common Stock outstanding used in computing basic net loss per share Weighted average number of Common Stock outstanding used in computing diluted net loss per share Basic net loss per common stock Diluted net loss per common stock Schedule Of Operating Lease Operating right of use asset Current operating lease liability Non-Current operating lease liability Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Total operating lease payments Less: imputed interest Present value of lease liabilities Schedule Of Weighted Average Remaining Lease Terms And Discount Rate Lease term (years) Weighted average discount rate Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Fair value at Closing Date [cutoff:PercentageOffairValueDiscountRate=0] Volatility Risk-free interest rate Pre-funded warrants Number of shares issued Lock-up period conditions Share price Monthly rental fee Lessee term of contract Security deposit Operating lease liability Common stock share price Net proceeds Reverse stock split Aggregate principal amount Aggregate of shares Notes payable description Warrants exercise price Warrants term Loss Contingencies [Table] Loss Contingencies [Line Items] Contingent consideration liability Royalty percentage maximum Number of common shares issued Commission as a percentage of aggregate sales price Restricted shares Research and development expenses Stock based compensation Discount rate Subsequent Event [Table] Subsequent Event [Line Items] Debt instrument interest rate Convertible Notes Payable Debt Instrument, Convertible, Conversion Price Debt instrument description Sale of stock issued price per share Sale of stock description of transaction Debt description of notice of default Debt default long term debt amount Debt instrument term Third warrant per share Receipts on account of shares. Financing income expense net. Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted Stock to be issued during period value restricted stock award gross. Exercise of prefunded warrants into shares. Exercise of prefunded warrants into shares ,shares. Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement . Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares Stock issued during period value issuance of warrant Issuance of restricted shares as compensation to the board of directors. Linkage difference on principal of loans from stockholders . Proceeds received from underwritten public offering. Deemed dividend upon trigger of down round protection. Note And Warrant [Member] Convertible Promissory Notes [Member] Deemed dividend related to trigger of down round protection feature. Prefunded warrants member. Modification Of Equity Classified Contracts [Policy Text Block] Significant Transactions [Text Block] Exchange Agreement [Member] Lock up period description. Lessee operating lease liability imputed interest Schedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block] Unsecured Promissory Notes [Member] Israeli Innovation Authority [Member] Royalty percentage. Notes [Member] Warrants [Member] Intellectual Property Purchase Agreement [Member] Aggregate sales price of units percentage. Trueup Shares [Member] Schedule Of Fair Value Of The Identified Components [Table Text Block] Percentage of fair value discount rate Marketability discount rate Warrants Agreement [Member] First Warrant [Member] Second Warrant [Member] Third Warrant [Member] Receipts on Account of Shares [Member] Less Than One Year [Member] Between 1 - 2 Years [Member] More Than 2 Years [Member] Performance Milestone [Member] Earnings per share basic including warrants and performance milestones. Earnings per share diluted including warrants and performance milestones. Assets, Current Assets Liabilities, Current Liabilities Commitments and Contingencies Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) FinancingIncomeExpenseNet Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Stock Issued During Period, Value, Restricted Stock Award, Gross IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Current Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature Net Income (Loss) Available to Common Stockholders, Basic EarningsPerShareBasicIncludingWarrantsAndPerformanceMilestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones LesseeOperatingLeaseLiabilityImputedInterest Proceeds from Issuance Initial Public Offering Other Research and Development Expense EX-101.PRE 10 gctk-20240630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - \$ / shares 6 Months Ended Jun. 30, 2024 Aug. 09, 2024 Cover [Abstract] A Document Type 10-Q A Amendment Flag false A Document Quarterly Report true A Document Transition Report false A Document Period End Date Jun. 30, 2024 A Document Fiscal Period Focus Q2 A Document Fiscal Year Focus 2024 A Current Fiscal Year End Date --12-31 A Entity File Number 001-41141 A Entity Registrant Name GLUCOTRACK, INC. A Entity Central Index Key 0001506983 A Entity Tax Identification Number 98-0668934 A Entity Incorporation, State or Country Code DE A Entity Address, Address Line One 301 Route 17 North A Entity Address, Address Line Two Suite 800 A Entity Address, City or Town Rutherford A Entity Address, State or Province NJ A Entity Address, Postal Zip Code 07070 A City Area Code (201) A Local Phone Number 842-7715 A Title of 12(b) Security Common Stock A Trading Symbol GCTK A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 5,478,436 Entity Listing, Par Value Per Share \$ 0.001 A X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name

Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1:

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15:

Details Name: GCTK_FinancingIncomeExpenseNet Namespace Prefix: GCTK_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1:

FSB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30:

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24:

210-S99-1Reference 7:

URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GENERAL 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Á GENERAL NOTE 1 - GENERAL Á A. Glucotrack Inc. (the Company) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the Glucotrack CBGM Product). Á Á B. Liquidity and capital resources Á Á To date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are expected to require substantial additional expenditure. Therefore, the Company is dependent upon external sources for financing its operations. As of June 30, 2024, the Company has incurred accumulated deficit of \$117,269. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods. As of June 30, 2024, the balance of cash and cash equivalents amounted to \$159 together with additional amounts raised subsequent to the balance sheet date amounted to \$4,360 thousands are insufficient for the Company to realize its business plans for the twelve-month period subsequent to the reporting period. Á Á During the year ended December 31, 2023, the Company raised net proceeds of \$8,730 through completion of underwritten public offering. In addition, during the period of six month ended June 30, 2024, the Company entered into (i) exchange agreement with certain shareholders under which warrants with down round protection feature have been exchanged into shares of common stock in order to facilitate its equity structure (see also Note 3B), (ii) private placement agreement under which the Company raised proceeds of \$500 (see also Note 3D) and (iii) note and warrant agreement under which the Company raised proceeds of \$80 (see also Note 3F). Á Á In addition, subsequent to the balance sheet date, the Company entered into (i) convertible promissory notes under which the Company raised gross proceeds of \$360 (see also Note 5A) and (ii) convertible promissory notes and warrants agreement under which the Company raised gross proceeds of \$4,000 (see also Note 5B). Á The Company plans to finance its operations through the sale of equity and/or debt securities. There can be no assurance that the Company will succeed in obtaining the necessary financing or generating sufficient revenues from sales of its Glucotrack CBGM Product in order to continue its operations as a going concern. Á Management has considered the significance of such conditions in relation to the Companys ability to meet its current obligations and to achieve its business targets and determined that these conditions raise substantial doubt about the Companys ability to continue as a going concern. Á The condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Á Á GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) Á X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Á SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Á Á Basis of Presentation Á Á The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Companys consolidated financial statements and related notes included in the Companys annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (SEC) on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Companys financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature. Á Á Á The results for the period of three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period. Á B. Use of Estimates in the Preparation of Financial Statements Á Á Á The preparation of the condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Management believes that there are no critical accounting estimates in these financial statements. Á C. Principles of Consolidation Á Á Á The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Á D. Cash and Cash Equivalents Á Á Á Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. Á E. Modification of equity-classified contracts Á Á Á The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. Á Á GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) Á NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Á F. Warrants Á Á Á Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Companys own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital. Á G. Leases Á Á The Company applies ASC Topic 842, Leases (ASC 842) under which the Company determines if an arrangement is a lease at inception. The Companys assessment is based on: (i) whether the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the asset. Á Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Companys lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases. Á Right of Use (ROU) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Companys leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (IBR) based on the information available on the commencement date in determining the present value of lease payments. The Companys IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, Property, Plant, and Equipment - Overall, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. Á Á GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) Á NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Á G. Basic and diluted loss per share Á Á Á Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of performance milestone during the period and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the treasury stock method, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants. Á Shares to be issued upon exercise of all stock options and stock warrants, have been

included from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive. A A The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of six and three month ended June 30, 2024 and 2023, is as follows: SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE A A A A A A A A A A A A US dollars (except share data)A A US dollars (except share data)A A Six-month period ended June 30,A A Three-month period ended June 30,A A (Unaudited)A A (Unaudited)A A 2024A A 2023A A 2024A A 2023A A Numerator:A A Net loss\$ 7,416A \$ 2,462A \$ 4,489A \$ 1,176A Deemed dividend related to trigger of down round protection featureA A \$ 855A A A \$ 855A Net loss attributable to common stockholders\$ 7,416A \$ 3,317A \$ 4,489A \$ 2,031A A A A A A A Denominator:A A A A A A Shares of Common Stock used in computing basic and diluted net loss per common stock\$ 5,226,975A A 3,544,000A A 5,460,081A A 3,987,275A Shares of Common Stock to be issued upon exercise of pre-funded warrantsA A A 162,510A A A A 325,019A Shares of Common Stock to be issued upon achievement of second performance milestoneA A 7,790A A A A 15,667A A A Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per shareA A 5,234,765A A 3,706,510A A 5,475,748A A 4,312,294A Basic and diluted net loss per common stock\$ 1.42A \$ 0.89A \$ 0.82A \$ 0.47A A A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/214748326/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SIGNIFICANT TRANSACTIONS 6 Months Ended Jun. 30, 2024 Significant Transactions A SIGNIFICANT TRANSACTIONS NOTE 3 - SIGNIFICANT TRANSACTIONS A A. Exercise of pre-funded warrants A A On January 3, 2024, a number of 395,294 pre-funded warrants granted through underwritten public offering in April 2023 have been fully exercised into the same number of shares of Common Stock of the Company. A B. Exchange Agreement A A On February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the "Holders"), pursuant to which the Company and the Holders agreed to exchange (the "Exchange") warrants with down round protection feature exercisable to common shares (the "Warrants") owned by the Holders for shares of Common Stock to be issued by the Company. A A On February 13, 2024, the Company closed the Exchange and issued to the Holders on February 15, 2024 an aggregate of 718,641 shares of Common Stock in exchange for 876,391 Warrants (the "Shares"). A A It was also agreed that the Holders will not, during the period (the "Lock-Up Period") (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction specific in clause (i), (ii) or (iii) above, provided however that the Holder, during the Lock-Up Period, may (a) sell or contract to sell Shares at a price higher than \$0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than \$0.80 per Share on any trading day with no limitation on volume. A The Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above \$1.00 per Share for five consecutive trading days. A The Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument was estimated as less than the fair value of the replaced equity instrument, deemed dividend was not recorded. A C. Lease Agreement A A On February 19, 2024, the Company entered into Lease Agreement (the "Lease") with Tapsak Enterprises LLC dba Virginia Analytical (the "Landlord") under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of \$2.5 over a period of 3-years commencing March 1, 2024 through February 28, 2027 (the "Initial Lease Period"). Security deposit of \$2.5 which represents payment of one month is held by the Landlord which will be return to the Company at the end of the Initial Lease Period. A A In addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the Initial Lease Period (the "Option Term"), following advanced notice as defined in the Agreement. The monthly rental fee over the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area. A A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) A C. Lease Agreement (Cont.) A A In accordance with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to usage asset equals to lease liability in total amount of \$79. The lease liability was measured at the present value of the future lease payments, which are discounted based on an estimate of the additional interest rate that the Company would be required to pay in order to borrow a similar amount for a similar period in order to obtain a similar amount on the date of first recognition of the lease. A As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option to extend the period was not considered as reasonably certain. A Operating lease: A SCHEDULE OF OPERATING LEASE A A June 30, 2024 A A Operating right of use asset\$ 71A Current operating lease liability\$ 25A Non-current operating lease liability\$ 46A A Maturity analysis of the Company's lease liability: A SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY A A June 30, 2024 A A Less than one year\$ 30A Between 1-2 years\$ 1A More than 2 years\$ 2A Total operating lease payments\$ 80A A A Less: imputed interest\$ (9) A A Present value of lease liabilities\$ 71A Additional information on lease A The following is a summary of weighted average remaining lease terms and discount rate for Company's leases: A SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE A A June 30, 2024 A A Lease term (years)\$ 2.92A Weighted average discount rate\$ 4.93% A D. Private Placement Agreement A A On April 22, 2024, the Company entered into a private placement agreement under which the Company issued 79,366 shares of its common stock at a price of \$6.3 per share for aggregate gross proceeds of \$500 (the "Offering"). The Offering included participation of certain members of the Company's executive management, Board of Directors and existing shareholders. A A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) A E. Adoption of 2024 Equity Incentive Plan and Reverse Share Split A A On April 26, 2024, the Company held its Annual Meeting of Shareholders (the "Annual Meeting") under which the Company's stockholders approved, inter alia, the following proposals: (i) adoption of the Company's 2024 Equity Incentive Plan and (ii) an amendment to Article IV of the Company's Certificate of Incorporation, to effect a reverse stock split of the Company's Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company's Board of Directors approved a one-for-five reverse stock split of the Company's issued and outstanding shares of common stock (the "Reverse Stock Split"). On May 17, 2024, the Company filed a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. A For accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements. Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share. A F. Note and Warrant Purchase Agreements A A On June 27, 2024, the Board of Directors approved the Company to enter into note and warrant purchase agreements with certain officers, directors and existing investors, providing for the private placement of unsecured promissory notes in the aggregate principal amount of \$100 (the "Notes") and warrants to purchase up to an aggregate of 300,000 shares of the Company's Common Stock (the "Warrants"). A The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of: (i) twelve months from the date of the Note; or (ii) the date the Company raises third-party equity capital in an amount equal to or in excess of \$1,000 (the "Maturity Date"). The Company may prepay the Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. A Each Warrant has an exercise price of \$4.95 per share and immediately exercisable and have a five-year term. Such Warrant was determined as eligible for equity classification. A At the initial date, the total proceeds received of \$80 were allocated to the Notes and the Warrants based on their relative fair value of the identified components (i.e. Notes and Warrants) as determined by the Company's management as follows: A SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS A Fair value at Closing Date\$ 12A Notes (1A) \$12A Warrants (2A) \$68A Fair value at Closing Date\$ 80A A (1) The fair value of the Notes was determined based on rating model using a discount rate of 12% which represented the Company's applicable rate of risk, as determined by management. A A (2) The fair value of the Warrants determined by management based on Black-Scholes pricing model taking into account expected stock price volatility of 245% and risk-free interest rate of 4.52%. A The Note is accounted for as a financial liability measured at amortized cost. At subsequent dates, the Company recognized a discount expense over the economic life of the Notes based on the effective interest rate method. However, during the period of six month, discount expense were de minimis. A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A X - ReferencesNo definition available. + Details Name: GCTK DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSignificant Transactions [Text Block] + ReferencesNo definition available. + Details Name: GCTK SignificantTransactionsTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENT LIABILITIES 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A COMMITMENTS AND CONTINGENT LIABILITIES NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES A A. On March 4, 2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately \$93 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the "Development Plan"). Integrity Israel is required to pay royalties to the IIA at a rate ranging between 3-5% of the proceeds from the sale of the Company's products arising from the Development Plan up to an amount equal to \$93, plus interest at LIBOR from the date of grant. As to the replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of June 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately \$73, excluding interest. Such contingent obligation has no expiration date. A B. On October 7, 2022 (the "Purchase Date"), the Company entered into Intellectual Property Purchase Agreement (the "Agreement") with Paul Goode, which is the Company's Chief Executive Officer (the "Seller"), under which it was agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller shall sell, assign, transfer, convey and deliver to the Company, all of Seller's right, title and interest in and to the following assets, properties and rights (collectively, the "Purchased Assets"): A (a) All rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the "Conveyed Intellectual Property"); and A (b) All the goodwill relating to the Purchased Assets. A In consideration for the sale by Seller of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated to issue up to 200,000 shares of Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the "Purchase Price"). In addition, if upon the final issuance, the aggregate 200,000 shares represent less than 1.5% of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5% of the outstanding shares (the "True-Up Shares"). All shares of Common Stock of the company that will be issued under this agreement shall be (i) restricted over a limited period as defined in the Agreement and issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and (ii) subject to the lockup provisions. A When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such

Â Except regarding conversion of the Notes as discussed below, the Company may not prepay the Notes without the written consent of the holder. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Notes (the “Note Balance”), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least \$500 (excluding indebtedness converted in such financing) (a “Qualified Financing”), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than \$1.56. Â Upon the occurrence of an Event of Default (as defined below), a holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the Note Balance. An “Event of Default” means (i) failure by the Company to pay the Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note Balance shall automatically and immediately become due and payable, in all cases without any action on the part of the holder. Â GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â NOTE 5 - SUBSEQUENT EVENTS (Cont.) Â B.On July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the “Warrants”) with an existing investor (the “Holder”), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of \$4,000 (the “Note”). The Note is not convertible until and unless approved at a meeting of the Company’s stockholders (the “Stockholder Approval”). The Company has agreed to hold such a meeting to seek Stockholder Approval within 90 days. Â The Note bears simple interest at the rate of 8% per annum and is due and payable in cash on the earlier of: (i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (defined below) (the “Maturity Date”). The Note is secured by a first-priority security interest on all Company assets. Â Except with regard to conversion of the Note or a Sale Transaction as discussed below, the Company may not prepay the Note without the written consent of the Holder. If Stockholder Approval is obtained, the Note (i) is convertible at the discretion of the Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common Stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price (the “VWAP”) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction). Â In the event of a Sale Transaction on or prior to the Maturity Date, the Company will repay the Holder, at the Holder’s election, as follows: (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the Note was converted pursuant to an optional conversion. Â Sale Transaction” means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the assets of the Company, or any other transaction or series of related transactions in which the Company’s stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent. Â Upon the occurrence of an Event of Default (defined below), a Holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the Note balance. An “Event of Default” means (i) failure by the Company to pay the Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the Holder. Â Each Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The Warrants are exercisable for cash only and have no price-based antidilution. The first Warrant is for 2,133,334 shares at \$1.875 per share. The second Warrant is for 1,523,810 shares at \$2.625 per share. The third Warrant is for 1,185,186 shares at \$3.375 per share. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Â A. Basis of Presentation Â Â The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature. Â Â The results for the period of three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period. Use of Estimates in the Preparation of Financial Statements Â B. Use of Estimates in the Preparation of Financial Statements Â Â The preparation of the condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Management believes that there are no critical accounting estimates in these financial statements. Principles of Consolidation Â C. Principles of Consolidation Â Â The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Cash and Cash Equivalents Â D. Cash and Cash Equivalents Â Â Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. Modification of equity-classified contracts Â E. Modification of equity-classified contracts Â Â The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. Â GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) Â NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Warrants Â F. Warrants Â Â Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Company’s own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital. Leases Â G. Leases Â Â The Company applies ASC Topic 842, “Leases” (the “ASC 842”) under which the Company determines if an arrangement is a lease at inception. The Company’s assessment is based on: (i) whether the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the asset. Â Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company’s lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases. Â Right of Use (the “ROU”) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (the “IBR”) based on the information available on the commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, “Property, Plant, and Equipment - Overall”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. Â GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) Â NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â Basic and diluted loss per share Â G. Basic and diluted loss per share Â Â Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of performance milestone during the period and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method”, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants. Â Shares to be issued upon exercise of all stock options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive. Â The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of six and three month ended June 30, 2024 and 2023, is as follows: SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE Â Â Â Â Â Â Â Â Â Â US dollars (except share data) Â Â US dollars (except share data) Â Â Six-month period ended June 30, Â Â Three-month period ended June 30, Â Â (Unaudited) Â Â (Unaudited) Â Â 2024A 2023A 2024A 2023A Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net loss Â \$7,416A Â \$2,462A Â \$4,489A Â \$1,176A Deemed dividend related to trigger of down round protection feature Â Â Â Â 855A Â Â Â Â 855A Net loss attributable to common stockholders Â \$7,416A Â \$4,489A Â \$3,317A Â \$2,031A Â Â Â Â Â Â Â Â Denominator: Â Â Â Â Â Â Â Â Â Â Shares of Common Stock used in computing basic and diluted net loss per common stock Â 5,226,975A Â 3,544,000A Â 5,460,081A Â 3,987,275A Shares of Common Stock to be issued upon exercise of pre-funded warrants Â Â Â Â 162,510A Â Â Â Â 325,019A Shares of Common Stock to be issued upon achievement of second performance milestone Â 7,790A Â Â Â Â 15,667A Â Â Â Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share Â 5,234,765A Â 3,706,510A Â 5,475,748A Â 4,312,294A Basic and diluted net loss per common stock Â \$1.42A Â \$0.89A Â \$0.82A Â \$0.47A Â GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) Â X - DefinitionModification Of Equity Classified Contracts [Policy Text Block] + ReferencesNo definition available. + Details Name: GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock Namespace Prefix: GCTK_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS), + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity’s use of its cash and cash equivalents, (2) whether the entity’s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name

Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap DerivativesPolicyTextBlockNamespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] A SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE A A A A A A A A A A A A A A US dollars (except share data)A A US dollars (except share data)A A A Six-month period ended June 30,A A Three-month period ended June 30,A A (Unaudited)A A (Unaudited)A A 2024A A 2023A A 2024A A 2023A A A A A A A A Numerator:A A A A A A A A A A Net loss\$ 7,416A \$ 2,462A \$ 4,489A \$ 1,176A Deemed dividend related to trigger of down round protection featureA A A A A A 855A A A A A 855A Net loss attributable to common stockholders\$ 7,416A \$ 3,317A \$ 4,489A \$ 2,031A A A A A A A A A Denominator: A A A A A A A A A A Shares of Common Stock used in computing basic and diluted net loss per common stock\$ 5,226,975A A 3,544,000A A 5,460,081A A 3,987,275A Shares of Common Stock to be issued upon exercise of pre-funded warrantsA A A A 162,510A A A 325,019A Shares of Common Stock to be issued upon achievement of second performance milestoneA A 7,790A A A A 15,667A A A Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per shareA A 5,234,765A A 3,706,510A A 5,475,748A A 4,312,294A Basic and diluted net loss per common stock\$ 1.42A \$ 0.89A \$ 0.82A \$ 0.47A X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SIGNIFICANT TRANSACTIONS (Tables) 6 Months Ended Jun. 30, 2024 Significant Transactions A SCHEDULE OF OPERATING LEASE Operating lease: A SCHEDULE OF OPERATING LEASE A A June 30, 2024A A A A Operating right of use asset\$ 71A Current operating lease liability\$ 25A Non-current operating lease liability\$ 46A SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY Maturity analysis of the Company's lease liability: A SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY A A June 30, 2024A A A A Less than one year\$ 30A Between 1-2 yearsA A 30A More than 2 yearsA A 20A A A A Total operating lease payments\$ 80A A A A Less: imputed interest\$ (9)A A A A Present value of lease liabilities\$ 71A SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE The following is a summary of weighted average remaining lease terms and discount rate for Company's leases: A SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE A A June 30, 2024A Lease term (years)A A 2.92A Weighted average discount rateA A 9.03% SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS A SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS A A Fair value at Closing DateA A A Notes (1)A \$12A Warrants (2)A A 68A Fair value at Closing Date\$ 80A A (1) The fair value of the Notes was determined based on rating model using a discount rate of 12% which represented the Company's applicable rate of risk, as determined by management. A A (2) The fair value of the Warrants determined by management based on Black-Scholes pricing model taking into account expected stock price volatility of 245% and risk-free interest rate of 4.52%. X - ReferencesNo definition available. + Details Name: GCTK DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Fair Value Of The Identified Components [Table Text Block] + ReferencesNo definition available. + Details Name: GCTK ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block] + ReferencesNo definition available. + Details Name: GCTK ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GENERAL (Details Narrative) - USD (\$) \$ in Thousands 6 Months Ended 12 Months Ended Jun. 27, 2024 Jun. 30, 2024 Dec. 31, 2023 Aug. 14, 2024 Jul. 30, 2024 Jul. 18, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Accumulated deficit \$ 117,269 \$ 109,853 A A Cash and cash equivalents \$ 159,492 A A IPO [Member] A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Net proceeds \$ 8,730 A A Private Placement [Member] A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Net proceeds \$ 500 A A Note And Warrant [Member] A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Net proceeds \$ 80 \$ 80 A A Subsequent Event [Member] A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Cash and cash equivalents \$ 4,360 A A Subsequent Event [Member] | Convertible Notes Payable [Member] A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Debt instrument face amount \$ 360 Subsequent Event [Member] | Convertible Promissory Notes [Member] | Warrants Agreement [Member] A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Debt instrument face amount \$ 4,000 A X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3

15,667 7,790 X - DefinitionDeemed dividend related to trigger of down round protection feature. + ReferencesNo definition available. + Details Name: GCTK DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEarnings per share basic including warrants and performance milestones. + ReferencesNo definition available. + Details Name: GCTK EarningsPerShareBasicIncludingWarrantsAndPerformanceMilestones Namespace Prefix: GCTK Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionEarnings per share diluted including warrants and performance milestones. + ReferencesNo definition available. + Details Name: GCTK EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones Namespace Prefix: GCTK Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK PerformanceMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SCHEDULE OF OPERATING LEASE (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Significant Transactions A Operating right of use asset \$ 71 Current operating lease liability 25 Non-current operating lease liability \$ 46 X - ReferencesNo definition available. + Details Name: GCTK DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) \$ in Thousands Jun. 30, 2024 USD (\$) Lessee, Lease, Description [Line Items] A Total operating lease payments \$ 80 Less: imputed interest (9) Present value of lease liabilities 71 Less Than One Year [Member] A Lessee, Lease, Description [Line Items] A Total operating lease payments 30 Between 1 - 2 Years [Member] A Lessee, Lease, Description [Line Items] A Total operating lease payments 30 More Than 2 Years [Member] A Lessee, Lease, Description [Line Items] A Total operating lease payments \$ 20 X - DefinitionLessee operating lease liability imputed interest + ReferencesNo definition available. + Details Name: GCTK LesseeOperatingLeaseLiabilityImputedInterest Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap LeaseContractualTermAxis=GCTK LessThanOneYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LeaseContractualTermAxis=GCTK BetweenOneYearToTwoYearsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LeaseContractualTermAxis=GCTK MoreThanTwoYearsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details) Jun. 30, 2024 Significant Transactions A Lease term (years) 2 years 11 months 1 day Weighted average discount rate 9.03% X - ReferencesNo definition available. + Details Name: GCTK DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -

Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) \$ in Thousands Jun. 27, 2024 USD (\$) Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] A Fair value at Closing Date \$ 80 Notes [Member] A Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] A Fair value at Closing Date \$ 68 [2] [1] The fair value of the Notes was determined based on rating model using a discount rate of [2] The fair value of the Warrants determined by management based on Black-Scholes pricing model taking into account expected stock price volatility of 245% and risk-free interest rate of 4.52%. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -Details Name: us-gaap_FinancialInstrumentAxis=GCTK_NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=GCTK_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) (parentheticals) Jun. 27, 2024 Significant Transactions A [custom:PercentageOffFairValueDiscountRate-0] 12.00% Volatility 245.00% Risk-free interest rate 4.52% X - ReferencesNo definition available. + Details Name: GCTK_DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of fair value discount rate + ReferencesNo definition available. + Details Name: GCTK_PercentageOffFairValueDiscountRate Namespace Prefix: GCTK_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SIGNIFICANT TRANSACTIONS (Details Narrative) - USD (\$) 3 Months Ended 6 Months Ended Jun. 27, 2024 Apr. 30, 2024 Apr. 22, 2024 Feb. 19, 2024 Feb. 13, 2024 Jan. 03, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Operating lease liability A A A A A \$ 71,000 A A \$ 71,000 A A Common stock share price A A A A \$ 0.001 A A \$ 0.001 A A \$ 0.001 Reverse stock split A one-for-five A A A A A Aggregate of shares 300,000,000 A A A A A Notes payable description The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of: (i) twelve months from the date of the Note; or (ii) the date the Company raises third-party equity capital in an amount equal to or in excess of \$1,000 (the ðMaturity Dateð). The Company may prepay the Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. A A A A A A A A Warrants exercise price \$ 4.95 A A A A A A A A Warrants term 5 years A A A A A A A A Unsecured Promissory Notes [Member] A A A A A A A A Aggregate principal amount \$ 100,000 A A A A A A A A Private Placement [Member] A A A A A A A A Number of shares issued A A 79,366 A A A A A A Common stock share price A A \$ 6.3 A A A A A A Net proceeds A A \$ 500,000 A A A A A A Net proceeds A A A A A A Net proceeds A A \$ 80,000 A A A A A A Exchange Agreement [Member] A A A A A A A A Lock-up period conditions A A (a) sell or contract to sell Shares at a price higher than \$0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than \$0.80 per Share on any trading day with no limitation on volume. A A A A A A Share price A A A \$ 1.00 A A A A A A Lease Agreements [Member] A A A A A A A A Monthly rental fee A A \$ 2,500 A A A A A A Lessee term of contract A A 3 years A A A A A A Security deposit A A \$ 2,500 A A A A A A Operating lease liability A A \$ 79,000 A A A A A A Prefunded Warrants [Member] A A A A A A A A Pre-funded warrants A A A 395,294 A A A A Common Stock [Member] A A A A A A A A Number of shares issued A A A 79,366 1,075,294 79,366 1,075,294 A A Common Stock [Member] | Exchange Agreement [Member] A A A A A A A A Number of shares issued A A 718,641 A A A A A A Warrant [Member] | Exchange Agreement [Member] A A A A A A A A Number of shares issued A A 876,391 A A A A A X - DefinitionLock up period description. + ReferencesNo definition available. + Details Name: GCTK_LockUpPeriodDescription Namespace Prefix: GCTK_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDescription of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermDebtDescription Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap DebtInstrumentAxis=GCTK UnsecuredPromissoryNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=us-gaap PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=GCTK NoteAndWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=GCTK ExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=us-gaap LeaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CT_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) 1 Months Ended 3 Months Ended 6 Months Ended Oct. 07, 2022 shares Mar. 04, 2004 USD (\$) May 31, 2024 shares Jun. 20, 2023 shares Jun. 30, 2024 USD (\$) shares Jun. 30, 2023 shares Jun. 30, 2024 USD (\$) shares Jun. 30, 2023 USD (\$) shares Mar. 04, 2004 ILS (â) Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Restricted shares | shares Â Â 30,000,000 20,000 Â Â Â Â Â Â Research and development expenses | \$ Â Â Â Â Â Â \$ 131,000 Â Â Stock based compensation | \$ Â Â Â Â Â Â Â 228,000 \$ 229,000 Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Number of common shares issued | shares Â Â Â Â Â 79,366 1,075,294 79,366 1,075,294 Â Â Stock based compensation | \$ Â Â Â Â Â Â Â 192,000 Â Â Discount rate Â Â Â Â Â Â 30.00% Â Â Intellectual Property Purchase Agreement [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Number of common shares issued | shares 200,000,000 Â Â Â Â Â Â Â Â Number of common shares issued | shares 200,000,000 Â Â Â Â Â Â Â Â Commission as a percentage of aggregate sales price 1.50% Â Â Â Â Â Â Â Â Israeli Innovation Authority [Member] Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â 93 Â Â Â Â Â Â Â 420,000 Israeli Innovation Authority [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Royalty percentage maximum 4.300% Â Â Â Â Â Â Â Â Israeli Innovation Authority [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Royalty percentage maximum 4.500% Â Â Â Â Â Â Â Â X - DefinitionAggregate sales price of units percentage. + ReferencesNo definition available. + Details Name: GCTK AggregateSalesPriceOfUnitsPercentage Namespace Prefix: GCTK Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionMarketability discount rate + ReferencesNo definition available. + Details Name: GCTK MarketabilityDiscountRate Namespace Prefix: GCTK Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionRoyalty percentage. + ReferencesNo definition available. + Details Name: GCTK RoyaltyPercentage Namespace Prefix: GCTK Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap LossContingenciesLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of other research and development expense. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap OtherResearchAndDevelopmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482400/230-10-45-28 + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13 + Details Name: us-gaap WeightedAverageNumberOfSharesRestrictedStock Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=GCTK IntellectualPropertyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei LegalEntityAxis=GCTK IsraeliInnovationAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=GCTK IsraeliInnovationAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUBSEQUENT EVENTS (Details Narrative) - USD (\$) \$ / shares in Units, \$ in Thousands Jul. 30, 2024 Jul. 18, 2024 Jun. 27, 2024 Subsequent Event [Line Items] Â Â Â Third warrant per share Â Â \$ 4.95 Subsequent Event [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Debt description of notice of default (i) failure by the Company to pay the Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the Holder. Â Â Debt default long term debt amount \$ 50,000 Â Â Debt instrument term 10 years Â Â Subsequent Event [Member] | First Warrant [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Issuance of common stock upon private placement transactions , shares 2,133,334 Â Â Third warrant per share \$ 1.875 Â Â Subsequent Event [Member] | Second Warrant [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Issuance of common stock upon private placement transactions , shares 1,523,810 Â Â Third warrant per share \$ 2.625 Â Â Subsequent Event [Member] | Third Warrant [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Issuance of common stock upon private placement transactions , shares 1,185,186 Â Â Third warrant per share \$ 3.375 Â Â Subsequent Event [Member] | Convertible Notes Payable [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Debt instrument face amount Â 360 Â Debt instrument interest rate Â 8.00% Â Convertible Notes Payable Â 500 Â Debt Instrument, Convertible, Conversion Price Â \$ 1.56 Â Sale of stock issued price per share \$ 5.00 Â Â Subsequent Event [Member] | Convertible Promissory Notes [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Debt instrument description (i) is convertible at the discretion of the Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price (â€œVWAPâ€) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction). Â Â Sale of stock description of transaction (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the Note was converted pursuant to an optional conversion. â€œSale Transactionâ€ means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the assets of the Company, or any other transaction or series of related transactions in which the Companyâ€™s stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent Â Â Subsequent Event [Member] | Convertible Promissory Notes [Member] | Warrants Agreement [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Debt instrument face amount \$ 4,000 Â Â Debt instrument interest rate 8.00% Â Â Debt instrument description (i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (defined below) (the â€œMaturity Dateâ€) Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-50-1 + Details Name: us-gaap ConvertibleNotesPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1 + Details Name: us-gaap DebtDefaultLongtermDebtAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionDescription of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1 + Details Name: us-gaap DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable,


```

J1C4S,31'S V=W,65F<RQ MDJ4BHDND(1C<25J VFW7@. H7N1J1D;C9N5W@J$J'G61=37J$(= M F;H2ZHC<V6Z02> .IY1JH4N<@E9'M(MI' HUDC+H;(H+0'TR0MZD(SV
55<D+C+<N1Y5U2D>JQD6J5,6F,1R3,2T2PH.UUJ%6M181'R= 4LV M17>K<Q>VGLA= 6,9QX4Z&K<O,AN<N -E 2V UKTZ>S[<=C<J'J MK<J'J/PV'~(11,WWWVL*1-
G'XTL/W2,Y.U5YT+1^5N?K4&5M?0@>P<., M.MO5WTKWDJ5EMJE?KF2RDE50/W^,5-3QO<9>#>T;8XWOP-02P,$% @ MO8 -6G;5%*HSDJ4B@< ID +>
MN20:NB615:2DB@:M$Q.Y/ ZK25A05$S1J=<R^EY2?7^,V727+4950ES01 MFXXN&WVAJ< @ 613806L$5/S5G0=>5/JWLJ3ZV=E@M$5=<31? *Q/L #38@ MD C1S$;MW2:
CRDR9 .PB2X:DGQ$QJHX+ 94W'-SF,1J(QCJD11<XEOJ:VIL >NP#8 +@>IHJUPM@<.'S< <66;6%>D<=1% M1DDC<=K,3>;>181P@J(UX1+>+>?>?>QY14B&Z$Z4A$5$P1-4PP6B1142
M%>X0JW+>(&Q) ' <= 'R^<3Z<CHOCZ9?T,NM/V4 M$A-.8@<M .E^4V=53. $J76 & U10MV2D4,3 UUI<:TGM65M$>MJOTJ?<=<C9,7?9 .MH;T#LOF<21I9Q
%>1@L7Y1@&QJ$QV*99(F<#$(HFH8W1152$4?<#<M+U M6<^1J1KBE1M62KX?<+<'M31 [-4+UNN1 M<^> M6YJ6721BJ?>P *L'UB@<=K-KI?<3?W9+1&ER^<^Z6B)JIEZU&9J
M+>W7BC.K<N W1->#&H<#<RKJ0J7GJZAT7J?>5X2M6%U1J/>GEP/G ++<M.N0RJN2K7OKMA5U*234Q3D>+4U6*QR?OP=<A5-WN^ *V5O<K<CV %4M; M'MZ<LD?
2=NB@<B+X;H2PSX6T73OKU1J,GB=20%NH@<=5C#A.M$HBSAEI M$= M70J'2W,1J(QM&KJR<KZ7CD+G^*7G6PKX128V;RS<1(E^E^X<K&5K M$?6P01R;2F#V=3D 1*ITE+ 17
9V^++9Z [AXY0'[47T@P 4UP6YJLBM?3.4UB#<@VON<M.PPY 1.2AJMLJ1%-7HN0U(U9%9NSG<-619J.R IKS1CP4B$.(5;1@QQR>PR MS6J.4UF31*S^OZ2O+U;NQ@JX%5E>+P5M$@<+66%
<0>P.FC0P^WD$<8 MN$0E'F1.S;J[M1P2UQ0^PD%PFZS1S(0B)>+PWSJ<K%L.3+RV^+>4 KUFXB4<4&XZS MW9^OSZB1H0?<S1-$<1<Q%>M>M>UGZ/IT1ZOOJ1@<N@J@?>@>W-QM<4Q,X
M1J5'8B@<DPH?>H0.OE&XP$3QP1W+ 12/04F3Y19HS1'<OJGEA'J<@>+X&8GD M;8?U 5W^=SOZE0'ELJ63LNT5E1PEL#61YH1!<-953$3,F9TYTY<@S159GLKVQV9$58 M5M1W35+<L
%> LLK<QE-VIL<AMEATEVJ?>^V3@ 'O4Y3<=YXWFSYJ>+7-029WV18R/Q1+118 M92=>2&U6&W.27<=1^>JX^WM@<G I1R^>#02P,8@<M -64L$M5'RI0 X<1@<IX;JYJW)K81K?
OTZ<61?>->H&R3?J6;EVJX<J'>+N^<'V23;M4P1-5:FQA;8VAG M;5=<+>J3C;W3C<Q;=<Z<1<-9B1J27?IO^YTO+>D7N^0MC6F7J 8>(<2>?<?Q M31Q)QB0J/BDJXV8 J<7F-RJYJW)H8-2BKG3J$#
2% MTOE<6%KRN'V1<=<'N@<WJ2B@1J>=<G1Y;R7+NSV<T^HX33 *27VCJ1@>7TQ?>2^LUAHF NZ4X<@TQ94BD2>- MDGW91J D?>BALQ?01/>[CJW?>LOY>X>P^<#FMX.
J2 L02JEF<7HNNBHQ M/S7$3#CFWVY3 +<#X?>+G4<-T4J1$*..D?>1<=>ESZ,18V@>2F1TQNHQ.XA M1J,34P656&X<+N9@J1N<J>=>8%VE<:S1I7520&05.E6R4<4J1$4E^<M
6EJ<#<UJ3U4=>2DV96Q,1H492ZOW$G.UK1N9C0$5TJ-RDJK6K+<@>T7B8E M2Z6T#A+I?>9C1<=EI ZE2DRDRJ(16E7@<J1$=<@>D1>?7C MRZJ#<J>U3=0S4L'J1<=<8^9X5J8R4'GDNE+3
J7ED+D0225&61SVB4*M$ M7G01W.O,1 YDZ>Y>J1M[FST>?<S8=F/BF YC&NAH$5@SA(O)<3%<8%<3% M6I$B6C^7^<1%R6>Z5Q8M@<VJ^*K^E7+>2FD(Y9^R^TXB ZXLQSU22;5J)
JTK6<LIDUSO&11,K4U?<+<+I<C@<7TG 1[B^VZ9143J3?>]>@DG^MLL TSX5 G<L<2:P2AHG(R4P, M.<+>D 2$KEU>0W<@<=N<N'D^#P<0>=<4$<J^UA+HOJ$>
S;D@<N0Q9E$<GP9C^MDGE4A+1P' L3J2746H-19M0$181#J340<B+M+HJ1J$5)TJ1H M3<+UW7+6V1$<LEK47>JVN' JWJ M^>=H.RWBV$P M432^1J1MVBQ+HXZY J1?7@O#&X'P[
WJ<@XUC<+8N+D8CD<2J3#1L9P/ML+D-FZHCG^<5, J1<C=C+Y+J$IM<+>[9&XU4<.&N)18NHTKYN<P>Z< M5W$M5JOKWO<@<840[F@/6I M039#MNCJN1D 1=02P,$% @ 08
-650<O%<C9 RY17W%<M$>#<QX&^Q#RVR9?6$9&091'[Z17U+>T1JJK6<X<+>2N;J0LU89GBQ-FVNPJ*J1< IN M5=<+<HX OJ. S55UYNXN<N>N6275N2JL4HU?>+WGPCJPM.(QO.
7J5ZL)UK M02=9&J,3L$2=<WMJ$>JHE18H J7JBLHP&AC AFON-502Q UY6V/TSQGOU M64BKJ@<H=J16?OZ<D-BGKKJHN^GY1 CPGM[YB,LO BP<7X8BU0<7(7UQDEBZJ+2Q9VX
IE.M+<+<#<K4KH MRSJW=<B-MJ1J?>706JN6D?JPAPBQJOK7@<O^?1?2?>=<?>F&E^KZ^W^TJWU MZMJJ)<J1NIE&0WSH?O.T<G/DGFK;626XII6*B)X1?=<K%0DH>J>+8LGTGA= MR#K5E41%8N
A<65+<B1$ZISN6J@DE1J1J0M9J1FFP(M142HKJ)<'DS<@<I^A M^AC.KDR=16^A1(3$EJ)5JL+<+<L^<P^CJ5$FSFX^UG#<
8GQ39;J2@<SXX@<J1=<@DSJ1A6S5U^Y*#<3<9BU+IQ.RU1D[17L]VDZ.514LJ LNS2F(ON)<+<K^C^WAGE%1@<1=<O J18DORDW1+OSV^=J8W M[XDOX %U1SFM:K&Z<:<[J3?
+1UUQ,9Z<@<S52H8ZVT1J4ZLS,Z5V6,1@< MJFAMK&T#>02@<7J,1Y^6?3$ FY1,'IEM#<= L M1Z1D^A1^FONM;E80R132)M1< Q<Q&5H7J14XD,8PZK 15 2,48JLJ
H^*Q 09J)ONU0T19241H34M, M+K<+ATV^K.EP DSO^M03MUM91H$QMI>?<2C^N1T35HJ,8//> >J^K<+TJ MCJ;>D5AWB1J1JLJ<MSY^D>=<6$7<GJZIH+8$9E^6M^>->=<7$<HKT
M&B+@<8R1J3, H-QRF-PIN^9RWPT90&E&DPA0W73J(OOGA<JMU/P^OZV778 MN-EAEU1D?<C^B14J7J?P8USU4KDLJL PBF7041KGA;<+<DWO4<033 SX #V=6<MDFJ,GXJ$Q) 2AZR21JJRS?
J1U/UHDD1<@<VTM@<7G51+<RW> S<=8,5D3 M7JQMN<^<MRVJ0+ HP$WJ3?>X5<XCOX,N 'C^#<4TDE1JJK=<1OLK$<+<PBH;2KMCIJ$>X,+<+N,N.HX^>J<O<8JSHJTJ1K$5N$Q M<8,HOHO#<S1Y
U<H<16.RU,3$UGB^*49^<K06<J@<RQ$STSIQH1 MB*,<+<D^F^X^01E8J$<A5E.RA>=<960^VJG80G^@.815.CFQOZ46$F1^1^7P MS DGT
```



```

(6) PYORE*YKLRRY&9B&0OCHFW&+<8G$-2)Y#MDS7G&-0 MQ(8IDOL.8K2L&:/KRIO&3E:6*2IL$ZRSI6%<X>.>1.>75RQIQQ)S$IX
MNI&KKN<%%>9$2K2D.B/MDY8=1CP5/MJ.S:A<-AU$DYH<%%>KN94XM"/-(<Y6L0 MQC&=A7Q!M#G#&.<F%&#>?)3AX<(<O>Q&FZ#)HJ(M*#M0G3D3
*#3.1.LJLY$PPEP&3/*M0456JQB*5$W2PYDSRMBYOH<IS-X*P.MSI.L4I9D->Q%HTT^W^31.74M0&#<#>.PU5?/
M6F<X3RI*TEB:3I4)HJ9E0F@6EV5?>.Z6Y.M4)JHM4EJ562V*220,_)JR<^XCGB.6)6E=*H6UKDN1M*F4ID-IHIF0ED6
ME&9#>0Z4YD)H16%VIERE+EMJRIM5:H.R.L+QNMV<^%>.JU:Y^VKLT.M#QQ=I<?#>AVOQY.4)HJ5E0F@VE.5?>.Z5Y*%I=C16/249N>2HUGJ$6KE*
MFJKN7+78I*#$6K2@M).$V^TEPHS8?2?C-0IJO>0<-UKPL:DIHIF06DVE.9:2Z4YJH=1%6ACI5
Mf@A14X1G1T$2IM*.:3J49D)H1F06DVE.:4M+=.K^XTJX>BU458><+4MTUA
MY#>9D2)9I0$<^M(Z.82IE?>#J494)H1F5E0F@VE.5?>.Z5Y*%I=MY7UIY5I.M#?IZL/>O3F:CH2?TWJH6AU<56V'E5NMS%-IDL_6?*"
<9'1$0YI(<?4$RAM<M17I4)HJ9E0F@6EV5?>.Z6Y4D)HJH7?MJ#>9@#2Y?#MLJX&09+I8T(XR?<1HO-$YA=J&V:<^AO
#@>=5E5J?C;.<#>#.D$<DJ0D'N.0^>+@>54.3MRN7U?>?Q-Z(%A0F@VE.M.5?>.Z5Y*%KI)G%GYK#2YS<^!-OO)MWZM-BU7T%L1HF:V&M'HKV80FM*+T
M&TISH#0720-0M+K1^D)5Q>+<5BHU58FE.DTN9G&*HWE.:+T3ES&05RN.M:H1ZJ6?TJ90FO&L-NL?
I6MH0.MA07ED6E&9#>0Z4YD)H165YCEK1+D.HJ.MTL-0)IB1E=IW0$<+3FBM32A'BLH3==>L.HJDPHPP*LTZ&TISH#0720-0
MM+H.*X>5)G=8M7HWJYS56H0NQ64IFNOC3ZCBU>/_UH4A*^LZT&TISH#07.M20-0M+H@*I>5)G=;W6=TOA.O#R>I5T=C_Y_590VA1*TZ$T
TISH30+2K.A.M=->2NHV*1-I@JE#<#>K3H30+2C+6NTM.MHA<#I>#7L:TPVE.9:2Z4YJH=2U6IBQ<^I7L1%)WHJ4GU(<#>4IYA.M-IU*Z
T5TISH#0.2G.<#>I=I^U^T^B-AE3&K<1$<#>M>B/+B>U52Y4.H72="C.M@>#>TJ:6.TXI<:Q18JHBU26X?T=I+W+QSV+I^U^2N-MV.'KL*788>OPXY?
AQW.#CN'"=0!4Y4)H+I7DH6EW.E0&H+S>SM*EE0FE2IBO7I6C8OWA5N4+M/E#>.4Y4)H+I7DHVE:/O:W!G&.+8HA.MRG.2B#?
Q?>+<W&P.IPMBJVRSG&SIDFYZ19J6822/LJLYQ0L2%7Q%<+<C>D?E6/2E2*F.M%QVC&I^/4241^B_02^KL1E>?
Q7XUUVGY6#3+EBWD*WZ=Q7I.M4$&ZQVR0).A1M8?I>25Z.HJ3?XJ+Z2UW1HT.FRTD2=U8CB)TM7M.W&OIHEPTH.>I^K1N0+<T#T-
K+JIM=U@WY!Z=8/>H4JUPWZVPUS>QILZ@:#MOW18U@V&A_9P6C9Z4U>+>7M7OF@<KJH00R3*WSXT'DJ>I_1"?>UQIO:IGCK7/W<$
NJVQR_2'ND=UVCYFQM89=7H(8L.N>1&9S$49Q0>I^/_D/HO'MD.Z72G=1IV.N^Z^Z^3*16>M$">=I^FE+U?2WGJ00:JOI/TIKW?2WFTN0USJ?
1^Q>B1SPV^<+U#ZIOI^O-6&8UEMI<L3A2)U#H%&N.MXAZ&6$8JE0H5I=>I57F.SHF@Q8W17'XZ)'8C<^W77TZM?WS=TV46NL4
MMRK=VJ?29$5KF7D1^F.IY.<#>2&2ID/38(GQ)MPHU@<:UVL#QDGQ6+<:(O.M#087H#A72&O_YB#HP_VZ?
B=E($S$B+A+SD)B:QI@2T^T8DAI=5KT<KX.M$RI$DT&G19Y2H03<KK75L1B_Q>X7U*ZR<#>+6UHISL&AGMNS02W;U<MY<@).8C.8;$
A"FA">#<:HJ8A_ED3L)T*A<#>+W+L^YX#K%T^X5F&*JJP.M-M6T5KVY(A&8C82JHBT0&V$G.OF@#?3F(S&G_O(HJ3?)T6
M<^TOXFY2'A5(ES.=JCL1U>C8IB*#<NF6K&CXV9'8C<0<+>..M)PYSU.M$&B3FW+18INFIH<IG^ZQ14I$5%#2IE9@0"?>=NI8<J-E1SDH+
MU3RHYM>JLM<MD.YM2W2D(S4.MJCE0S85F'E3Z.LQ76H&R26=IPC<PQO&AKGM<ESJHWE@H>F.HU81G&YH/M%CP7WGLI_YJHN5#<@VH<
M5&0+4ILBXU55<37G8UH757J&9#>JN5#<@VH<5&0+4ILH8T15A37X1M/M76MM>8N5O00&XN@T0&H&Y5^AF@25?C&H%I-TM0?
JXKZ?RXHYM%$M6Hf+ZOU152S+ADG.O180*6I%#C94KXXM.M<10-17%Y/EWIA9:7JZUS7.$HZWS)C:TP>JN2WC^VZ.WXAV2_0(XV&*T.M-
52:2I^IK9B-Z.T2I)YHEDGWOR*5HHAHFV5:>@F@O5*CF054I&04H97M4$&V1_Y$K16#_5LJ_9-1>J>5#_AVHJ_4H32WD5E/+IOI@<JN5#<
@VH<5&0+4ILAHTE6VJKVR7$R@9IM5'E0L2$CGIFL@Y-M5CCC96J$.SGIFH%DR*.97(LIFC260^N>QDH5+>I#<JGP#>45^A&H+J4I3ZXIEE-
XL9Q.B+50S89J'E1SH9H'U7RHQJL@+4J&S*MY51Y+<=U^T3>2@17.HYD.U^M%ZYI4Y/>@RJ2A38?F$Y4M%<IQYIH(6.M5&#<15W1S:027A
MU<XTI8<=>NS8Y$BUK4JE&MNS)6BG#E1SH9H'U7RHQJL@+4J&S*Y9:<5^IP.ME&J5'MHIEZKHV."6E:>@Y4Q%I^M7GT>_EMI/6WL1?
@AA.UQOQWH4AXJON>U^0ZMKY9<2.6I^W5KFLIBBRM=TV.MSQRS9.MKGGEMVWWS^C^WNJ)TNIKRVV8S2T(#<ED.P3H1#E7ITQ9+1^9
MHKHQOE.U194<#<G^W$<#>G+Q-N3LH/UG60$P.O2P$@<O8-M6G1'f6.***0CS8_1D:W&K&ULM5M=MJLX$GWWK
IG4$<9&UIV(13)@%:NXI8EMD)TWL)@<6DMMI*H(2FH.O.'MIZ7(6)*M.-$.W8=47SPD#RI0IR&OKI>?Q=K0B3ZD2.9N.FOIT*F=W$D
MBC3?2/>.)<QFT_7ICPI^IZNU5<#>AMJ0K<7ZIC.MHY@L<F>(WIGV^VZ<9Y.M$4M@1=MS=>T6'D'PUA:$M%<EIO3(3#<HXC>#^N%<^XO.
M(5)C.YR<2<WQIS=D6.M2G$1#<^ZYH5FQ-ONY$JB^T^L$>JTG(X(G&O'Q'AF@T+M@<1>D).6HK7E#<MGSY92Y<16R@LNVXD@+17ZG.D.MJ?
BSC1P-VJ^4Q/_M@3D_)SB+2_J5L<8EEP&G<(UD)R@+TYA_5Q_IY7O1<@AJRTC$51P3G)4K^T.KN>.)B1R$M$E);%:3%.$M%$X8JO&";
WAYU6.CD)X@IHU.HU.HU.HU.2>3@9E.O4&FA.V6.4QZ1V>3A.M10@<4G.WB.2>J.Y8TE.***HJWCV=6B*8U.M+/IRJ+7+
fH420RU9"9H"SWB.4P9CWS&.&O.RYN7$#G<WLUKUDP&N-R7)M5$B+L.F<LGS>.%2%Z4T91U5>+<7WTQJ@WA8NSIPENU+^E*OJU=6>JIN

```


FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) (parentheticals) Sheet

<http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetailsParentheticals> SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) (parentheticals) Details 21 false false R22.htm 00000022 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) Sheet <http://glucotrack.com/role/SignificantTransactionsDetailsNarrative> SIGNIFICANT TRANSACTIONS (Details Narrative) Details <http://glucotrack.com/role/SignificantTransactionsTables> 22 false false R23.htm 00000023 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Sheet <http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative> COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Details <http://glucotrack.com/role/CommitmentsAndContingentLiabilities> 23 false false R24.htm 00000024 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet <http://glucotrack.com/role/SubsequentEventsDetailsNarrative> SUBSEQUENT EVENTS (Details Narrative) Details <http://glucotrack.com/role/SubsequentEvents> 24 false false All Reports Book All Reports form10-q.htm getk-20240630.xsd getk-20240630-cal.xml getk-20240630-def.xml getk-20240630-lab.xml getk-20240630-pre.xml <http://fash.org/us-gaap/2024> <http://xbrl.sec.gov/dei/2024> true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "GCTK", "nsuri": "http://glucotrack.com/20240630", "dts": { "inline": { "local": { "form10-q.htm" } }, "schema": { "local": { "getk-20240630.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xt-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/irr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "getk-20240630-cal.xml" } }, "definitionLink": { "local": { "getk-20240630-def.xml" } }, "labelLink": { "local": { "getk-20240630-lab.xml" } }, "presentationLink": { "local": { "getk-20240630-pre.xml" } } }, "keyStandard": 143, "keyCustom": 26, "axisStandard": 12, "axisCustom": 0, "memberStandard": 12, "memberCustom": 19, "hidden": { "total": 144, "http://fash.org/us-gaap/2024": 100, "http://glucotrack.com/20240630": 40, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 116, "entityCount": 1, "segmentCount": 32, "elementCount": 289, "unitCount": 5, "baseTaxonomies": { "http://fash.org/us-gaap/2024": 459, "http://xbrl.sec.gov/dei/2024": 31 }, "report": { "R1": { "role": "http://glucotrack.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": { "b": "span", "body": "html" } }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": { "b": "span", "body": "html" } }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R2": { "role": "http://glucotrack.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "R3": { "role": "http://glucotrack.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPSHares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "R4": { "role": "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "R5": { "role": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31 us-gaap:CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "R6": { "role": "http://glucotrack.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": { "tr": "table", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "unique": true }, "R7": { "role": "http://glucotrack.com/role/General", "longName": "00000007 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R8": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R9": { "role": "http://glucotrack.com/role/SignificantTransactions", "longName": "00000009 - Disclosure - SIGNIFICANT TRANSACTIONS", "shortName": "SIGNIFICANT TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "GCTK:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "GCTK:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R10": { "role": "http://glucotrack.com/role/CommitmentsAndContingentLiabilities", "longName": "00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R11": { "role": "http://glucotrack.com/role/SubsequentEvents", "longName": "00000011 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R12": { "role":

"http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R13": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R14": { "role": "http://glucotrack.com/role/SignificantTransactionsTables", "longName": "00000014 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)", "shortName": "SIGNIFICANT TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R15": { "role": "http://glucotrack.com/role/GeneralDetailsNarrative", "longName": "00000015 - Disclosure - GENERAL (Details Narrative)", "shortName": "GENERAL (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "15", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31 us-gaap:IPOMember", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true }, "R16": { "role": "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "longName": "00000016 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)", "shortName": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "16", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-06-30", "name": "GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true }, "R17": { "role": "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails", "longName": "00000017 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)", "shortName": "SCHEDULE OF OPERATING LEASE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null, "R18": { "role": "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails", "longName": "00000018 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)", "shortName": "SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R19": { "role": "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails", "longName": "00000019 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)", "shortName": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R20": { "role": "http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetails", "longName": "00000020 - Disclosure - SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details)", "shortName": "SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "AsOf2024-06-27", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "GCTK:ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-27", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "GCTK:ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R21": { "role": "http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetailsParenteticals", "longName": "00000021 - Disclosure - SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) (parenteticals)", "shortName": "SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS (Details) (parenteticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2024-06-27", "name": "GCTK:PercentageOfFairValueDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "GCTK:ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-27", "name": "GCTK:PercentageOfFairValueDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "GCTK:ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R22": { "role": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "longName": "00000022 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)", "shortName": "SIGNIFICANT TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-30to2024-04-30", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true }, "R23": { "role": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-05-01to2024-05-31", "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-01to2024-05-31", "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock",

"unitRef": "Shares", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "span", "p", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "longName": "00000024 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2024-06-27", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": ["span", "span", "p", "td", "tr", "table", "GCTK:SignificantTransactionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "From2024-07-302024-07-30-us-gaap_SubsequentEventMember", "name": "us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Legal Entity of Counterparty Type [Axis]", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": { "r48", "r54" } }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r37", "r478" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": { "r13", "r14", "r55", "r95", "r346", "r362", "r363" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "AOI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r1", "r7", "r14", "r263", "r266", "r302", "r358", "r359", "r523", "r524", "r525", "r531", "r532", "r533", "r534" } }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": { "r49" } }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r373", "r531", "r532", "r533", "r534", "r567", "r593" } }, "GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Deemed dividend resulted from trigger of down round protection feature of certain warrants granted", "documentation": "Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities." } } }, "auth_ref": [] }, "GCTK_AggregateSalesPriceOfUnitsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "AggregateSalesPriceOfUnitsPercentage", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Commission as a percentage of aggregate sales price", "documentation": "Aggregate sales price of units percentage." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": { "r506" } }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r257" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r72", "r79", "r91", "r118", "r147", "r151", "r152", "r153", "r185", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r258", "r260", "r277", "r343", "r407", "r455", "r456", "r478", "r491", "r563", "r564", "r582" } }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r88", "r97", "r118", "r185", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r258", "r260", "r277", "r478", "r563", "r564", "r582" } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": { "r506" } }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "GCTK_BetweenOneYearToTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "BetweenOneYearToTwoYearsMember", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Between 1 - 2 Years [Member]", "documentation": "Between 1 - 2 Years [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Contingent consideration liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [] }

"auth_ref": { "r28", "r69", "r254", "r273", "r274", "r275" } }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/GeneralDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r16", "r90", "r450" } }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": { "r17" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, and restricted cash at beginning of the period", "periodEndLabel": "Cash and cash equivalents, and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r16", "r59", "r115" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Change in cash and cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease) Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r59" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r85", "r92", "r93", "r94", "r118", "r138", "r139", "r142", "r144", "r149", "r150", "r185", "r205", "r207", "r208", "r209", "r212", "r213", "r231", "r232", "r233", "r234", "r236", "r277", "r368", "r369", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r395", "r416", "r433", "r441", "r442", "r443", "r444", "r445", "r512", "r528", "r535" } }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Warrants exercise price", "verboseLabel": "Third warrant per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r237" } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Aggregate of shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r237" } }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r257" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets" }, "lang": { "en-us": { "role": { "totalLabel": "Commitments and contingent liabilities (Note 4)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r44", "r75", "r344", "r394" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilities" }, "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r65", "r197", "r198", "r446", "r555", "r560" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" }, "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r481", "r482", "r483", "r485", "r486", "r487", "r488", "r531", "r532", "r534", "r567", "r592", "r593" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "Common stock share price", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r47" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r47", "r395" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r47" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r9", "r47", "r395", "r413", "r593", "r594" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": {

"http://glucotrack.com/role/BalanceSheets" }, {"lang": "en-us", "role": "label", "label": "Common Stock of \$ 0.001 par value (a201eCommon Stocku201d): 100,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 5,501,164 and 4,178,438 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, {"auth_ref": "r47", "r345", "r478" }, {"us-gaap_ComprehensiveIncomeNetOfTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, {"lang": "en-us", "role": "negatedTotalLabel": "Comprehensive loss for the period", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, {"auth_ref": "r15", "r100", "r102", "r107", "r340", "r353", "r354" }, {"us-gaap_ConsolidationPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": {"http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": {"lang": "en-us", "role": "label", "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, {"auth_ref": "r29", "r451" }, {"us-gaap_ConvertibleNotesPayable": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, {"auth_ref": "r12", "r74", "r591" }, {"us-gaap_ConvertibleNotesPayableMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableMember", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, {"auth_ref": "r38", "r73" }, {"GCTK_ConvertiblePromissoryNotesMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ConvertiblePromissoryNotesMember", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Convertible Promissory Notes [Member]", "documentation": "Convertible Promissory Notes [Member]" } } }, {"auth_ref": "dei_CountryRegion": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": {"http://glucotrack.com/role/Cover": {"lang": "en-us", "role": "label", "label": "Country Region", "documentation": "Region code of country" } } }, {"auth_ref": "dei_CoverAbstract": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": "en-us", "role": "label", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, {"auth_ref": "dei_CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": {"http://glucotrack.com/role/Cover": {"lang": "en-us", "role": "label", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, {"auth_ref": "us-gaap_DebtDefaultLongtermDebtAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt default long term debt amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, {"auth_ref": "us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt description of notice of default", "documentation": "Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet." } } }, {"auth_ref": "us-gaap_DebtInstrumentAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, {"auth_ref": "r12", "r38", "r39", "r73", "r74", "r120", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r460", "r461", "r462", "r463", "r464", "r476", "r529", "r556", "r557", "r558", "r577", "r578" }, {"us-gaap_DebtInstrumentConvertibleConversionPrice1": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, {"auth_ref": "r66", "r216" }, {"us-gaap_DebtInstrumentDescription": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescription", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt instrument description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, {"auth_ref": "r12", "r25", "r35", "r38", "r73", "r74", "r286" }, {"us-gaap_DebtInstrumentFaceAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt instrument face amount", "verboseLabel": "Aggregate principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } } }, {"auth_ref": "r214", "r286", "r287", "r461", "r462", "r476" }, {"us-gaap_DebtInstrumentInterestRateStatedPercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt instrument interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, {"auth_ref": "r41", "r215" }, {"us-gaap_DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": "en-us", "role": "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, {"auth_ref": "r12", "r120", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r460", "r461", "r462", "r463", "r464", "r476", "r529", "r556", "r557", "r558", "r577", "r578" }, {"us-gaap_DebtInstrumentTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": "en-us", "role": "label", "label": "Debt instrument term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnTnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "presentation": {"http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetails": {"lang": "en-us", "role": "label", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]", "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, {"auth_ref": "r546" }, {"us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "presentation": {"http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetails": {"lang": "en-us", "role": "label", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, {"auth_ref": "r546" }, {"GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature", "crdr": "credit",

"calculation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Deemed dividend related to trigger of down round protection feature", "documentation": "Deemed dividend related to trigger of down round protection feature", "label": "DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" } } }, "auth_ref": { } }, "GCTK_DeemedDividendUponTriggerOfDownRoundProtection": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "DeemedDividendUponTriggerOfDownRoundProtection", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Deemed dividend upon trigger of down round protection", "documentation": "Deemed dividend upon trigger of down round protection" } } }, "auth_ref": { }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r5": "r24" } }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": { "r10": "r31", "r32": "r33", "r34": "r119", "r134" } }, "GCTK_DisclosureSignificantTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "DisclosureSignificantTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Significant Transactions", "verboseLabel": "Schedule Of Operating Lease", "terseLabel": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate" } } }, "auth_ref": { }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards' or 'Other'." } } }, "auth_ref": { "r505" } }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": { "r503", "r505", "r506" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": { }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "r504" } }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": { "r492" } }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": { "r505" } }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": { "r505" } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r507" } }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": { "r495" } }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "label": "Basic net loss per common stock", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r108", "r126", "r127", "r128", "r129", "r130", "r131", "r135", "r138", "r142", "r143", "r144", "r146", "r252", "r256", "r270", "r271", "r341", "r355", "r452" } }, "GCTK_EarningsPerShareBasicIncludingWarrantsAndPerformanceMilestones": { "xbrltype": "perShareItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "EarningsPerShareBasicIncludingWarrantsAndPerformanceMilestones", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Basic net loss per common stock", "documentation": "Earnings per share basic including warrants and performance milestones." } } }, "auth_ref": { }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "label": "Diluted net loss per common stock", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r108", "r126", "r127", "r128", "r129", "r130", "r131", "r138", "r142", "r143", "r144", "r146", "r252", "r256", "r270", "r271", "r341", "r355", "r452" } }, "GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones": { "xbrltype": "perShareItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Diluted net loss per common stock", "documentation": "Earnings per share diluted including warrants and performance milestones." } } }, "auth_ref": { }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": { "r19", "r20", "r145" } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-

term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r576" } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": { "r498" } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r494" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Entity Domain", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { } }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r494" } }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": { "r511" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r494" } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r508" } }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": { } }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": { "r506" } }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": { } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r494" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r494" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r494" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r494" } }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { } }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": { "r509" } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Entity Equity Component Domain", "documentation": "Indicate the domain of the equity component." } } }, "auth_ref": { } }

"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, {"lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r9", "r86", "r103", "r104", "r105", "r121", "r122", "r123", "r125", "r130", "r132", "r134", "r148", "r186", "r187", "r196", "r238", "r247", "r248", "r249", "r250", "r251", "r253", "r255", "r256", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r278", "r280", "r281", "r282", "r283", "r284", "r288", "r289", "r302", "r351", "r358", "r359", "r360", "r373", "r433" } }, "GCTK_ExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ExchangeAgreementMember", "presentation": {
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "Exchange Agreement [Member]" }, "documentation": "Exchange Agreement [Member]" } } }, "auth_ref": { }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": { "http://glucotrack.com/role/Cover" }, {"lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": { }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": {
"http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetails" }, {"lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r230", "r235", "r268", "r276", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r352", "r458", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r479", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r541", "r542", "r543", "r544", "r568", "r570", "r571", "r572", "r573", "r574" } } }, "GCTK_FinancingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "FinancingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, {"lang": { "en-us": { "role": { "negatedLabel": "Finance income, net", "documentation": "Financing income expense net." }, "label": "FinancingIncomeExpenseNet" } } }, "auth_ref": { }, "GCTK_FirstWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "FirstWarrantMember", "presentation": {
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "First Warrant [Member]", "documentation": "First Warrant [Member]" } } }, "auth_ref": { }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, {"lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r57", "r418" } }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": { }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": { }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": {
"http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "label": "Changes in assets and liabilities." } } }, "auth_ref": { } }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": {
"http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": { "r526" } }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": {
"http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": { "r526" } }, "GCTK_IntellectualPropertyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "IntellectualPropertyPurchaseAgreementMember", "presentation": {
"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "Intellectual Property Purchase Agreement [Member]", "documentation": "Intellectual Property Purchase Agreement [Member]" } } }, "auth_ref": { }, "us-gaap_InterestPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "label": "(a) Net cash paid during the year for", "documentation": "InterestPaidNet", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r111", "r113", "r114" } }, "GCTK_IsraeliInnovationAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "IsraeliInnovationAuthorityMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "Israeli Innovation Authority [Member]", "documentation": "Israeli Innovation Authority [Member]" } } }, "auth_ref": { }, "GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors", "crdr": "debit", "calculation": {
"http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": { "en-us": { "role": { "verboseLabel": "Issuance of restricted shares as compensation towards directors", "documentation": "Issuance of restricted shares as compensation to the board of directors." }, "label": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" } } }, "auth_ref": { }, "us-gaap_LeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAgreementsMember", "presentation": {
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "Lease Agreements [Member]", "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset." } } }, "auth_ref": { "r27", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554" } }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": {
"http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": { "r301", "r513" } }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactionsTables" }, {"lang": { "en-us": { "role": { "label": "SCHEDULE OF OPERATING LEASE", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": { "r580" } }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": { }, "GCTK_LessThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "LessThanOneYearMember", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": { "en-us": { "role": { "label": "Less Than One Year [Member]", "documentation": "Less Than One Year [Member]" } } }, "auth_ref": { }, "us-

gaap-LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r294", "r301" } }, "us-gaap-LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": { "r294", "r301" } }, "us-gaap-LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": { "r293" } }, "GCTK-LesseeOperatingLeaseLiabilityImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "LesseeOperatingLeaseLiabilityImputedInterest", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "documentation": "Lessee operating lease liability imputed interest", "label": "LesseeOperatingLeaseLiabilityImputedInterest" } } }, "auth_ref": { "r293" } }, "us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactionsTables": { "lang": { "en-us": { "role": { "label": "SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": { "r581" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Total operating lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r299" } }, "us-gaap-LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Lessee term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r579" } }, "us-gaap-Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r12", "r38", "r39", "r40", "r42", "r43", "r44", "r45", "r118", "r185", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r259", "r260", "r261", "r277", "r393", "r453", "r491", "r563", "r582", "r583" } }, "us-gaap-LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r53", "r76", "r348", "r478", "r530", "r545", "r575" } }, "us-gaap-LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "auth_ref": { "r53" } }, "us-gaap-LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r40", "r89", "r118", "r185", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r259", "r260", "r261", "r277", "r478", "r563", "r582", "r583" } }, "us-gaap-LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": { "r40" } }, "us-gaap-LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetails": { "lang": { "en-us": { "role": { "label": "Fair value at Closing Date", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": { "r272", "r569" } }, "us-gaap-LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "auth_ref": { "r40" } }, "GCTK-LinkageDifferenceOnPrincipalOfLoansFromStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "LinkageDifferenceOnPrincipalOfLoansFromStockholders", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Linkage difference on principal of loans from stockholders", "documentation": "Linkage difference on principal of loans from stockholders." } } }, "auth_ref": { "r40" } }, "dei-LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "r40" } }, "GCTK-LockUpPeriodDescription": { "xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "LockUpPeriodDescription", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Lock-up period conditions", "documentation": "Lock up period description." } } }, "auth_ref": { "r40" } }, "us-gaap-LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r199", "r200", "r201", "r204", "r245", "r459", "r561", "r562" } }, "us-gaap-LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": { "r199", "r200", "r201", "r204", "r245", "r459", "r561", "r562" } }, "GCTK-MarketabilityDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "MarketabilityDiscountRate", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Marketability discount rate" } } }, "auth_ref": { "r40" } }, "us-gaap-MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketingExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "label": "Marketing expenses", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } }, "auth_ref": { "r57" } }, "srt-MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": { "r200", "r201", "r202", "r203", "r240", "r245", "r275", "r337", "r356", "r357", "r364", "r385", "r386", "r436", "r437", "r438", "r439", "r440", "r447", "r448", "r457", "r465", "r466", "r469", "r470", "r474", "r475", "r480", "r565", "r584", "r585", "r586", "r587", "r588", "r589" } }, "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": { "r200", "r201", "r202", "r203", "r240", "r245", "r275", "r337", "r356", "r357", "r364", "r385", "r386", "r436", "r437", "r438", "r439", "r440", "r447", "r448", "r457", "r465", "r466", "r469", "r470", "r474", "r480", "r565", "r584", "r585", "r586", "r587", "r588", "r589" } }, "GCTK-ModificationOfEquityClassifiedContractsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ModificationOfEquityClassifiedContractsPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Modification of equity-classified contracts", "documentation": "Modification Of Equity Classified Contracts [Policy Text Block]" } } }, "auth_ref": { "r40" } }, "GCTK-MoreThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "MoreThanTwoYearsMember", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "label": "More Than 2 Years [Member]", "documentation": "More Than 2 Years [Member]" } } }, "auth_ref": { "r40" } }, "us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",


```

"weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r112" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r112" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r59", "r60", "r61" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": { } }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "http://glucotrack.com/role/StatementsOfCashFlows", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "negatedTotalLabel": "Net Loss", "label": "Loss for the period", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r56", "r61", "r77", "r87", "r98", "r101", "r105", "r118", "r124", "r126", "r127", "r128", "r129", "r130", "r133", "r134", "r140", "r185", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r252", "r256", "r271", "r277", "r350", "r415", "r431", "r432", "r489", "r563" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" }, "lang": { "en-us": { "role": { "negatedTotalLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": { "r109", "r126", "r127", "r128", "r129", "r135", "r136", "r141", "r144", "r256" } }, "def_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/def/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": { } }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "(b) Non-cash investment and financing activities:" } } }, "auth_ref": { } }, "GCTK_NoteAndWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "NoteAndWarrantMember", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Note And Warrant [Member]", "documentation": "Note And Warrant [Member]" } } }, "auth_ref": { } }, "GCTK_NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "NotesMember", "presentation": { "http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetails": { "lang": { "en-us": { "role": { "label": "Notes [Member]", "documentation": "Notes [Member]" } } }, "auth_ref": { } }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets" }, "lang": { "en-us": { "role": { "label": "Notes payable (Note 3F)", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": { "r38", "r39" } }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": { } }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "negatedTotalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r78", "r454", "r536", "r537", "r538", "r539", "r540" } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Recognition of right for usage asset against a lease liability (Note 3C)", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": { "r295", "r477" } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Present value of lease liabilities", "verboseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r291" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" }, "lang": { "en-us": { "role": { "label": "Operating lease liability, current (Note 3F)", "verboseLabel": "Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r291" } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" }, "lang": { "en-us": { "role": { "label": "Operating lease liability, non-current (Note 3F)", "verboseLabel": "Non-Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r291" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": {
```

"http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails", "lang": { "en-us": { "role": { "label": "Operating lease right of use asset, net (Note 3C)", "verboseLabel": "Operating right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r290" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails", "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r298", "r477" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails", "lang": { "en-us": { "role": { "label": "Lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r297", "r477" }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": { "r36", "r70", "r365", "r366" }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": { "r96", "r478" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2", "r351" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": { "en-us": { "role": { "label": "Other comprehensive income", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r9", "r11", "r99", "r102", "r106", "r130", "r278", "r279", "r284", "r339", "r351", "r523", "r524" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "label": "Other comprehensive income." } } }, "auth_ref": { "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r39", "r478" }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Loans from stockholders", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r43" }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": { "http://glucotrack.com/role/Cover", "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17i or Item 18i specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": { "r505" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth_ref": { "r566" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r58" }, "GCTK_PercentageOfFairValueDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "PercentageOfFairValueDiscountRate", "presentation": { "http://glucotrack.com/role/ScheduleOfFairValueOfIdentifiedComponentsDetailsParenteticals", "lang": { "en-us": { "role": { "label": "feustom:PercentageOfFairValueDiscountRate-01", "documentation": "Percentage of fair value discount rate." } } }, "auth_ref": { "GCTK_PerformanceMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "PerformanceMilestoneMember", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "lang": { "en-us": { "role": { "label": "Performance Milestone [Member]", "documentation": "Performance Milestone [Member]" } } }, "auth_ref": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": { "http://glucotrack.com/role/Cover", "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": { "r499" }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": { "http://glucotrack.com/role/Cover", "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": { "r501" }, "GCTK_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Prefunded Warrants [Member]", "documentation": "Prefunded warrants member." } } }, "auth_ref": { "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": { "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Net proceeds", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": { "r110" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": { "r3" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Proceeds received from private placement transaction (Note 3D)", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": { "r3" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit",

"calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Issuance of notes and warrants through private placement transaction (Note 3F)", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": { "r3" } }, "GCTK_ProceedsReceivedFromUnderwrittenPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ProceedsReceivedFromUnderwrittenPublicOffering", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Net proceeds received from underwritten U.S. public offering", "documentation": "Proceeds received from underwritten public offering." } } }, "auth_ref": { "r1" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r6", "r300", "r342", "r349", "r478" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": { "r200", "r201", "r202", "r203", "r239", "r240", "r242", "r243", "r244", "r245", "r275", "r312", "r321", "r337", "r356", "r357", "r364", "r385", "r386", "r436", "r437", "r438", "r439", "r440", "r447", "r448", "r457", "r465", "r466", "r469", "r470", "r474", "r475", "r480", "r483", "r559", "r565", "r571", "r585", "r586", "r587", "r588", "r589" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Receipts on account of shares", "documentation": "Receipts on account of shares." } } }, "auth_ref": { "r200", "r201", "r202", "r203", "r239", "r240", "r242", "r243", "r244", "r245", "r275", "r312", "r321", "r337", "r356", "r357", "r364", "r385", "r386", "r436", "r437", "r438", "r439", "r440", "r447", "r448", "r457", "r465", "r466", "r469", "r470", "r474", "r475", "r480", "r483", "r559", "r565", "r571", "r585", "r586", "r587", "r588", "r589" } }, "GCTK_ReceiptsOnAccountOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ReceiptsOnAccountOfShares", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Receipts on account of shares", "documentation": "Receipts on account of shares." } } }, "auth_ref": { "r1" } }, "GCTK_ReceiptsOnAccountOfSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ReceiptsOnAccountOfSharesMember", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Receipts on Account of Shares [Member]", "documentation": "Receipts on Account of Shares [Member]" } } }, "auth_ref": { "r1" } }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r246", "r449", "r455", "r590" } }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r80", "r521", "r527" } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "http://glucotrack.com/role/GeneralDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r50", "r67", "r347", "r361", "r363", "r372", "r396", "r478" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r86", "r121", "r122", "r123", "r125", "r130", "r132", "r134", "r186", "r187", "r196", "r247", "r248", "r249", "r250", "r251", "r253", "r255", "r256", "r262", "r264", "r265", "r267", "r269", "r288", "r289", "r358", "r360", "r373", "r593" } }, "GCTK_RoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "RoyaltyPercentage", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Royalty percentage maximum", "documentation": "Royalty percentage." } } }, "auth_ref": { "r1" } }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Sale of stock description of transaction", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": { "r8", "r30", "r71" } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": { "r1" } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Sale of stock issued price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": { "r1" } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables": { "lang": { "en-us": { "role": { "label": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": { "r19" } }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r257" } }, "GCTK_ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ScheduleOfFairValueOfTheIdentifiedComponentsTableTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactionsTables": { "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE OF THE IDENTIFIED COMPONENTS", "documentation": "Schedule Of Fair Value Of The Identified Components [Table Text Block]" } } }, "auth_ref": { "r1" } }, "GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactionsTables": { "lang": { "en-us": { "role": { "label": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE", "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block]" } } }, "auth_ref": { "r1" } }, "GCTK_SecondWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "SecondWarrantMember", "presentation": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Second Warrant [Member]", "documentation": "Second Warrant [Member]" } } }, "auth_ref": { "r1" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r493" } }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": { "r497" } }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": {

"en-us": { "role": { "label": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } }, "auth_ref": { "r521" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r496" } }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": { "r502" } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r4" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://glucotrack.com/role/ScheduleOffFairValueOfIdentifiedComponentsDetailsParenteticals": { "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": { "r242" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://glucotrack.com/role/ScheduleOffFairValueOfIdentifiedComponentsDetailsParenteticals": { "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { "r244" } }, "us-gaap_SharePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": { "r1" } }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": { "r1" } }, "us-gaap_ShortTermDebtDescription": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtDescription", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Notes payable description", "documentation": "Description of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant." } } }, "auth_ref": { "r522" } }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": { "r38", "r556", "r557", "r558" } }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": { "r37", "r556", "r557", "r558" } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r62", "r116" } }, "GCTK_SignificantTransactionsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://glucotrack.com/20240630", "localname": "SignificantTransactionsTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactions": { "lang": { "en-us": { "role": { "label": "SIGNIFICANT TRANSACTIONS", "documentation": "Significant Transactions [Text Block]" } } }, "auth_ref": { "r1" } }, "dei_SolicitingMaterial": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": { "r500" } }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r85", "r92", "r93", "r94", "r118", "r138", "r139", "r142", "r144", "r149", "r150", "r185", "r205", "r207", "r208", "r209", "r212", "r213", "r231", "r232", "r233", "r234", "r236", "r277", "r368", "r369", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r395", "r416", "r433", "r441", "r442", "r443", "r444", "r445", "r512", "r528", "r535" } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r9", "r47", "r51", "r52", "r86", "r103", "r104", "r105", "r121", "r122", "r123", "r125", "r130", "r132", "r134", "r148", "r186", "r187", "r196", "r238", "r247", "r248", "r249", "r250", "r251", "r253", "r255", "r256", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r278", "r280", "r281", "r282", "r283", "r284", "r288", "r289", "r302", "r351", "r358", "r359", "r360", "r373", "r433" } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r121", "r122", "r123", "r148", "r289", "r338", "r367", "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r395", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r433", "r484" } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { "r1" } }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { "r1" } }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": { "r1" } }, "us-gaap_StatementTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r121", "r122", "r123", "r148", "r154", "r289", "r338", "r367", "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r395", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r433", "r484" } }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Exchange of warrants into shares, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": { "r9", "r25", "r47", "r51", "r67", "r224" } }, "GCTK_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoShares": { "xbrltype": "monetaryItem", "nsuri": "http://glucotrack.com/20240630", "localname": "StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoShares", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Exercise of prefunded warrants into shares, shares", "documentation": "Exercise of prefunded warrants into shares, shares." } } }, "auth_ref": { "r1" } }, "GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b":

f {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement, shares", "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement, shares"} }}, "auth_ref": {"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues"}, "presentation": {"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Issuance of common stock upon private placement transactions, shares", "verboseLabel": "Number of shares issued", "terseLabel": "Number of common shares issued", "documentation": "Number of new stock issued during the period." } }}, "auth_ref": {"r9", "r46", "r47", "r67", "r368", "r433", "r442"} }}, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of restricted shares as compensation towards directors, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } }}, "auth_ref": {"r9", "r67"} }}, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of shares as compensation to the board of directors, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."} }}, "auth_ref": {"r9", "r46", "r47", "r67"} }}, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Pre-funded warrants", "documentation": "Number of share options (or share units) exercised during the current period." } }}, "auth_ref": {"r9", "r46", "r47", "r67", "r241"} }}, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Exchange of warrants into shares (Note 3B)", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } }}, "auth_ref": {"r9", "r47", "r51", "r52", "r67"} }}, "GCTK_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrantsIntoShares": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "StockIssuedDuringPeriodValueExerciseOfPrefundedWarrantsIntoShares", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Exercise of prefunded warrants into shares (Note 3A)", "documentation": "Exercise of prefunded warrants into shares." } }}, "auth_ref": {"}}}, "GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B)", "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement." } }}, "auth_ref": {"}}}, "GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "StockIssuedDuringPeriodValueIssuanceOfWarrant", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of warrants through private placement transaction (Note 3F)", "documentation": "Stock issued during period value issuance of warrant"} }}, "auth_ref": {"}}}, "us-gaap_StockIssuedDuringPeriodValueNewIssues": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of Common Stock upon private placement transaction (Note 3D)", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } }}, "auth_ref": {"r9", "r46", "r47", "r67", "r373", "r433", "r442", "r490"} }}, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of restricted shares as compensation towards directors", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } }}, "auth_ref": {"r9", "r46", "r47", "r67"} }}, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."} }}, "auth_ref": {"r26", "r46", "r47", "r67"} }}, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Issuance of restricted shares as compensation towards directors", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."} }}, "auth_ref": {"}}}, "GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Restricted shares to be issued as compensation towards directors", "documentation": "Stock to be issued during period value restricted stock award gross." } }}, "auth_ref": {"}}}, "us-gaap_StockholdersEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": {"http://glucotrack.com/role/BalanceSheets": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 }}, "presentation": {"http://glucotrack.com/role/BalanceSheets": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Total stockholdersu2019 equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } }}, "auth_ref": {"r47", "r51", "r52", "r64", "r397", "r413", "r434", "r435", "r478", "r491", "r530", "r545", "r575", "r593"} }}, "us-gaap_StockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": {"http://glucotrack.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"label": "Stockholdersu2019 equity"} }}, "auth_ref": {"}}}, "us-gaap_StockholdersEquityReverseStockSplit": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } }}, "auth_ref": {"r68"} }}, "us-gaap_SubsequentEventLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } }}, "auth_ref": {"r285", "r304"} }}, "us-gaap_SubsequentEventMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }}, "auth_ref": {"r285", "r304"} }}, "us-gaap_SubsequentEventTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } }}, "auth_ref": {"r285", "r304"} }}, "us-gaap_SubsequentEventTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }}, "auth_ref": {"r285", "r304"} }}, "us-gaap_SubsequentEventTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"http://glucotrack.com/role/SubsequentEventsDetailsNarrative": {"lang": {"en-us": {"role":

{ "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": { "r285", "r304" } }, "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": { } }, "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsTextBlock", "presentation": { "http://glucotrack.com/role/SubsequentEvents" }, "lang": { "en-us": { "role": { "label":
"SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date
through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale
of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to
insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": { "r303", "r305" } }, "us-gaap-SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative",
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]",
"documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": { } }, "us-gaap-SupplementalCashFlowInformationAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": {
"http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow activities." } } },
"auth_ref": { } }, "GCTK-ThirdWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname":
"ThirdWarrantMember", "presentation": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, "lang": { "en-us": { "role": { "label":
"Third Warrant [Member]", "documentation": "Third Warrant [Member]" } } }, "auth_ref": { } }, "dei-TradingSymbol": { "xbrltype":
"tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": {
"http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as
listed on an exchange." } } }, "auth_ref": { } }, "us-gaap-TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": {
"http://glucotrack.com/role/ScheduleOffFairValueOfIdentifiedComponentsDetails" }, "lang": { "en-us": { "role": { "documentation": "Instrument or
contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on
potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial
instruments on potentially favorable terms." } } }, "auth_ref": { "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164",
"r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183",
"r184", "r230", "r235", "r268", "r276", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319",
"r320", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r352", "r467", "r468",
"r469", "r470", "r471", "r472", "r473", "r474", "r475", "r479", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r541", "r542", "r543", "r544",
"r568", "r570", "r571", "r572", "r573", "r574" } }, "GCTK-TrueupSharesMember": { "xbrltype": "domainItemType", "nsuri":
"http://glucotrack.com/20240630", "localname": "TrueupSharesMember", "presentation": {
"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Trueup Shares
[Member]", "documentation": "Trueup Shares [Member]" } } }, "auth_ref": { } }, "us-gaap-TypeOfArrangementAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": {
"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/GeneralDetailsNarrative",
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, "lang": {
"en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by
collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": {
"r257" } }, "GCTK-UnsecuredPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname":
"UnsecuredPromissoryNotesMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": {
"role": { "label": "Unsecured Promissory Notes [Member]", "documentation": "Unsecured Promissory Notes [Member]" } } }, "auth_ref": { } }, "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": {
"http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Use of Estimates in the
Preparation of Financial Statements", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial
statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r21", "r22", "r23", "r81", "r82", "r83", "r84" } }, "us-gaap-WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": {
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation":
"Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a
specified amount." } } }, "auth_ref": { "r481", "r482", "r485", "r486", "r487", "r488" } }, "GCTK-WarrantsAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname": "WarrantsAgreementMember", "presentation": {
"http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, "lang": { "en-us": { "role":
"label": "Warrants Agreement [Member]", "documentation": "Warrants Agreement [Member]" } } }, "auth_ref": { } }, "us-gaap-WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingTerm", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us":
"role": { "label": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying
unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in
PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": {
"r570", "r571", "r572" } }, "GCTK-WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240630", "localname":
"WarrantsMember", "presentation": { "http://glucotrack.com/role/ScheduleOffFairValueOfIdentifiedComponentsDetails" }, "lang": { "en-us": {
"role": { "label": "Warrants [Member]", "documentation": "Warrants [Member]" } } }, "auth_ref": { } }, "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": {
"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "label": "Weighted average number of
common stock outstanding used in computing diluted net loss per share", "verboseLabel": "Weighted average number of Common Stock
outstanding used in computing diluted net loss per share", "documentation": "The average number of shares or units issued and outstanding that
are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } },
"auth_ref": { "r137", "r144" } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": {
"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "label": "Weighted average number of
common stock outstanding used in computing basic net loss per share", "verboseLabel": "Weighted average number of Common Stock outstanding
used in computing basic net loss per share", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable
shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that
common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r135", "r144" } }, "us-gaap-WeightedAverageNumberOfSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesRestrictedStock", "presentation": {
"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Restricted shares",
"documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares
have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that
prevent or inhibit the holder from freely disposing of them before the restriction ends." } } }, "auth_ref": { "r18" } }, "dei-WrittenCommunications": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": {
"http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true
when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the
Securities Act." } } }, "auth_ref": { "r510" } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/21474827401/830-230-45-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification, "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482099/360-10-50-1](\"https://asc.fasb.org/1943274/2147482099/360-10-50-1\")", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481203/810-10-50-1A](\"https://asc.fasb.org/1943274/2147481203/810-10-50-1A\")", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481203/810-10-50-1B](\"https://asc.fasb.org/1943274/2147481203/810-10-50-1B\")", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480434/815-10-50-2](\"https://asc.fasb.org/1943274/2147480434/815-10-50-2\")", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482739/220-10-55-15](\"https://asc.fasb.org/1943274/2147482739/220-10-55-15\")", "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480566/210-10-S99-1](\"https://asc.fasb.org/1943274/2147480566/210-10-S99-1\")", "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482790/220-10-45-14](\"https://asc.fasb.org/1943274/2147482790/220-10-45-14\")", "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482790/220-10-45-14A](\"https://asc.fasb.org/1943274/2147482790/220-10-45-14A\")", "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482790/220-10-45-5](\"https://asc.fasb.org/1943274/2147482790/220-10-45-5\")", "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482740/230-10-45-4](\"https://asc.fasb.org/1943274/2147482740/230-10-45-4\")", "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482913/230-10-50-1](\"https://asc.fasb.org/1943274/2147482913/230-10-50-1\")", "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482689/260-10-45-13](\"https://asc.fasb.org/1943274/2147482689/260-10-45-13\")", "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482662/260-10-50-1](\"https://asc.fasb.org/1943274/2147482662/260-10-50-1\")", "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482662/260-10-50-2](\"https://asc.fasb.org/1943274/2147482662/260-10-50-2\")", "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-4](\"https://asc.fasb.org/1943274/2147482861/275-10-50-4\")", "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-8](\"https://asc.fasb.org/1943274/2147482861/275-10-50-8\")", "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482861/275-10-50-9](\"https://asc.fasb.org/1943274/2147482861/275-10-50-9\")", "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482099/360-10-50-1](\"https://asc.fasb.org/1943274/2147482099/360-10-50-1\")", "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481112/505-10-50-3](\"https://asc.fasb.org/1943274/2147481112/505-10-50-3\")", "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480429/718-10-50-2](\"https://asc.fasb.org/1943274/2147480429/718-10-50-2\")", "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479876/805-20-55-31](\"https://asc.fasb.org/1943274/2147479876/805-20-55-31\")", "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "805", "SubTopic": "20", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479668/805-30-25-6](\"https://asc.fasb.org/1943274/2147479668/805-30-25-6\")", "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481203/810-10-50-1](\"https://asc.fasb.org/1943274/2147481203/810-10-50-1\")", "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481203/810-10-50-1A](\"https://asc.fasb.org/1943274/2147481203/810-10-50-1A\")", "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480434/8](\"https://asc.fasb.org/1943274/2147480434/815-10-50-1\")

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB",

"URI": "[https://asc.fasb.org/1943274/2147481326/860-20-50-4-1](\"https://asc.fasb.org/1943274/2147481326/860-20-50-4-1\")", "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":

"860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher":

"FASB", "URI": "[https://asc.fasb.org/1943274/2147481326/860-20-50-4-1](\"https://asc.fasb.org/1943274/2147481326/860-20-50-4-1\")", "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef"

"Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI":

"[https://asc.fasb.org/1943274/214749532/912-730-25-1-1](\"https://asc.fasb.org/1943274/214749532/912-730-25-1-1\")", "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",

"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",

"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/214747877/944-210-S99-1-1](\"https://asc.fasb.org/1943274/214747877/944-210-S99-1-1\")", "r592": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section":

"45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478009/946-205-45-4-1](\"https://asc.fasb.org/1943274/2147478009/946-205-45-4-1\")", "r593": {

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":

"[https://asc.fasb.org/1943274/2147479134/946-220-S99-3-1](\"https://asc.fasb.org/1943274/2147479134/946-220-S99-3-1\")", "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))",

"Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479134/946-220-S99-3-1-1-1](\"https://asc.fasb.org/1943274/2147479134/946-220-S99-3-1-1-1\")" ZIP 44 0001493152-24-031610-xbrl.zip IDEA XBRL

DOCUMENT begin 644 0001493152-24-031610-xbrl.zip M4SLHJL@+Y#5D8VQV@< &4J *97 @ S,2T0^EAT>U:77/B MAIHTS @t.L JD\$R? ?

HIOH.R2073HI2FWTWTA4M@OJ:(NU: CH3U7 L I M B&HSW.Y%=@ TJZNCXGWB/AICOFEO.UU~UW_6f/P R ^FO_ NRWG7TDH MK66/VY?

#W@= V8W^XI/I4I508 UFC/HN9+0.AV958/L \$=>&BE ROY/R+I5 = - O.M3<2VIH AY-Q ADII + Q5U PL =>QUHF" , # 158RH9ITV^-Q"SSGE_Q \N:N==

M>S^IM2PDGS?ONUOV#\$&J=N>OU5! .+PIPTR37L M79 -=I .?CP.VP.H.# K<20^M>O>VS/KGA-A>L/>QB?7I7C1O6+h6 JPHO<Q_R.I:S5TZ_P.B

6-IUBDHOG/GKNE^LL MF\$SI219>>=QAHD5XZI.S.Z? _ Z3C .#JI4<5>L5<-KW=[O?SZSR5XL MHUM^5U,UMLK?)7A5<3ZZ:8SH9JDNNV45(\$P)RBX'

JISILTI6F=MV M+l Pz H2GLHO4+ D8 J E F Z M : BG21 T I & H 2 M & A EO IN IM = K 4 M 3 I 8 X XI ! ~ 5 RP M 2 RE 6 ~ 7 TR MU Y CYP , # OE f o _ 4 U ; , @ N 5 i 2 @ 3 ?

57YJD(9H)V-F-RN353H8OW/M/R+A *DLPL/KHA/F/O/243141-VXM @B=P-U9YO/U@W>EK4IE.CH?IIFFSUITLM?

K3WE3WC&NN/EON6I#94^U^XSU#31^VK^X^ZD.5) AS&7(>+AD2LA-B6_Z MYKS^GE:H\$3F(B#666&Z/L/@5.16@B.8JM=L P"(ACM.:1DDP"?BL8HH^

>Y1.MCL'9OE5F&H.,DY20"\$S.WA"&GC&%E(I3)E.Z-J^Z.<(NS)\$A!(DOONRG.^MLL933%/#/A/\$7DUB&.SY\$(BX)L>8SGIA:6X_C MS\$(X^CV7(?

/P'.1CPP=/Z&L QR5%M0"B5EKOQE @ / F9/O^J(Q.O3.T&) M^ZECCBRP2.P IO)XS'^.-P/66^KQG8IVTDIE(CPV)>@3C=3O^&E5<*->SW9_M/R/85?

EN_-DL_OI.=1#IHFI4S@&6*A%(GR)2L^18CG8?"[9=CZYCI MP^2LI2 UE,S)^#RI 1^URMF^HJT(G:45B/ET^OI>!

MO'L#>l@HK)E=-."Us)S\+7C/KJO_H/OBI^6A:=>TOW_8I_V:3HIO,>P-M3&E~/46JO_WKWW)E2^OX(S(Z6^0^41.D!:G4MMDC6L1+CZH?W&*LV72T4D

M2^XHD2F")..RMK(SOOXF4#U^TJ7+4/h/H6SM7DG2I+62ITSQ^JFGI).6:I.E M&^<4AKO2

@1%"#72,"(G/J2)AGLE:E29IBUAFA(49OHTE&\$JHH+UP|SF MB5MI+Y_Y8/Q_U_IY 2-P.G=>"V.Q -(YI(EOC^MODX5D'MPC10ZD8A':@YH M4\$SREL?

IEO"1HM&UHKK? OH%URLQHBB6%;PKM73:A61+-O^MMDS(#.;XS6-MGX@O^LT'N_\$S(BV9OIJ3.H@T%O.4.M>*>f^COORILXA,>=>^8GV4OX'^2^

MG_{>=HM0+L3?<CAHO=RNWWOIT^#U0Z<I(A+%XDHLIN5Y6UEH.V/L @EHWS MC9?)EDDX\$%^+.G^AS@ HMJ'=2^5(-4)3^KJR<2^>;

(5 4-H'R2LE_LD&=>O MI&^VIUIHH>_,^3ZOGO\$>?*!!QAXAD7I99XYCORW.(I2=3X5)X=>_*ULHX7D MHQI@>'<=4QQ/_/+>M62^O:l5^=B^U9FH

<8>=>X_KKQFA_/Z/3%W(L8\$I"/_99 MJOL.%';,@4V)@P_0=MM,%0US@V*I&*= "&GS UT&00RCH5XH-Z %00;/75"C\$-2.@D

@Q83.9KNAN/85^5SDO:LKLJ^TG1>5% M2+(6D)=.70IYS<K'OQ^YY/X:&56^RC+I1%GG./VM>Y=L22QHUV2+YH.=M99>JSA609._?>|^+WZRIGP

PQC25^KNOPG>_0_A\$M.# MQP3Z@+QOI>+_B.DEF<3+4+6SIDW^_WW+VOO/KWLIC@?'IO:_W^+4JJ9I3

MS7HJND^GSIRREFLYN?@_.YR|>=>.>.>CK5>#RADUT72I47H!"I02P.\$%@_O8 -68EKIDRF:P.RH M H IE>#.Q+3(N:'TMf5I=<^+&GUUU?

Z""55)>_N\$ 7/D=8%OA0W>}>5K M^RIET7IQI9^2VQ^O^+Q5/A4E3>I1 MMPFP9.)UNQR-5.!#IMAL3L12Z^"@IAZN\$N9->X%@(MX)%ADI5:+I&?

DRKM-YM02TL9Q.DTKGW"LHU:I-KM=T_ZI=NEO7RW3GZ=R+I+VV@<=>C=V,P>PM&ZSYKG/JX^RC(MOV7#\$6N_#_:V/(^>o_oPOF^>_\$.NSIJ7-

AM> ML<, 3L^LY+B>]>ZO>GMW>]BH_X.Q/SIK9^P/RTBW=\$%IZ9_5OW^2MW_6.3A MI%f OP2B?

U_=2&H20PLIBLG#9<|=N?^RU,M SEDQYTGP&YHYUIRSNO< M_F7 ^OKNMGLYN^CW2Z5>=>WW5ZON^ZR?7DE.*5OY%'ANKV!5OU5^<SR.M

\$M_G:G1644W+H_B:8410<I[A=B6]^><J5OY^AXZXDM82IDS RH...Z&-4#=#/'/*KA71,.1AB_*JI%)8%jH6+E@P>Y>#-%Q6-MML^YLKH^J I5

@B^?OI(^1ROQ)!W_SMPFD MG311F=RSQ@>#7DUBE .SQ\$4BTLD>8\$G^4.6X COQX7GDNOI02@U^CPP=:ZF6IORM M^1>=%%%\$#J7A#@ @

@F9/Q^<j(Y.O3:U.@^5Y)BBR12(P+ IO)XS^3.V_P/66>MK_Z<+TLE)*CFESB3CTK^+9.<79P^DUNK^6!'54OG M_L9^Q40Y7D2EV85!X\$PN

FNR^OC#=3P^D8U_j^8F36(#B2064KEVT15 I M%.HK,*SX 3Q3<1K(N^4H2CNK?CXDWJA

MAKS3578IB=F&6!)Z_RMHC#%=DRIX3>0VFCHI>57TOIT8@O_IOM2^CRN MATKT#DTHDC4MV)#OJP3MT.KF^OQS_JUY

^HM8@T.3 7^OZAICPAK9WH_(M@4HC*\$!9G4EMBC6DI&CTTYC6>976T4L?&Y2(F<=>2UA>=INA AQ(E'I9HY4N7 MO);0LR.NY+\$DIV3&

```

MFECHQ@N/F"8BA17"3%MU;+H.AJ!0&7JYGVWU*4-?S1K7(8J@3@H8Q$P!>^HH>E$W>J.MA90QN/WLOX&B.O+UE;48E215ZF0*Y$Y/$?
K/N:D.1-1TTH16G^RRMRIM MPWT30<30GCH!>=>8/5X=PSNPQ@FW3+V=2(Q0"4GH*!@!#.9#0+9<^I<MSFWUYMG+/GBIS7W7?&HUTB
TY!8J&2=7ZPTD^?2UNJ"SAHBIGVZ-6UZA-M8-KUXMNGWJFLJ&7O<K%-%M.DN/O:6Y9SVY?=-7X@R)UEX6V;.(G+)(V?:
MJBZ)S!&F#22).:=W;Y<8-BWT+&"&5SA(BTUF^YJID.M<=1TP6!-B8.EDKA"%MN=SAU!69Q*W-
H1/CL+L.0!=D9Y1<Q)BODM+JDB#Y#>R.H011=T:3<M#JF%;G2JO.$8!+23D6?ZHCGEI/+UL:LT+7VB@7B/GA2M<C;P$>V!OA.JN88
MI>E/;QGSH(L8<3Q<%V+^I92BG#H+>P!6GBX>95<C#B!<^I#1P+D&CPO@M$JMR;N#N!D<@+U$Z.AYWLSL7A)IO:R?&SDP!&
FHGQ!<"/KPFH9R8NSD.M@X.#VYLEQ!/>V)MD;P!$J3XZG!G1SYHCZD^O)QI(1.CK=>?&A.O.WD.M!P!$Q!P8M9/C82=-4T9ZC*
C2F8B=KN7YUL.@K&S00!&BH*1A2A.#PEFH-.M@HDQ!0!&FH*QL$4/2T)DE&AUS?_248OY2!9S.$!<C%6MPQLB3"U)MLF8FID)!$UH-J2B<17-
24CHT1-3.8K%=-I?9T$SI>-7LVK.-I^D#)YZF-M=$!1$W1.O2^0$1-63;SHG#&4E(Z^1U7V1N5G/ZB(F5*1V.H=A.VJ=M/G:B:THG
434E(ZY9T$%&3J&F+)+14WV1C2.8.O/8&+C!1.KN<0$FNSV?3HJO.#MA=X$516K(Q!FBMLMC(6W*3$S.LM!L"Q%K$7AR+V/I
"6"6VG0G@<Z8.6!>R.K@<P.OY"MS!<14LFF&5#H1.2Z"3.OI^0B0T!$E.F4.C$!SHOMG6$&2=J<^?0'9G9$=1MLWA)/*#ATYPY.S0%3?55&B"?
Z(KS!S1SC3=Y@7R80=8=GH!V$Y9.)<^<QI&L"IZH?>R+1#Q0HQP?<L!98G/*(M(3.SCI.EYS!NCS-.C!Y2GBQ.A<MFLI/+?$#?+%-
H#LF<89+%">0HUBS#W7K&P-Y>$*#IB4!H5!>1^2T&D8.M.J2!QJ.RREHVBX5.$52!BT<M-L#T2MH82?M0#22CQ"V20#<1NB9-FBBLX5+
#&$<[S7).6"#D"E@O.$R'WM;+SKZ<*&MR)9)WSSP.S+!<H!$!>+2$QI#_BD9WMYX3^1$Y6-%&3%UW&+G3W%Z@2$
M4Y_9XV7T!R4=H3F4Z.3F!-2@C5-TY!5%YL9L!#W8"DW~ZW9J<A!>9.M6UW43&BFNQCO^KAVUS.ZE&Q>C6I!7Q!&R7AG=&8P1-
JW*Z=>M#I'K#B9.M2FID.YGV!<1N^F8AM6Y4S1E.WHD-5!&ZX21!>30-7X^N02G!QKNSK%MU2L!U56P$=1L.M!926!6Y@7XP3"O8H
&R^6*"(Z)N):AG$J&JY5??>MK9^B+9BT28IPT^IZ!PDTQZ.9_/S3/KAI.H*L%OCWM#A*ZSQO6U@!5.EK>:MA+!#K&J#%6GN<
R4#2=>X!Q4$0"U"NA@<GK10+M^V(EMBGJY.WOPXC*!%MPP.YZ2Z.U.A(BU$H49.5D737$>16!HUKHM%<K=3Q^02)0-3X.M+M!7Q!LPI2WBY5VF-
FEXIA6B=U!G8"U">(50K3>J^W!&HK@<X2@M.C!5$H#&1JWS!F.I027J68.43DIAM@AA.@6L#Q:"P#L.UYE-6MHS4H1.M.80JF>M37%
>)#J!#HB$03=L.EXH9W@N.O%>GW4I>EYZ.G>3.J!+!7Q.R!<TNZ!7R(KSQ^Y.PQ%<L.M(3!2U!3?>OKY+G!CYW^O#C!6RIA.Z.8/$L<C^#D^G#
!&K!<03!S!KK1P.H.M<IR#.5!&3!>4W0..Y2Y5?>05=S2+YVW#ECZ^I7UHN;H%&K+>OGS#X&2.M(F18&DV1%@!<
F2#R%T@!A>=)/(4.7XKYT$YB4+7EH00=(3V.41WK-3.M$(KN(SI@9YBZ4C.A.@+P9.E"2D#%>2+L!SSR&M.8J7)H4&=_9#AV
M9#6M"03!V1.$U!$&HYXL4TX#J00>)&8!&7!$<NC2Y;^?&3QTZ!>1$M.D#&#%>O/YLC45M0!HG#A5U!>."UIC(!DGGE-1R!7OK!3WP!O!
MT66"%<^F.G.2>9>:K!D6&.*DCB3WVW.L.7G^&43%GD!EYH!F=4!WNJM.MT"YSQWM19&N.WL^YWSHJYNP%EV!KY21>F)RX#T^?H!S/
M762G=1Q9CR#C.G=A#1!6H!864D*U0F5@P+>?RH5YK5RMGK7!787+!S=Y.MLS=2.M?
FC6VK5JQ4KS#5Q.*74OVR10=>W>U5J06!<=>+!PIO!B7!BT.MQ!KJ!&12F"X=ELHGC(9Y"W.WPWF&=GSA.1A00-D4Z1%3!IDHZ7=$E7"!
MI6@!$M!JY!L$1$=3KX4PYN!B27557U>^<=>JQM9%JYNX0V$(C.N9@Y:$JN=M52U!PFCYVW&C.=8RT^K0Q/1MAX=EY!_DEQZ.8Y-
C.HXY9BA!MM^Q$S8M.MI3&OYV3!Y?SY.Y!$=H.M1=7D5U3=ULTX"RKXR88Z&EK76JMW^$7/WQVITM%UKKX.ZOUC.CRJOUL.OK.M$A
URL!H!BCK>JFC!H1H1CHKY3.ZKVWR!1#DT#<=JZEL12LUVYMGT!13.MK.XWFFW.J9>BC5VTRIP4.CI.TM#883F$3X+OY=>XYH7ZDR<_MD;IN4
MREWT.U<4.DNJ&(X8.L>(<ZHCU!POF=EUJBCW#T25M6Y@.JP!8/Y.503GN+59
M@<J$DLOPNV;#3=PLZ8CPS!YJHB@<6U>3UBHJQ!T.M.E$<R59;EE/XD.M>LTC(DI2!A&>+!%L=C(C!H!6!5.2!>N43H<+576P.P*8;0.15DR(%2/
M!H!<8WH.D2OYX.FL$F=>#>DK<UQ!62#G(COQ27.IY^2M$5_8XKA.MM64.M.D.Y!UET4TOU2)9!>753(B;J2#O!Y2RI(T57NB.H!<@7/
MK2.*E.ZQDFD0L=INENJM&C)J;5Z2O82M5.C8JU.R4Q-5=17)#IK/P#6;KV.M'35ICNZ%0!5)%!<E.YU=*!B@!J!XR/OB9V%6?MH$N=*
!T7+M4>Y7W+!SO.O.M$AG.NKXB^W2@<1R2+2XS+OE^<R9J3V36D3.M2^A!V@<(COW!&K!QON^Y=<6BR>ISR!P0Q<19D!&M!6:S6?&^11N.U-/
YK+M9E!&?Y!>2&GN9-M'X%KX!D.Y!>UN29!8S2AUS@<2>Q08+!1Y.MZL$5.M'2Q2D!&6!XQ#<K!Z!>BT.CYU!69!PC<BND1@!<Q@<=G
JBI..C+ZH*!A.M!<D>88AH72M.Y+!H7K0M.7G4X404QG)KY5"RCG*CK%<^?H#3.Z!>IG0/M/$5K!E@!<+!8G!&2S)L@<^T.WC5M$
Y!T4<5!UN6X#A!E!Y&_9UE#(H&M.G.185<^YOZQ-C73<2%6FD60+!WK!<IOL&?GO:6^4^MIKI=B9!<+<0^5JSB_9/P2
W3PLFJ@NHYSM0X!9&5!<E9&H.N.52+<E!<M&H1!<ADW!V0Y#U&)<4!0!<13RN*!%(!'N=8TXK^XUS!AY.PD@<?&XTGWG!_MVF*_OI!>
(6Y.EWW3+!Q4!Y+2!<J^CZ?>S(1T<+<C/V5U!A.&#&X3!YH96A)O.&K!L@S<5X&2CPF.G2$MHTXO.PRF.WM.Y"
I^8X!O8G7G0?O7H3Z3D0^4Z8^!>Z$!3RP51*HBF+2WU.MX@<=A!<19S>UM^<RY.HK!D^A?TV24!0+NE.XD0=>P>B=3W"!1SAK".T.
M!0!<UWV^O7H.CU#A7M$457&G;X)OK*VBC"?>77>+!>YVVL^5+!<8.D.MICCG&U5F"J(SN.M%Z.C2(P.17Z^*122-?
5!>CR#R.#80UFL!9<@<JL&O.DYX94L"5.2B=Z.M!U=7NFC66.'ND5D#%<%(O.DYO.R%<E5Z!<X&IZ&S!<P!>PBI>-R2"83T.M4+!$*0!<8V=
T9W.H8@W<DE<7WJ!<HDSW%!)S!M.<LW7Z!A!J6B.7H(H23-1&F!HFRM^U.05WG.7-!T9>T&X($!SS?<O^"A^Q)T!HBM!<W$0A!W@W@>2W-
F8G!&4HTK.H8(XTG.IBBU1%14)5U!<4Q.2W+M=JOM!>9R>F=>BFLG./!<L.S.K514!UT&N0J6+G75D!>BC!B0T.264XHf>M#2>TJ?>
!H
```


MA3Z?ROZ7XU0^4Q\W+H*9MJY@Y%X\I6:GV;3WJ%+^0Q20W/I0*%[*IC2I^Z^GPP478D\$2H\$A6 M?>Z8&F
Y;X@1R#N3;2HG\QWYY%,\$\$Z\I\W&EIPIHGDFOWQ;C.N8VH>OX&I^1ZW>8XH^R9J6&93Z\$SFA=N\ MJE IQCJ= \H\I3 002;.(?D#S^I\Q\I8 _KZFO>
MZF" IPTGZV&<0W?&*G1(KY^G3>IU&CZVRX=5X.W-HI^KM;D1N?L^K)I^!#L7R-MN^H=)%864;LTK-J^JS^?1+@N\IHJZ7C5%L-NS^8S\=I>
<4XZ;A6FTL^<9 65+>J\B5YU+G64\$Z?@0>^>\$>Q03T WRZY+Z MI<9D090)5Y^.;.OD/NE\$=^U\I4+^0XZ;3F5I2^=*G&?2>^HC1ZJJA+Z@UU
MG0\$7IC^M\JBB5+Z13Z6^4AYT.N<H KI?2EU2OUU\I\UJOET#>@WWKXSX+I^% MNL;=N%H^#?15^UWJQO&?>91?>9<640T^IRJJA+Z<JH;LLK
M03JK\JZLV7VA(KK=03(334916=%U(S+KDS^=N&.F^*0BPRNRIV^7LB7G^0M MJ-FFE\I\EP>5F0-M63U?Z2^FKR8F5^M%)<=>KCI^F
^IY+I\V4JW(QI4I M84\$TN+%)J\3HXE66^15-L0;3@3G1^R\JD7+J\H\W42)8@W\&P%;=C%AP0-MQL?I-W#POLAUM-3B7J9#90K9U%?O?
A8%H@OK<^<L^1YH&Y)T6\$+J%);X M;J> 3H(B5K9Y%T2^N^Z^O^T^IA MRLS>KY<@%HB\KLL^LN!;_%#>WDE ?K>I^GE?3;\$=YU&99Y
R-DB_P2RWNN M9=1+GN42?F^BBDQO&PYOJNA5T%P8H!% 8+I^X^TLO7SBEP-NBNN(OU&OJ&76<)>KFWU6
M; NW\$V02V6)1V^IBV;N;H\ /64;7W;G7)NZW24 M (MD>;\$S<Y@IWI^362 M?2@SFE\I^YQIENDHSYEFY+ MO8\$D0A_ F4;RE\$JWR4.LX7WPF)Y\$-
&A9;5DF?UX9_1@G7 MO1NJC; 16 M3^YR6;WP5+@^I^A??\$;W\H@9UG_XM@/SX^9?D)Y3+95/8D_IXS6I+QF2VG
MR\I=I87/19%=>S=M+);P5.EKD;2IKF\I/B6&1YX\K^HWSIGMT\I/P+7^TNT MJH^N1+GDK@00;P7/CZ>+&^=N%I\$*2+U@M6X^DA)0
I7AM^/N^76E=NTLM<955;_HH?I;7I>FJQGU^<67_I EFXFLW0(E>T\I.ZON*%;5%#+_FC*^;AUR^*MCV12%A_9+E913)Q53#D7GHO;
<<?>T^GM^I.S.M^K8I53D%Y6&I5ISGSIFFV MEU7^10HBHUQX_XK2A5^4W+L8E\$V.4-2KZQ1A^P2YVJOZV\ M_KI2U=>G\$SYFU;10A2I^>9PI
WGVGMMD;Q0QGM^JQI4;QO.S5_1R#0G8Q\$Z-M>F-E**Q\FBPY;LY&9Y7IW=7W16EA=39QMA9M(C(3S;RK9>W8>OWA
IGL@<(K4W3G(BNUBO.XA\;V=T^3I2_803\DS M84IY\N_3B0SE2B^9^D^*I/D\$S^*)_C@>\$D->GODLW^*KAX MTAH^H\I-VIA1
IPM0Q&X&I^F\$S\TSBR_&?2<K;U\I^<P12%\$8Z7S+I^EYMKJ+1_6L M^KMKANXH9E_ZY_Q&WXDT<@&@>^<0=V\N\3^C^"(0(4#H>T2/T+ KA8A=
M3V_IKD?TWX\^*_X\;SW62100DQI08PIHDM@&=OYCGPMWIZUYUPY>21WJHC;W6@VW^A7I05FM8?FHHV+6J74C^..05205PK M74C-
%GQQ6-VWFM^FWKHE^*WS\I^@*M;AQ^W>@^I^J/>3<21856JA\TY0J_MR&A;X\I7%D7)87TF_?@SX5ISL3JRB;)_ID."2F#V7V/MJ\$H;H8;ZW0+%
MTV\$;G-6^EYQJ3^GW;5GLO&=%S+NS/6D^W=XJ97^G#P_M_UNABG\I^4W\KHX2MO_2\I\T^>UVEFM7^JW;_H6;I\W^H\H;_#IX^DH-MJ;EH-B^*LI
M#N;JF3^NRA2&_Z0^7\$Q^XZ7-S7^M;^*Q38_ZI(W\I^T^&3D^N\NL.EOGD M4A^*190D^*39C5(I E+ =JRI_8P(60\$4&S;A/S9&\$^X+>E4^0.YIN2G
MGY)\^?3Y>J92V(JE\TQK\$US\I^PIPM0I890?F<IVFI5CN^EZ4DY4Z;8A^2 M^*)&LAVIC "<";^TW#Z PE_H\U;+>HV%;2W@-
>^%TR_2^ID#6^TQ_*5_0AG;3F78I\)/J0P;=R1< M93@C^9J#1E7;2I Q;XDZ+P3/AS<+>O-H#7B1/0 &;-HR^!\$N220^D%;Z@_I M^<
<^WE.VF\WIEW\&_I_ID^F88^5U_X/E^/I4\I^P+>4U0;Q;WZK);&;R6 M^*#1;Q0B5=XPI^J1A\ND3S;\$%B@P4HI@/<+N?#L<";8_&2LMYJ\$SP;M
^N_<""^Q^3BH\$N18Y\Y^AR7U^>7TP9^I^_>32A8&-W)GON5S0BSB7YR^XQOD;O MARE3SELT%P2^W9;#>7DAGW;E.ZDKSK^5&KORUKJKX?
9(<=0^Q^UE2HK\$ M65\$S9@TS_<R0LKK@M6&P^RG^AA2WO.L54(IU^8G98FOIA\$;KP15W9;^*O>M%SYQF2APZ4)7K20C)O.UV-EB7
HL^*I^JN+^>I74KF3>^#P2^D9 IV^W^ZUC MIREL&C;0HK0+4UP;P_U_6>=>FM%LPS79/G(=D#A>%(U3=(-.R4IE)2I MT^>4H4D2^+52+I
(H)E;C)I\RE^@>J^I^E W+>I\TJ2^"KT<S^ZAC+ZIC#L M<D;DAPK6P^R^;EN+ CTP465+P>PDU^X/Z2Y<^PS^#P3+>I\BN15+N)I^#PO>S MMU
WIN^J%\$O:618^8; &@(�#=@.IPGC>=D8ANZAE#(E1;5&HWO\<>DFF O M;FA7M7%7IB=XZ6_8^P\I2<#1T/M;Y%=CR7K21ZYT#^4H38VPOX-&
R+EC;8 MV(3I(HUDTIXM103=1^8Q4IDQHE\5@198\$;JVC2FM9_8DKW8;G^*7@I82 B MT Y\I5P?BE^%)U3;7^JZ_UV8=1HCAK\V2;8CVL6<8+I
(#8H\$M9@5HJG M^I^DZ\I&OF_XYNWU)\@601^5&BKA&UN5I8&-R@QP7=&4^AJH&\$(Q05H<-<= M\H<+>4QD^<+>1H40HML^L^&#_I5
NVE9%\$CSI;6R?=>;T&\$^<2@MT6U\< MAD^BK@SZ)I-S\^EP GZ/P9UREV2(I?>3I\&WNL=5;V50Q^#(PG@CL39C_<KGN4E \$67(*\$&(AI<+I2NIP
M^H\Q1A^49TRK_6HI^IV^L 26<=>OY\YAL^YVD)T8CIU0;IM2+^MH^4Y MJ^2IP^0C%I\I2 E@_R1^9<(QB)0^DY/AE-5;^<0%_L1^7I^G^H\$2N;ZD6
MC^<I^OT;H&D;I\X1\@0=FT0I5^>^<105F0^@T_IBC(^YTHU%>DLX77&^I+>C M;H;=2U^%JRN+9IVQHV
ZBRR8B#_BBM\6Z&S3^4C;I7^+Z<@TF^Y#^A# MGD>@@TB811^62NJI^% M+N@;%F-WJK<I.75M)G#=#33;I
^Q^YTR.K1I^%;<T&Z;5=I^I^NHWCK<7K1^<M+V3IHJFZ7=I^Z<^3RW@<9B1R^DM6E5\$BBM68^LJB^C8;P75E F L62P_MK;H8^
^O(XI=9D0F.98P^67+4K&93I<^" QM#3%T& M;VXL F706\$U.64@SZ^V4QVO)ZNF\B(%.)^F8P9.79BOS LD=L@P^R KP M5O6T
J\$2G>I^D6V+>Q34N^>E5DPI^B240)058I^9&M19.4 MW@65IG^H M?2^I^QL&2J1#^R=SL(TI^OKPC?UC;=+>^UJ@6X\H(57P_MF
T6@^A4Q9;4CBS=ID@HJLOH\$A2^3WVP%;09%W1_7U^C(I;=8B\T&2X;NB3(85;JH%5_P5%TZ.Y&G8_<I19R891^Y^I^M^B5+0_AIH(UV;LV@
LC5&68;M3R/D.M;^<FZ;W@ECW&CK;9(S^HYUV8I^M<1U1)^M_-W^D1W1W;I=I/8_GATCCZYG6^NIR>YX)P^WVC.CNB??)=I& M-ABRZQ9-
S3X I^>#8F3N9T^16\^<DWOI>3WGRH7K7I\WTH^I^U^V6 HAI^SORJX^I^TVL8 ML^G^HDTOTW(R^2%<=^#H;83^\$%-W/I+L^1;5=8
OL^*07F^@HE^*1+V01B MSO^\$Y\$K+>@2)H\T3^4PX#;I;L\$X9SA7^F;A=I5B\$AG^MJI^\$S^T\$0AHQ2D+C7#IA;I7#3_BB7Q.YGH3/IL;Y;C6.VB?
@6FHBRORUQ^ M27&Z(NRX^*39T^+5);I.LC2TZD07G7S^\$6T^0I\W\X-3%>Y+58^ M4^H^HT^F2^D\REX^&>Y3X3HFHJDC+?>
%9H&HGM@6AA(I^8MKG5F6;QM9ZEP8+^%G;98 M&J^+I^JBI^GZ_JAK_X\W\I^I^EJNX5^VU_HOQV/LKN&H\N&I^TLX;EQIMU^C=AI7Z33^
IT^I\UD(SI^E^KI^#^YV.M3&U5R^=SG>>2=9W?^?W.G2LW MJ7^+I^1P^SIO47I=I^DXGWIQU%3/RCU;F=4^*Q%#J\$IOS32U/COO9@8E//MP9PJ?
CIWPEO+H2^SQ&^&F@OPX(O&8N;I^?FEVOE9MJIWCV5I10M\@8I+I1VY7 M+I^P_2 L8_CJFRDQ)8\$2(IY2^XO8)JDETO&B;L^IQU76O;=RAN7#-
MIW.C0WAM3+S\$T^+I^7I^J4TH(608N\$EJL2MIW_YR32%I>E\I+V5%IH\I^E9^U^I^43>@+I5J^U M68R^&X^DRO;FV;I^Y;6&H
)SI%G^6JW<7%3W&F=2XZIZ76K5ZN=I%I52 MLOH_I_ZF;(+>-7A83;N4H MS7SSZ;I\ALBO\5ZMECZPU0\VF@R^I MT)3I;+9
@CI58PYV^K\IG IV7T2^2 QKP18;+I^X>GOBTG^DP&1&^&QB MF>OU_WYS=8;R;53^W;2I@2<ID+CJ7L+I^T4X^>N^K^6VJZR>2I6K.KY?
M8-W^LW5I^P^Q5C\$UXATC=X^Y(MH;=I^MGGHJ^> QSMST;0U;9^X89 M^8C^F\$T^G&^<#%2I6B16^I/140M_NASO\WIC^>I^PE;8^"<<#5&
I^*2LXG M9K^6@+>0^7=;T)NJA^LE11^Q^I^PT62%A5;S9IE48ELIQ>I^C@X?UWOJBW^> MXGQ?7-DQ;5>I^LHB;=>KIWBBDW8Y;5F
I=P5)BMM41R>B;6^<W;I?@K^K M-HZL^A+V1@VSD;O)2C(HIT^9_&I^&R6I\JC^E^>>3E^X^ZH7=I^>DSLK M&;=I^KT5S>@/I^I\W&3^3;P?
0F&L#=#>Q R&DBJL^T/QID;FN::T^<MxB_CN&5;676P1^I^HKS12;N\$3I^+U;Y^")J)I#@WS/I=Q>4YM6QSGM;>7-O/M30X^<^J)K%Q;Z_B2A;KV9.QF
12K=&#@>ZP_RIQ ML+>7WY6\$^>DVJZ62UA MJ<=>HBN^2+4NOFM^N5\$JERY^<6M^>ZDIF2IHE8ZK5W;SM\I^I680C M.NJ5I^%U^I^V1^<OBM^
IM^\$I1_3;2U^BYV^>S;L^K^<4E2I6AC>^&X>@RJ^<^%V M9 WKV(+>XO^YK8&L-W3RB\BFVYZ@4I9JZ<I^W>BOWZEM)A2E>=>0AFO4ZI75 M-
(+I^YV6X5)YDP_X8C3IF&EM;(+>T^O1G160ZT+690T(018DR)^+I69DP M=O#A;N7;@U;3/^1K\I^P^>A+>K;DRI07^I^VZ^?K2^=YY+^7EB&Z(0#
MKZ(L;I=1W25=QUR0\$7DDBD1^%>^<XLTMX\GV.GTG8B\I^U^V1%QV^O(I^I^JX MEHO^&YK15L4=N3^/RIE2I^E=U9<@+MH0R
M#I\$^C4W36@+9%Y9HQ702Q;QM>;8^JW.ERG2S;5%D67P3;&IQZ>2>I^<I^MJS>DK7(K+5;^%2AU^A^YV%
0\$;I9&=02_I^F^I^Q^>^8DPZ;E;ME;BV6 M\7K;G13-WZIU=9Q1S_Y69N^>3GP?5G4S^SR)ODI0F5IR80\$G-IU\$4S^HNI^V MO-
E3=48RM^N^SACMF^13;E^I^#&=&^XRN;781^\$TTNC^I^TOZH1 WLIHR%)F%;I^ROWNJ>
M&^5AUBS=DZ.S^T5RK^<^JM2.OV^<W=%N+I^U7I>OJ9;E6K17>09VJWHV91^ M\8I4J37+C9MZ2IHNM7;-05;QYICNT0CV/MO;DR M);<(F53XLM?
>TIGP^>IMT_I\B)I^>N+38I;B6X^4I^<1;2;I^V47@I^>3K^Q M\N72&L^>C@G^WJ&L\0^R^C7R3;^G;L^H07P;K;HWOUB^M^B=GDQ+@H5D9^<
MU)FTCN3B\8^>;.9.Y>IG+6XGRXEC_C^XW;T4>=W(I\$P5_N(7GEF^>R6\$Z MMWJ^WJCS+O9IAULI8_ZYJ31NU^60N>VYK\I6M%>
<=OORJ^V^IRU4&+ MA#PIU\$>LSN5R(FVIT/J9 M04I/S<^*YNI+(/#A-WIU6I06OIAVBM)BZX^F;YI_R&I3VZ^6BX@WI49M%8 M;=6C7.6)
88MQE_Y0FSK^>S^LINJS2^Y&HC^7K(29=IU;220@C769C8U(2;>=&-(QOQ75)W^M)GKF0 BT^I^IBBN_#0P.99KU<^>XW&HJIG MDZL^IS=5M.L;I^Y
23HV8.P(81&)^VO-2^EPPB6^4HPWV_6J4I^H M>+<IPD&C1\$Y02C4)E9FJ^>R M>^&D6^&B1JM6_22^#^I2>I+I^H^>X<=2E^Q M&^?Y2^2ABH
RQCH>+>5+I3B.@C^27P(I^DUJ);<I0S>U-T3E^0I^KH MJ58Y^<8^9.3<=>IUT^I^AGNNDYV;G+9\$@;S5EZ;0_/6#^FX;H\OXPZH MCGU^T;FU2P%B.8
<I^TX^Y<I^L%I^U7WAHA;AL821T\$B40^HINA=;B^ERQ M^D\$T^YV%>=^HG+I^I^IRJRS^I<@I&280D^>N&A^0^ID9WG&12W^<@F=XH7-I MX8&6I?<
ORY^7K=Z7IY^I=RH;P@>H^XD20F M^VNIHXE\HCCX+>B^BIE^=GPP7745HVO^T1;CH?X6^K&X^Z^H)W5^ERIE ML90YCF+5/56CB&C\I64^I2
^I^A9N)E6X2I^>5TUC2^R29 P^P^F3<=^PU0BM^ON+>VW8H&BL;5HV7UFEZ)W^W KIV#7= MLDT^00_#CI3H2VBFFER^#19
HN4L>I^>#K^<I^4NI&I^I^M@GOBW^S6I^K3 M\9ICURPMQ2YV7I93/SQ)1ZP\$Z)=#>D(I.WB29ME04SEB@4PE^*UZN9IHC_MDG2IX+C^I^WJ3W^49
NV@DO9ZVOP8(C;I=2)LKYVYI79RF^I4V;I^TL>H0V52%6U3I<RGZEZ M\#2Z^VYSV4P^*5I^QON.Z2^6^K(3KM8M^E)I^9X+@R>
M^ABKD4I.1QIQ^4)ZSBJ3 WZYKBR\$J0&5A; (K#I18D\$@I^I^R4_0^O^MX+ MCI54FM2^B3KCI2>B82XE+U@&4;..QN)^7X&=<ZK^I19ZWJH?
_J%*^L6 MP8DIJD<8^H6^+>B=^51ZH-ID;5F=>5AW^>_5<=<#M1^0^KHX;P6%;09) MGT+AIT<I1;_50I^*P^P\I^0=2U<5P M;A07=>L;I^%4Z\I^%
KRR4^4A2ID1X^I7>8%M^X; Z@=>I&I^O AT\$=>^MB\I^T^C^95=>#U8S^I^EH AX;AMT0C\CAJ12(<N&L^I^U_2^<CJHX^>I86 MW^ZIK;9PURX
>I>4W7Y26I^PCC^I0+)^R^>ONZJ9GILS_4KJOP95 @C^M\T^7;F>?^Q124^>R6N77D^X2^X^X^I^T^A^<I^A6DEKF^22\$KK\$HAGN\94^<3 MVZ^?<
AHL\$;L^82%MH;2%OU%?270(R5_4<99TA6VTG^<I\$^>T_K^YPO_25R7 M3DN^+G4;I+ID#^VZ=//RL^WVZ.OH5PD>LW3I0GP\I^JH(0P^H)ZL^=TP-M
JVP_P6#I0>I655L2P;0ZF^43ZIBT^ BUZ4C F+V^&5I^H MO0F^0K^>=>I^Q%L>@SHTD^I^UUFEX2I;SKXI+I+3I@JRI(3A&42;45XQ
M^E\AD0^>OUBPBM)MPK+I6=A9W7M BE\$8=;=NP=E=PMF\I^9+I^4&6_9 MI^2RNKI^M^2
/Z6I5IE6H53NKT83TRZM&3/((M7K;FOU/SBDQ;_F;I4I^"L\OGV13NFD\OZ_I^O^DX)E8ODB\$S;UIF+WA^070;I6-C?2W9Z;=1LIHJEYTZ2R7RYIU);I
M2F^Z^N^VITW-BJN^WM0W^AA#9I^YK4I^L3I5NH+P=Z1O3+I3U3IM^2;I7S;77 MBY_AOLE+@<(XKF<9-DUD16R) T^9\$^I^JYZ^V29;1NXA^<^
/TDRIS\$@P^<I^I^M^>P0^14^D7AH^\$23^H5Y=I@^TP_>^<D^O^Z;I^I^2M^2S30I?;UN3;YE7U+@M^L9NQI^<I^>MV5JTHJ?
5VYOGIRUKUY+Q6_7W;0^WU;Q_>FJO;OJMI^>74 MOY6\$ZYNC^>I^V_7_S^Z(HG190J20_NQF7C.OSV_2O^AWJCA_ZW\^>#KK# M6T5^<6^TSHW^Y
MR\I^<23W17B^ELAN2^MR>IRI^>H>VW25X_7);5;ED2;L@_CL0ID44M^@Q6 M&QHF^IHUY@MOS^*C_PNYU5GFKD>
<0^A5GM^*T^I8_>@>D\$;I^PP^ODI^T& ME4URB@<MR^*Z16B@<R@^YTI^M^W^9IR7GF13QGEDQ MV^4P>+4IAG4I>^TAZ;#Q
#8LP(E&7@<=>D8A^I^15HXB^4^0P^I^T@E;E;L M0ZED2Y;3I6B#79LF7EK\MB(EZIHG=IA.QI1MNH63S_#6E&(#MQE^MPFM
M(I4G1S>RI@+E^<0^P2)3^40^<FK80_>\$%20H<I^>VH6I5H^>ISZRRR(S4
M^DTP5;)HJX_U6B3I&70V9RW>E3J_ZTH=CAXGVY4ZO^M^05E^I^U^W601L^W= MGO_6#L_OJOS;I1HB9AH
2I^%I^TBGS<^%R4BD7WJDU\I^T^I^I^<I^RK@U2I^Q M0^I^3&9I8;S1<@H3HU_IPI^*U^O@CI5S;NM0^FIO+20ITFGMHM;J5;VTIWE8FUUB_ZI
M^E;KO;2I>@MO_4VMO&2>)>RV1U(>6P%D^<M8&J6^1-I;#4=UXD;Z5^* M<=>RYP^U6NDCH@^A@8;X7WZ^I^N3-7&H13XM\$
0>2QO)/G;E36LCKK^CIR MA7^&+&L8_>=^SPQ2XL^>3I6IHDW0I^L;8&OH1&Z5^2KPI^7SOL^RDK; M8K;H97IAR#IR^9XCJ>O>7D;XJ1U.KX@?<
5FKPLOI<^7IG>2;20044-YA#R M+2^YVOIT60+SI&AZUWQO^>E^244HJ2&=I>P<^+I^<C+MIK_DLS\IKGO.4<I)M\>83MFVX_G/Q+&
^#@_I^5/U1MM1^C^?H;C^A2^W- MZIH6I3^AVMA PM23H<^>NIG\$+I^_LM768XDHJ5K/^<523^4-BCP?3&L;9C^>
MZDA@;&Z\$9R(R^ZGW144HT38ZHL^@I^XIME^?B;G;_#4I5^M45Y;CLBYYS^;P6^H^A^ADR MY81G<0QH^3.90@^V^H1HB;B5M+
4JQD+I^U5^7MM^M89)HUD35 MJDI_I^I^PD3(C;N)7;8;V4#;I^T3^I^A^T39^GI7^>@>7F^YD5I^B&S8N09_ MGH?9Y;W^+I=K^<PO2Z^WLF^1#9
9N;C\I^<I&^O;I^I^IB@<5\$6XT MR^K7^17B7>=>^4XPVA^<^6DPW# M3IZ;8\$=QQ;8Z_1%>8;X92&N^>XT;KHP;=M^I^2D&QAI4_F6(A7;2I^<
M8GCUF@EOFY#HEHJ6 GR^D&^&P;7=O L^2^I^V16^<I^M(3\$CQ5IR(ZRA^I^D M2G76.RHTGG8+1E^>M5;6BVY8.5^3JNXY@9KJAMX3Q;I^I^U5^&
<0I^;SW^T=C^I^N^M^W^XLIW^>M^<+3;Y^P@SW5A3I^#166S^+@L^3\$MT1_5N(9X^&8^OG^<^2V^>+H8V^40 ME58@>^>?
PV\$+@>Q\$9F9I^W5)RKPJA4/D5I\JZ9B2GO MS;N1/Q;Z\$5>N&P_6I;25^I^_OC&+^&I^H;=3RB4FIH3>J3;O_7C\$P;P^I^00OJ@MI5^#49<I>^@CZZAYI

(R6A) MY+Q2<9;9^X1N=YU%/@Z:#E+0974*#=A9RR4 M5^I2AA*XX(KM&^I^&X&VEH:|^-.Q.100G11YXS:F-G0B*32|ADDT9MLRX4@' M^&^9-
 CWD0Y3ZS1:75FH1Z1?/60|>V^CZDT61%FE_98OSS^Y#TGC=J/G MRR3YI(EI(0+%-K@4@G^X^RA/0,38?T>O^R1X>R%HQ=>+H.X4A1C^Y,+T_I
 M/Q=5+V^_B;XAZR0R0)LTN^<#/%MBDR#3YID2?H(1^3ZX98EMX^?T1Q8; MTI2F7=.(@O%HL/7RUM5;HUIH)Z-YP
 MR5;+\$(S(4B0D@HYD2Y.WA8Q&FOWP&EUD@R=YE^I^JX6\$ JE9P^FA5^R@ M\$Q@B^P8A^H(7L@1L_1J6G^
 (E8NEQ\$W1LC.AG.X^AU3?2.TWTL^P#M.#XIFHEH^Q1\$#=#:S064ZQI/DQ:B9HKO_GIWU5_SD^_7K30G^C^1/2%J3^C;
 M<1^J/C15!>#;2^#FO&MNN-QF+^\$V+T^KXP|MB^B\$2^R5;3J=CP0%|H%K> M0\$^NM8>+<%(1>@/A^_Z\$H65TLN0)8P5O8GJ%0GJT+Y*^2>?>
 8V_VL^VP2 M2^3(5B)_HJ^#^FYBEQLH^H2^_Q_ ROP_9C^1G7=REFEJAGLJ^#^Q_8N(KTU2ZK&LZ;2)RDL7^8T^H^#E82I+
 M79I8;SDZL7EPAN&H0F=D4N=6)2^XYBD#^@&I^RXOM^DU+R1LNG_14\$Z(DI_M+I^Z@_#12RQBI7:F8/OK(PWTRP^D6E9I5?P55I3A>Q_Y@)-
 >AK0^ TLW%I MYE+48%;02.IB19WG#++D6)21@-WL1N%|H|Z6_90@_->X^C^I04!|_ (67 MN4XWFFHHJES9^I^W:36=S1C(0^Y!_3IZ7B_/I%|>
 <KLP\$S1&B^?JINOY_MG^#TN2(8BW^K0=P+>#VIO^IBN^IL^XD+H0&+WYKYK^ZB8I^B69N++8.Q0 M\$9^C/ME+^#XPM6X;BUX^B^6^6TW1&?
 M0&@NWK%_||Z^Y^XY=9I\$#<@F+TD_JL(-.WF|WL^K^<0K5<1R^#%_|H|U|>U1WGNHH\$W2%(%#^<O^PIKMB_MV^>Y0MJ38?44?
 3^304+4U/VZ+^#8A^G/G^TZA^I^T9E@EQ:24=|^_#V*W^X^Z^XU^CXH1^PTB2|QFS^QJN;_ MU9RU^I^3V^NBW_2K+P/N^UE#O^|HC|&BE^C8=>@F
 =_2AK5I^NF^KPII^?G^M-1J0SU^G^I^H+I1N1KZ7QEI/SL|B1XJ6+Z|ZHM^P^X^|FH|WSL2T#6^2G^X+>| MANE^1(13B0.&^#1A_?)@IX^I8#SHO:/_..0
 -0NTRTL\$3 WH|Q&06@RI&_M.Y5XZ@^<^>#%)I625=|>E.5:2JP6T9?G8LW712S?_YVM.G^OOO?_LHA4L MKOG.G<4V^Z2X7C_31%\$=#8I2-FD)C8
 M2\$15I2(4HROG/G&T^#;#J25C1%FE&O.LNN9H|0426|PPBZ2D8H|9X.KXJ12 MGPIG3%7A^#K^E.KWQ5NW_U.MZRW^=3E23S^P^_6UW^M.Y
 9U30#K/KLCU|H^REF:DZ^3FC8L^I^ROXQQGIFU^V^I^ECIBOACZ^5_L E9J MOFFE1N=6<_GN+Y5H6_0#E18J35!=ATCW!G_#GC^Y.9VZ1ZAJ^"&B,+^E
 M<0R:54^C(4^DJFWM)=(Q(O.OY9Z_0R^QOK^>|RO&S^&6JE^AZ.14?%I7J M6_14V<_<ZKETG|78\$3+5++16E
 I>SHJ=IYI^TKYR\$6EBG|SLR|G%CH\$&2 MA/DJR^Y@+IM^G^IC>Q2%&E^3R^KI2\$YAHJ>C3YDOZ^M:8O_E5C=X231A0\$^M^28U@_ZO2ABJ
 (AGV7^S2G@DV^CV8BM^N3>Z(D3>|4X^P^M1R^JN^#(JW.F^)|HL8|3^3^RK^UC^>Z.T.HY+4MMN^N^D^H;LK:B^J^#=>@1HW32N2_MKWV/
 (->K29@.MG@K1^A_N.12#>44K0U&H8J@W|I+^#AF|WY2TOS90390?^M^#H%J2H+^#BXZ^DRZ?>D^TYR^F^M/2I#B(A^<^>V=F058JWF^7JSGBI
 (ZC4CZCY9GM@KIV^XX>Q_LI\$0HK4I^O_M.%T^=ID>%U_XN|8CH\$2V^8=HN80P@XOQZRM|VT+^&5(\$9.)G11FW0IGG M&O9J7I|>|^*(Q
 GRU@<^&YK)2^_2Z<I^/ 93;&2^E/)>+KP6P^K1P69D=(IN8Y#2^M2^#K^L4C+3^V-IWC_HBEK=RIP^H8UC!M56T^E.F^2D8I+UXUX
 MH13P36KZUB6_-6@;WLH4^T^5^F^#%;5I8L|5C+<(S=O=D8M2^JFNU2(FLT^# MB^1PKI^CCL_4\$ 1^X^9;BGF#_5D0F4^>3^Y>D?>
 IP^D>GW2I2F^I9ZIN&97F^AX_I02A=8ZFW^_ELQ_&8UCAANNB1O>^E7ELZ|P6 MW^_A_4I72E23">@9A!QI/V/OA:E2JPT3A^98IC^+P=3-GF^#QP-
 I=U3^_M^G@D|L|H9_<#>ZD2I^4^R^I^XLL^T^J>|(FNOI^080D>?>6I06.5\$S^=V^N4 M0_K4JTRI>^#I.HQR.F^@;L5^W/QP|Z^+@23P
 L^_||H8|H8M^LWB.R/6^J\$%_M.G^1^#B^2QOQ^L^I5L_7UJ\$^T^I|Z0B^I^|YHY^AV|A^2\$FY^EH%G1Y+R^M9K6XY4T^AAJ^+JY9W6^=E27@^#0I
 5OPGI@J^L|I?68T1_ZJ=SI^*NOTWJC_MC%|_Y+M%_N^<K9LSH>S^I^T#L_""7YD1+>7)P<I_KDID7^X5(CC0XGCU\$ZE M^I^N5F9DZ^2+KJLN28+2WY-
 S63182V M\$<4^K10KR^818^F^&^I^L0@>#> MK&H8U=D9I^V03GRQCBZ^I0D^APZ@E+R^GHT+M^(|U9W^I^=9V=ROL^@>9 MM^F^C^PZE&U^+?2#J
 IS>5V^7^C^6%_.ROWGB3>C^H^+>BB\$13CM^2#^6U^M^M03814VZ+5=GRV0^6882;46_8VCB0)F0|TGUMV^C^0_UH4I^@5SZRW^#^P^YI9
 M^N^9=I^Z^MJ+8U>EDW25^F^29TZOC5|NS<85O^SAP=R^J^RXS;M|XXW<#.^?I7B_GGFLP<H6:19Y?U7\$ _VOK2I<619^|M^A6|B3D3WVP^:8
 QSHD(8Y.FV3?K2YTO+>E6(TM&M^|H^C>7JE^I^)|QB:Q3^<^<9_Q42U96+D^1_7ZU|_DHVLAOC=AD.A06GA M|O_EJ8?K_H930^E1-
 V.G.N3A^<C^U.@P5^|G&1^2R(|ID=>MH+I^F2N^QB7^7 M<6(M&3B.M^/4^T^<LGC^>OH^I^IOMKS.P^<AM1^|U35D^1^LX_I&.\$CR/
 MN3^Q5N2>^WE_1_ZIAW&>?D@C A|P^3T4+^|HTNC3Z>_H^_#YM^%4.SI^MFAVPTOOHZ^I^S&_I^71%_IBN|5E|VEL3)<25-
 QD_XFX%N^YI^W3^WYVSS5\$^A2G@IQ_M&B^ZD08K^(&B^#2^F_L^X)U\$|^1_4_5C9LGC72|/1<.<(\$BZH^K^VI2|>^\$H@H^PLH
 MG4@N(I^Y_K=7>ZV^RSD2;Z5JF^I^_A|P(AE^WID(OE3FN^022\$S1B^V5_MRP_ZI7^I^KIQMWAZN|H8M^#;UXI#^6WNBYG.CC#|CC\$54L=)^-
 <#>DX6IQ_MA6%|^R1^9D30D|V(RIS)\$ S^H_2I06AC0IG.S^&IG|I^0J7\$^9ORG.7^XA M+^C) H3%N.WC.AG0(362AB5^Y|P(F^Y3_8FDBJQHFE6@&A^#T
 5N^JH6+M_2J3H^CN0_#^X>W@TZG(OQVM^7I5Y^&D^#1N|_YB_Z^FHX|H^/EC?I0D^*M5IOGZ?^F\$YR9:W^M_(<|CVL^_K+2;<5|_C|9.I3|_""=|
 <_LLZD^WX MR2@|+|^JP.IE2?>7.D^CF\$1^WM52\$<L^C8M^Q_NBE|/W^D^A44=^&A_MV8A^1C^#^LP^)|13@|A1I9NZJ0^"
 QU^<^G@^#P@2#>#C4YR^6I+HLT^I^8E M3^ND.P^ARE^2^C\$X^>GX^#^)|^*W^UF5|HT8IQMA^%1.2NV1Z?^OAM^M^M\$HEJRV3F^>6RP^L8:9;
 (&25NG@RZ#^+2^<(K&O^)|6H.IK70/^+2^8_M8HTF8ONC^+R%RX|^D<)>((0|PD6N&=A|_9)GO3^IMYP^HVO?|^Z%I=8DT^MD+|^IZ^|GTLOBA^M^I?
 X15A<61GE2\$|S.FR|HW>^?72YUZ|^3CG9.A>ONA MNTX|LOR754_ZA1M0Z^8;XLU^S|OWM^4:560_M^W34P_O.Y|+^_0S&QT.L|2>2)
 M.WT^@SDD\$^HE|L^D+DQJ2^N^H^L.S.H>^Y^MS>^I1

@N=1+0Z8 MY.GVPN>DLS4\$Z?L.F<.)E(2NBY4)+F"C6\ LHQK@8UMQ7F40B'0% R1Y3
 M2<1YDOA3;KJHD\0KF>SML^L7+\$A=^%<^U\G.T>..OBYVM#3#CLZQH Y BAF\ M7;BCK'%#&DSAX<LS6D+
 (<CP8K&6+'\$>NLI^C5L<.&2;/H=Q(\$S<W F#19A3K'Y M#A3'RYPT6AH\J7'ZN\QQ)\$%??5J>16ZQCI28.SZ\$QSEV1&3B04^NL^6H2 M.I=9LRJ
 (ZK)ELVYK&'K'@> KGY.C&Y^23\DUOT 0-ZC(H2)<@FW MZ3'RYPT6A'YDIB\ *?/6I^XEL9&QI2.89)OI^6YI(=-F)/E4;JU-6QJ1 M.C&8I2
 +HV^8IS=E3746IF2YI\$M9G<T BUET^BP.582D>\$S<IRD%> @46 -4 M5=>TO#<)<OQ7RV\(^%Q.O.U\$?AJ+;PSS:1HSBPM.KN\$YS7 MHU^=#
 (H#N.N.OS0IW2JF3.M3^F0\<LHDM\$D%<\$<2K.D/P/U+H^0'X HTV;3 MZ<76\|SNSWP7 U6J>+C\$S.A85H6N87T8WR;+&^&Y7JT=IAIT=8N^VG2\$2
 MAZ6> V\<C.BYSL+RWN\IAVLGVSLV@JN>MRZ@EMN.ITWY38PIU<^W6:5 MQUWMP)H0\$>J8U1O=(^IRG\$7HARIN:=#80(\$28J WCB7XH6J
 I7A\A\PNB M^D3 DNRD^0>.>I21PN_3I23%<+XG%QJ^Y(V\$#2X@)/J.JTD+(L3M\NR^%=>H\&C" M8@FX%)N(HS3;Q ZMZI39R-Q3.N^W^OK J-
 W5&XF.A\\$.A\CYM AS6#1ZRPU% MRF Q.JH\$=>+JM3&Df3 A .R.B.W%TW^T2D@AL9 I 0U VYX.%VIGI=ZOV P MXT\$K>.<ZU#H_)I+&
 I^I5C H6RD6(3D4^A)I+00BEPQ+X4AYO M2V=2X; P2=P-H\ BAKVVP=UJ+9J2@/QB2PO150&18J;K8)49DB@JHJ2
 MZIG&ZJP(F Z^@L5P|<B3(OFI\$U- WYX+)>4OKIT33(E+YH=/%3JW13BMV)F<M7V+(3GJFUG\I(-+@7Y)=1.BZ75 TL82-
 8T^W&B&POMQ.7C7NTA\IA5Z\$E4 M(MFE%D+0H)OI\$;@J-ICE %4?#^4^%<C.LI>D;@;8HQUE<^ M)>+5P66VH&K^&F&0 4HAGTPN"4LK^<V\J.F-
 @>@>6=AIR5 P.1(62D1D^U) M15.TKJ360V#EIT7GA<L8SDU=A57NJA\HOL68<@3YB4\ISB@50#=>EPXIE5 MQQ>8NO>6B7I^\$UN\$@F.T.J
 J24.#+ 2LZSM6R);K/##<^>^@7Y30K MDEQ&L;WXN%&7&#>@2 0.GU-9\$HN=,1OE.)U@%\$7=Z 2A-\$8V/;(-6% 4C<M4O/XF\U-S=>VITGE6I+
 ARNO<+>9J M^>XTE 6#<N2< K^<R=27 H F M#&8.DC9S@M12SL89" AIXM\K\0 F3LD Y\$)I12 KA2G\|<^<^T1<^D)DPYG\$SC:# 1@8H^@19Z-
 +5 2PE/#TE/87<+>M.JW&32\$KHC<69V^25 HF M#<^XGREG<MO@7H8GHW9MW@K^VYHR 8E)8Q\$89D&DE<6">ID N4PXX%=>@I M6^Z!
 I33=B^SST&E.M0I6BI=E)PA6.1PNJH7PO>X@28& MK#(D7M\YD^DU>Y9O&BPE@Y1/4?/5499^3BD^RN^43CA^@OPT.45^U)
 MUW3G5\$+R#J.Y.U\$2>@HBC3K1QO7&.<WB.08I#<X115C0\IVX5%18(C M3.T<1>AB8W^@<D1M.9C02I@.6HJ)<I#OP\$<D(OB\<@.P+I#L\$!B&%
 <R^?0Z8I=Q72I8=3D\$8.0D8J\$T^3B<^L%|RT7X\ FE4USLS0+ABB;X35N6\@<1VIXVOZ J5FV8G-I0QKA D4K^+T2^A6CX2^YN2PB%<C JIE%&8<-
 D;#R@6LQC.E^LT2F4RH&M.E:ORDR^07^UE@95@>^JOG7CM^L%\$S- WWI2RV7>#KY>1@<^M.>N+I.ZW/
 M&L.U+J@U/H>GJH\>^>7CZ2?#W#G8.CS9KYIN^I\ZIMGSTM_NU\<@P+M.MH.9Q>SI<^V(2^TJ6W1\6#\$J1&\$>.%| M\$*^(FQ4B0^P)*
 (LDR^D8I)=&HP.HLW;H=7K9<@IT;C/O^A M<K\I^X^BDH\$7^H11@> 1+80Z^81248^?TOLB Y9@>F.X&URID^Q.Y ML^?SL BJ;5B-
 J6J^X2=>3<8JHJOGV^M1259.848RP4.F9.9WU^1L^?9 W\$Q4%46Y>Q2)RVLW0^MT M&#<Y4B\$G2O.YQL900A\$_.@D TUR_5
 \$>B8Z5ATG#<ML YPL<M\<RD.#<^FYZ19I6%7&8^9^Q X+J.%<=>I>#<RY.#H Z_HH.<C.DQ(2F
 M6OH^VX^I\$D32+1L.%>E6AQV%<U^QX1%50."8GB47."J8@/A/&\$1^40K" MI#LZ %C\N37N\DRAOH9."BD87VSEFZA>
 (P9.1.)16&@XD6ASIHJ8%UEF MAU5.GT^EF IMWA>NE..\$SDS@G5 %C8EZ#M\$<Q7C2/SE.QU^5N^Q I\NJBS
 MHF7HU@OP.31%\$DYU3^(&0=UW^2I.>^4W\$@ASY.EV)=LE5V.T0;2H+@U MW-<)RLIE8@SE/(4R)26X.UN@)HK(83VN^J;N^I6-
 T;RWA160>@Q(T^U MVV4;3DP)&T3NIK406J^%XIMD@Y0^>PRV&EV.+VH^LTYJEX.HJ0E M\W\N\JAK@4L&L@>Q.#.&#Q^H650DX"
 3I9ASR\>^>@QTF<^<*>1N M+1B8)43 2Q<=<K).MX\HNE3)<=>6PQJO@FQ8H\$KTO@H\W^@*+&^K5 #ME-MOH=25C.Z<5KR M@W3Y1A?>
 4>FL@GBI&+E|^<2BN8/="6<0-9CY\$8OUYO\$RSM@<V(T-DC^X6*.64L^%#1486*..B6J+M8\$5HK 1NED4VN7%VBJ^JHCAI\$%&9A=Q&2N-
 G4QMRX21#8(OJ&GVD E(2X(3 ME7+NW\$C4=HL6JR>@>|B9C ^XFL7C=EM3Q/63.T^92)3(VP&VFA^Q/4=8EBIC MCWY^*YQO=+^EQ<=>..B-I
 M9^1SZ7K 21SQCZY82145%437^AVI-N8M^ZNP.8D P MEHMT^ VPM9&K(K% MP4 MCE@V2)I@<^SVAF L4F>Z<9BEO(XYPD3#I MJ6H-F^5
 (-T/<80<@5Y\$IP M.SK4.K\$7732I9>?V9V\$QGT^>)6 M>9CEWRCS<).7I BZ;WH62\I22X^91YX^R820 M-
 3RGK8\$>9LN8D(POH2@1H15X=3Y7K>CIS^YOR) 3P.2LT^H^B\<^7\$S\$R(QE&K M.U5&=S%G6H2IUIWD\I6"N..GB;Z3DQOI"\$C3U7JX7E^>7+Z6O7Z?
 MYX\J.YOUT=IXSW59^CNN.08\$=>X_K<(0J70G44:H4NSA(D6D)J&8 #MF%|+F<A^((P^T T.S;D;FVPK^JJS PGZC=^16YZGP)-)4HXL4
 4MOFQ^8^JW79V^2I0226MDMQZ=OH#>7X M^J600.D^M^O^B37ZPM:7J^25AA^0@J3TIOAT8FV^T^S)J^<^IKJP&B MF.
 I=5+39<=<8U;440Z6F2T=+AJD.UYI^J0<^<NK^<^(-0\$5%5V+1^JH MDE.^R20TMYCP64B2^9KTWQC>6X>J/59VQ\$>H.T^JLH:71L5C(D.Z/O;P6
 MB>7BBOPKIX^EJ^@P5@L>+4I?K^<0.2E-E\<VABK MN^<Q R(SXMB&(P-X) B5\HZAL AH\5FB%A>R JI6%XXJ&^F#VRYGF3%)>,
 M3.TPS12HFE@.IA.DZLKAOIF>63O7IDH8 I+U^<2I D6@15KWR7 W^4.P^P^+8&F M\HJO\$HT60V(B^@I22.PT<3
 M26HU..#72YV;7%P1&0V10TTC3.GV4@<RK^>LZ^V MT7I\IZK^<F\$N^<KIS9A6V^H7>J3I8 ^VSJH&35LNIWV^<FWI2NH6.7.2VA&R.J^KY#W.M2-0-
 ASZB.4BUHHCIO6\$7TRW<5P.M< M\Z.FU;M4BT5^EOA(UT12SXR^F(4300D XQ^<1^@=>ZK R^E..OS01^<@ MB9&+DANUHQM+IQP^Z7UHR?
 D4UO\H56(OLPV 4BSU^LEIC.#+ UHXUX(L)MS^<UJ\$668 B@Q6^IPI^ M;H\K\CUU>11QDQ@JL5KE^XF0A^9&Z^0)>#8\$7I.OSR.<#4T\$IA^0Z<
 M3EZ+G(0)#.08H^P@<6624/87ISZ72^*^I@>G|>^HNF28I^+884E>SCL M^QU?I^<KH@1BKVY^2KJ@G+BO^G\$Y%YD>49SE^FA@>9>RD)KT

M\$DHLR^IO^+|^|^@3&YUB#24_Y!264^OU:1&BOEEC=AB7=#9^4M9GK!_H^KA=[M&_JE" JBXXKH8^D">,DLIO,5J!ACVZ#=-!P!^G^_B/X
#KJH7AR^M">S-MR^J#5%IGQ-2592CO@2DD!P6-R!T%";X!&_A+2!QC2.#24_M<^U^+B!_K/@*%\$J!"/YF8^YJT9Y2O/P24\$!^!1Q (-M+V_#5F-EE3%U@L
#_-5_9V-T:RTR,#(T,#8S,%IC86PN>@ULI5U9_M<|LX\$G!P?JOT/6&W55N9!EH;D,W^BG;)U_*R11^T_9_T!9.0C#4%*0EV_I^M&H!A4KQ_742J)@^Q)0-
IOXZ->L00+U+7+8@G^&_M,=(IHIZJH7OH^S-Q7+L!S^2,^!S!Q!\$F^>IQE5MSAH,N\$N^+X2!Q^%DQIV"/,2B4!M!9B^W^FH7B46X%=-,@ZP
MQM9,>G>P)V\$P1VYQCS2P)NB^M+G(565Q2@>7P1K7!SE&#R@<=MITN^S^H+7,J2
^JS+12E6/HOXI^%8!QESX54^9MT\$Z6IW^N^J6X_-YA>YM,HEZM&R!_M&V#Z3/?L^T^9SXXMAYWJ4U)OJ(^43D8IV^+^+3W,1+;#K9#++/;TOW\$^VW%*
M_5@I/9H_M^JT^C_Q_NH22!TCKROE-D7&7R@<=6!O\$Q=447>D;+HCB69!LV!6!ZA.#2F_O\$ M&AN^FD=-N5RE2WS!Q&#?2R-
T!N<3QX#H#4_(BIU!P!P^RK6_4^FD3^P+M^Y\$Y_?#<=B#^#2#^!_!AV7P4!QQ^LNSYQ?7POS7Y#<@X27;PKL!^OQE;WT.B3>5
M!M&@!C@!^A#P%I9QWQ4_+W,+4R!4!VQZ8!;@!^!S!Q!7@!I+6!Q>62!M\$!B#2Y%=<@^!C?79#,"6.IH!I^L02!8L6!A_!3G9_+\$MF/W2#^!
W!ST(H26!%L;QFVN5V4%#7UK+X5LEH71<_#E9C+I^Z!M5<M5"<8SVH2H3Q?T;^!H_Y@^CUQ9^&\$+IV?>D,V)-V4/Q_U6_^U;FM8K!1>
M928OMQ3!D+6&17:3#;7P2Y789,1!VZ&#(K3MV4+&8_AV8A!#0^N^A^K!>IG_M1TF7C!/_X\$O5^!7R740!0P!<5!SX/^!LN!T(^_MY^G;7-!8-7
N2P4G74!>D@RF+?C=>D;#K67LO!^!@ON;(^T\$^QC_/^WN;_M^KL@S?Q5!-8!HY!@67_M!M?>2^4@QSY(DZDYZIEP5!1BPUA^!^04A!%)T_ZA/A
M>12&D\$DZQ^YG=H(K2)^A!LSI_5W!VQXR4V^="^#K+?^2^+@LMVB,B@9HNJ\$2-23;P!J^2^8%[SKRR-MG;_R3FH^T
HRF7!4_9!3Y3M^5^!RA99!W02+O!F,D,NM_\$R^*G!_56!_B4H0_MF35/^C^CN^WTCB933!HEFF^G;N!PBGD;04%+^_Z^HY0TM!0J!H_!;^!Q+!+@
M!M!9!G&_1>8L_B!V2_+O4S=-C@^AG;GD^E^M^MH3?>^(YH#^#^X^H>I!^08X!N;ND8Q0F6G^_J;_3<5Z8!R7UYN9!H8!DV MXXB02 TRIG-
K^SFSU7^!D/Y6^HK0B?X0M&>P9PB05+^S+(\$#%79TI_-\$!%+M_=-FQ_/TS\$EEQOX!XJ2@^#7<2LRPBLB;=_M^FIA?;MM2MN^SB7!_DF!WBC0@
M7>W2@3<12C_35!QE7J3^FE^VJTM^M^M(G!I^EJZG;Q=IWM!)^18_D+QD67!550TF34^825S2!@_X8S!8P^?IE=FPM+M!L2RO;S!J2HH^T
FTC6AQ0!3^!T>K_Y!Y!<@K2@=<\$\$2+6!O@^B!V^Q-Q!M^M^Y3M^PLBC^P!P!E\$%LN^E!90+)+7%R0L;X!HU&HYS>?O!\$HH!_77^S(G
ME;T7%?3;J!)1%0CD+)^CRWN_7ML>;7_M:IVRMVYQTSBNYO4!^Q1!(D>8XF;_P+J^>U
M5.Q#L\$+!+!NCN;_D!X!^!B!R22MT/^9RBB06ZWD4LL<9=J!UQFT_0V0^MA_C^M%)QWHE3VM?Q!_Y#>3J^O>"NO>5#;98_0?
X@ZUBV;N;=6:LV6PWHCOH^74A_M#0N^<<=W;J!F_FULAJNO_Y,N\$HY^?9L4KW910@H8;O;S!3QCGJT@GK%;E-
MMH^@8K!D;9%&27>MX!>@5#^DAOQC#G%0ZEWE=Z5!6H%;H!FV!ZQ9=IX45H57
M2I!%<^EB#ZM.1%_!LOAL0!P@^GS+!K!D!T^QK@!J;YZFUIN!7OR9#0!\$^7!Z_ML^8C;)M?\$2R_Y^*@O6>|^CYA0?F#2YU+QO<@5DKF4Y2(H!AD!?
1VD58_CYL_M?)^Y+!^/X/BT08Z?49R0_2UJWU^;IBB=O9R;SU_+!HT\$G^0T2!^!WM@N^R!_M!XVY-W>"JA\$!N^DGR#;1#_W,TSEU^R4!C^T^7O!^D3!2
&\$+!+O_C7B6W66!E9_M^J6+124Z5\$K!_!H4Y!G^9HW^#XEL+!5N5B^M@8L8%=-N!^!T^M!L!H!>8\$<+M^SSWHH-6!M!Q^05FAAXH^H6-
SR_9!4R!(-^!_!Z^"X7H9!7_NMD<M^%>FG>J!3X%!!BQ/FP;W0!1GUH6MWGLFSDY2!A!B_-M!F06YV->PTN!_!M,KH_!^QH^CZCMFC^3!H!V&)
<+Y1^OZ>?>_XPD!U!R!&A!Y^2XN_M=I^Z_V;)S!RGV9_4M\$R^M!A^P2^K!>M2!Q!B!1^C_D_(F^MT+O5?+0A<3H!=-NEXA0^Y_U+V+VZ-V4UH9@&
&V\$9H-XW4;<?)!YDU6!YN^MWYKW=-ALX\$X_!#177_C^JZG_M;_WHP<="M9!A^#CSU9M50>#8D%M^QY?Y4)_M=3?
N>_<S;DHG;G%;58W^")D2^!"IE!BC#Y>#)\$4_!_!AD0CQKW_#K_!NP^Y^M!4^"H!;!Y&M_DBIQ2XK!\$^R!_+G(DON^KV_*H?JRI!CQ&TL!PL>OU8.S-?#K
M!8!Q0^!^Q!_N!5!%9\$!G!J\$)_L8PU^T^J^7V^TOP_@ZOR^>0Z5OY^A_2/^8^<V_!87;?H!XV^YVEIVV8@R!0V^!S!>1@!^!F!^FO@!_!8A
MA370.LP^NC?;H^#3!&L3F0U/2_4;_K4J=-SND\$F!>2_6_I!BH@23!V!\$1^!MET76+!6R5XJ3+^!666!^?+>9^W;45C^5F!G_Z3;U7=O1;2+Y)Y;18)T
M059>5_XGWW_-W_P?4\$!#;!0 (-+V_#5DH_T23@A@_(Q!T_0_5_9V-T_M:RTR,#(T,#8S,%ID968N>@ULI5U;<|NXDG!P?JOT/7&_5UNR^8SNW23^3/45+
MSJS>69!4_7>7ZX^TV_S!YQ!W^_B!B!0>%(OYZ%_MZ_QQ_!_O_VA_W!C_-SZ!@:22%ZB+WW^GGZ#<K^"%PB_4AC_""8!^!LZ#_M8\$W^@F!_!\$96!ZT>
IA_-\$!A!ZKPYNWX!U!B!HG<8>BBZG3B;=I=)!A!_MN;AX>G!Z\$Z!^!2B'_#%ZWD&IPF(%G^F!8NGR^S_!+JOP=^!^+^><Q_#"
M!@KC+!^Q_6.D)MU^_3N^8H6%V!O+Z!N_C70GH+N+G?DCDYL^SO!9H!K>
MU>2/GR_HKWG!G9+!U!U0!_N!B=C!T\$!^U4LV8!%URD!Q+^!IRF!T3_!>8_M;.%SV?2SH?G!Z!>1?>68X3?7:\$_CB!P_PCG^A^LWY!R!D;SSA^#^Q@!^I
MX3!1!H!E"CR!E/7^600!BS3!4!D!<00X=\$^!O_0142!0!E5!1EBH^X5#=\$!J9_M+N05^D00H_G47X3^!_!+%=#ZW#!_0_0!AUX=B0=5J!1!G!MKYW-
(A^5_M04@LOYH!JZO!T7!D)3UT^#4(3W^W8@!^P8QX!P!HON^!^UZ;_9H!^MMO>X!_!^!RG;H!109%UX_IVC^&Y!+!+!WJ!>X?<
T?L;_YX6^W!A!0!22_M_3\$^P6_E590#>NW!X!>T@%;_777K!H8!>52NFLT<<=I?EY;FCS47K_Y&)+U_M>22^R_U)KBI<(!A>K?<
Z52BF9VOX.J>^!J!D5NN>GA:0!14_MHY!6.#Q=(4K!NJ3E=8XZ)!M^PFRB?QUO+>1#F!H0>1_MG+2H+RM-/34CR\$=5!9Y!0POB;K+?<
V8E3P^<=7VT!);S=\$&P_4!HGW\$;_0_MY!B?^#S!&^>E!5DY4T=B>9!8VF)@7=&+!+!>7!WX=DI(\$EM<3>@>SD&7!NQ_MT_QZ!<@^H6>5NK)
(7!8OMR^8>SZN>ASN^>RP)FQ!_#_MBG^STM^Y^O&>QCO_N^RPE5E+^123!Z!^"_(A!VP>H950E)G8\$>#HFPQ(6<6_MBO^H^GIV=?
E^2X#PR/QZED3K!^!#%ZSEV5_-\$S+^JLLA!IR4RN^JXP^M^RH>SQ7(Z<H!B!QNMDF8<=HKA23W3V!^!NK)\$_RQ\$W;_@Y^0
0(MH!U!5R=0_#0!JBE7%\$5)G!0!^!72A_X/M&V^V43>3Y2XL\$S+5+7N!J9E4R^0!9^!H!82^FF!H!EYX38GH_H=<#>F98D^YK\$)U^!OWYB!%
MH9P%RWMML+M^#55GH>VR=I^!@;&8;629_A!NF^!%HG!)TS^C4<%=+!+F@!^M)<5_E;+@R%;TG6T&_V7#(U#8>M)6DEF!\$!_YPXG@>O>XZ(@>?
8.0C%SYFH!^&L3!4P;_!6!Z!^!1K;_!H8A_M2RR8;Z!P!F!G>_ZWIC?^#H#&_5V!&26Z_JOP=^P@=X^WH9#>+!^!7^Q!B-
MYEWT\$!P!P<(!RB!+!W^#22KN!HWH\$!V0W!D!PXP_U!<^!7!6!G;2!TF6/N_M_!%M98_&CBDC_&3_07KDZ^HKJY^Z(V^%RS!P!C4,OW27V!S_K?
IM1;"#1\$;MCPR#D^/6OD7<377#!M!\$!LA1?+0_&X9Z.F(5;29XC;45;2%O^MTHZ^FXQ90_M+!+!(-^!@);RGT^D!3&J!F!QV;JM#7<
!>6R&788N>5.#%<0_M1_N>H6NH8!Z!ANW9RZ8^!J!+!_!68T!H!"F?R;G;T+!H^!Z=(C!>D<_MBFQWZ!1_BS9Z+#+>^!A@)!Y^!)6ZM^PD!H-
8!QO!<^!8!B;T^!J!A!O\$A@!7H_M;=!Q!T!F?UNC&FCK!Z!T!&^!ON=\$_W!PYDS_&_1WVGX_2F!V5!>#&L
MQ;G^!X^A!_F!G!F!V;_!^A0BNM\$#BM2?W6Y37UG_!@XLT^O_M;J^K^+OU_Y^MX^!6W!&OG;XS!3T62^2H!7!0Z=ZVGO!^>\$T-
YWOK!^0<!=_%>OFP!^Z^>!MZ<Z#<#<);E;B!>T^!#8_!Y9!>+AD9>R!HWS_@EU6(QT^0S!U8OV3UK4T^M^MEMRO;RC
&R!4TF^3G<4^Y!O\$<4NX^!&Y\$9^M@+Z<44_Q)#!/@;=#^OS>+>RGR&NQ^XP+JZ^!^/QOZ2(YU)M8^H2KRTN94_MT!>1+Y^V\$!MS>A5PF.T!T!"
U!H!B5^3^6%EV>+HPL3!6M!82T^S!MOP>C^2!:(7VQ!5!HC^K^&F!>R^#O!((%!!L^_Y@4GA\$BH!5Y^!XR_-G_B_MH-8!\$;FZT&U^!H\$!WQ2^0&^
T5T!E_M^"(G!K!JB752A<=&^!G!V!@N_B^P^3)R;#8_#MT^K<K^J!GE<_0LP_7AC!P@6H!>P^M^T^GZ)ZM^*Z^+WDU2!9^L2!3G5!CYHTFB^2;_#=#\$
@NM^#XJ!>J4C#>M^2ARCZ(72Q_U_B^K=230!FD66#A!U&^!(\$R_Y=55RH9;_!K_#L+K!P;"ERS
MERSFH9E889;I!N0WY(G;F=5Q77O/NF!A0A5^299R&N_M!W@!XB5Y!HK_!T!N!H!8!RB7!X&^!@AFAS!4YQPR9ZC!Q!+!R!B!>FCD0NA
M^Y_P8^0@0\$;7YHX)!0GG_VSN_Y!G+DD!9=SA);G3!;(HJVZP;X^T^Z!M!A!L_MF^DU?
F!PN2Q+6%R!D^!S^7+BTNOFCSL/LSM!+JW_!Y;X^!X/9!T7Z=-_G!M!B;6?W1^5P^&?/?/?;K>U!^!B2^VMMWD;?
B8!>U!^!WOB5RCHY7QD;H!_KV@S(C^M&_>+<=I^7&!)<_>9#P!M^ADD;6!;MA4N\$SG!\$!W^RT9^A@JK+BU=^!AW_M)2>N^&#
<=Z!(>_>5N6G>=&_""7%5C(WB1_MU8SYF!@!T)FYX1R^!)<2V_M_BB5>ZQF0ZU^E!H^0^O5M7F!WYXUY7^CO=O_X\$;T+^YA(8^Y^""1DKZN%<
M!C!H!_!Kf6_.JCEVZ26HVX36!F29@!(G!>2G_-2QK!ZX^MC_V&(^LP_K!GMQ_G!>E#^W^GU_G2OZ8!@P_!3!WU!1!8Q!A^!L!OY^Y!E
M!9=^PH!MZ_59_FNE;B5C+EGD!H!>@!(1#G_C!H!Y20L^9!#R!H!Y\$Y_V^!^M74_G!>_O0!>DVZ+Q=1_KHG!<
7!H!ME#%#8GS_O852^Y!)U!^8#S!J2V&R_M/LR6!R!R!\$!(JYAOK+LG9!>L_0!0!^4J!U2&#%^!ALD3A^GW_S!H0N0#_!#)M7TE7E)QZ@!P@>0F!9@P&^
0D#\$C!Q!K!P!K!_!63_H3R!Y!S2!<+!(*!J_H>@M+^E^W_6!A!9M99?_Y3X^!>FNC62SQ;?736VDAH8!5!C!FA9!JOTT!+&O\$EG^M;0_M!G&G!T-
2T^28D+AIT!4^V!+!>R^14_X!40!\$O<=1.0!100D?^/9;C^X^M@C5!YZ7Q!>PG>+KW656FPS2!1E=9!7H8EL3>W9T>H!^!H!>J!S&^QY>+VY
MGZ;13>=!0!3P=B>>2%\$!_!8S!L_!5OZ;29^SW^ZO>_N7%Z)>#8#P^TKGS_MFBUJY_G!P!J2/R^P>YD!D8@P!\$3/0#8HZ\$?1^!E)=PMJVSZ/Z_!W^)_0
M!>S^NRP\$K7N\$%C!+^!@AD^!O!B^0G;^>G?GAY@#^P203BE!PQ^S@C!H!W!X0!3G^!MC_O^4+>C_8R!(H!S^Z_%W!S!\$ZF\$?@9@X>125!XDL5&H!T6-
V!&#%#LBO>7;#M!HT;DVVA^!L;648VXGFA\$O@!>@Y&^YFXB;GAD0R!4J_VMQZ!S^8^!AJ^BZ5_MFU3W_-!YO3G-1>CUPP_MCN^
!&=+V.8!OSR4^2!EDL!R!J!Z!W;Q!S!>1!H2!OE!G!W^3S!P!Y_OD!^W_M!>28D!^W!A^!2!34VW2.53;9QZ!>=K06;C!F!N=9S3XZ^_D\$R2^R%Z!2
M6@637<?9!#_5Q2E!P^W534C+60#XA!1^!1!<1!N96!1EGO!H!P!Q(A=IF5!_MUYX^0!E!D<^F!T^_ZD!<+Y5EEDQ3\$#U\$X!H2SEU
M2C@!JR8EY>Y%3PM&?N&^HHIR7NL<^!<YYROMG!^MA_2^06!GE_!<^/7_FH_MXCLL^Q\$55FS=P!L!M3X%\$X_1EH(H?7^KJ!GB!_1P^/759-
YA&H@!5DF!W_M=\$>U^MR&_7E!>+!TZFQ_YE3!H!^AY!<=<^!J!<4E!+>H!XW2CUU=\$50!9ZK9U=Z4KLZC4Y!F!&+U&UG=ZXC&R
MA\$^T!<XK%9GZ+0=FBP_5M!LYV1.T>U#2D?^!Y2Q5C^&RQY=>7&W6K!T8!//M92!OF=VFC.&B9!J!G%VNI_V_M_8.HKOE@R?+O^!OMGRE#_Q?NO
!Q;P4G!L6\$B>DDF!6_#^!9K!M\$9^>=>RX^MA#_MEP!8!CAN#^!1!C!W!\$!G95Z!3!>J!>Y>TDRPL^ND!VK@>8MFGCS3!6C!%MP7A!^CN;#Z\$3?<
N703YN_8DQ46E!L!UGD;SM_G!H!0!2.22Q!A!>A!P!M9;X_M!OD!<2!C!AJ987!>#S!L!3^Q!6\$=BH^H!>#B>#3;K9&T82!6!K!DM=<@X2G9
M\$S\$#O^B5_!9X5Y)RX!FS8?^25;_@<\$!<2A^_1%!)>YUJ6_L^Z!AOD0!BEG_M7^T^5ES0S(UUVQ^W(RS!Y!35-2<^!CNP!83!H!>Z^>6!37=-!W&1Y8^*G+?<
<*>JZ22!M!%CM!M^G^!B5!L^0;7BW^>2@_QH.G^F!FT@20!H!R!R(*_!U5;_#Y^#0AZ0_QQ^X!>E!W!LPH!39<3AU^NEMBD!Y2AC!EC0F!)(9EVR-
E8#Q!D!LEP9VC>G3_MBX^X!(9E76=<@<#&!<0Q?^4!Q!4!>D!>0!PYPF+!3@UB8QB!E+!P0_Q2^!<SBU
MO>A+@,+^&AV09!4W!WPK!NHC8T!_Y7!K!63DD^NMYEW<0V+;OL;1%9!>COD_C_M;0^3/S^Q5?^?3!Q!&#@_V&(^!@%\$%)W@XSPFC_MR4!1-
6XX7^3FZC\$G^4Y_MCI+!_727B7^;09!3K_D_OE!>H!T^M!<D4A>(T4B?H_R87ET!J0^PR%;K%4_N!2!^!R_G#%;<@!QGV!9;S4!+M^M!D>+!B.6!
Y!S)5^B6!CZ+Y9H<+>#_!H8&^5YGB+!6!D;IX5!A!Q07^54D_M!Q>X!>Y!86Y>=<=RB6_K_PX\$D;_@>KXU+U^C!5EO!A6Y^C^LJR16^?T
MP7_0!>H!E^M&K<=>?C+^ON^!1_QD5VE94!H!>!H!U!%SD6+M^%S9S!J^>^MA857!JD<_#HA7!C%>1\$TKS!>U7^?1P!>L!CG8+WG!W2HSLX
M(QP!Z67!J9_V0!U_O9#2_!J!3^X3^!YV&S!V=Z4!MD5_MEZ_F6!J!KG@N3=+^!1!J!M;3!85^WK0!5WRK4!@!>1^!E&1%8;_H_MXT^%KP
!S!JZ!YVMB+10076;2Z^=QY@!UBP47^V>3_468%_!%>9V0!L7&3^M3!S!>2NX+U^Z!B8P3C_S^&U=A?+OYWT^M.V5)=0U_6_MF0!HCS1E;6<
<8T4P5&1A8#%_ND=O\$^STAQ64^G^_M!^OH2P!\$D!8&W/MX^K^A=HJK@9^0V!J^M@>5W^!<@5W^!<6%M2D!YB>>+5QH^S^57Q!E
M)^&JHNW0AQQ_#YT^<^B_B7_E8%37J!(\$^!%+A?@E\$>+^!ETD!F#^SX!\$!\$S!J^!_1YV\$0;JNM^22X(@_MS0!S7Z!_#^70M(PG>4=70C1_!%B4S!H!V"
MNG^M2!G<=<AFB297Q>?>#1^2#J!M!<D7)N!<^Y%=>TNZQD5+>+!T(RCA!A!_MN!T^9!6+HMFY!9(GU^94883!W;CQWX-
!@LB0E^W\$=3V^7UNE&8_X!X;MKT29UT8!0!1S9_PM^<6!MPW!1_N!O=V^7^EX%VW_9_)7ZUS^4K!<!\$6_M!&L9!R!R!>R!R!>5#XE9!5Y8K;#@&G?<
<^(DGDXTK\$DSNW)JM\$6A/CTLP^2!H!S^!ME=S^!<K^T9#^#Q8E5L(&Y!5%+H+H@&D^=HK;2/PD6RFW-M_<F!KID=3O!#?)^!U!+P04_M^!"@
U9#0AS^!<_!7!0_!%<C=&L!M_C_R^#V.S!?&B+GAM;U!M;7^C!Y+!E!S7_Q^K65N3S\$C5!>F95G?&@HDF!^!\$AP2!>U6MB9+9@;_G\$!D
MOGF!PBO!K_XZ!XTP<5\$!>V!Y9=>#WSQ<9+SPN^X!_!HOV!P!X!R!L_0OW!S^Y
M_O4W^"=A^L7!YB_?^P!XG!SW_%XMO4\$%&_!0D68K_!DV;??_<^V_A=\$_O?G_M_W9^C!YBG\$0_HHLL!%<^DZ^Q/Z#8XA_1!YSB^!BS_\$HIR^!Z#?
959S@_!YS_M!2!H!28!>2_B/Y^<P!O_G!<^F!WYQ&62!Q!M^22K!72^C!U>2W_!<^V_M!>H!9_JGX/LRV=^@82R!^LBM;ZR^OZ_!Q!3!G07!H!Y!HOKA_)"H!P-
SN_40K<02!H42!R!03=??_2M7!>28!%H!M!CGG3!>^!>J@<=>K&@OD>DB!<^!6!PKK_P!\$%FUQ^<#E!+TK_&MDQ^=>?F!F!H!>^!>OF!>W!>^!>?
>@>KQ\$KYH_ERXY0!8@!\$!Z!IOWO^!5H_M!LGS5U3_58HW08DC^!_T@>1^0-!T#_57UV^CSCY!E%)P@!EN^XXL^4KQ7<
M!@!G<19=I0NA^FM!@D_3EX>4^!<^OO_BK+(R2/8^W!>T^OL6!^?&SWW;YKX_M^>S2F^Y!G@1^4^>_KE!S6A7UZ33P.(^\$M).C<2^T^8T^9D!@^4
M!N!6>MA0_!1^27F626G?>S.SZ^!Z9X;HXWP3!CCS@!0^0<6S3?G!H!OV\$NHO2!J!M!<HBM+V!08K+^!HSD\$6_6A;S+W!1/L5!>?
6.J!A>\$>L_R!C!1^!A!>22WQ_M^!LQ!A!8KSW^!<K!GZ!<L_VUE^#JY>#0^OR6+!>X2^=0%\$4;""6XR^K!A!>!Q!>H!>X!KE

```

%="!T"/#1|&Q=%G2SZE4K WS^@A6($T39+^HL_#2 MMX|X501:(N>22DJ82?H(HHT(VI@F70TP0_Z70_M1):C|C5:B+BI6@|E:A|OUI
%FL*RV54+^L_OR">^TXWQ$Tz+^D|OTC%:8KWI_MLM=WZLJF%FO@UFER50Q-S7|2^NUO.%VA6EGG(6)7|8X)1F1^FY|&|R|FWN_R MB%
<709Y&J<N4_T^LDH|YPGW%R23^TTL(3^1^1HTT^815(4%_KVB_Y)G_ML^<^%HW051).YT_ZB$^H5R43_LTN;_TZB31DP<47DHD|14;2>2^KD41J
M9R05A$H@K1<22^%<51^0Q$T$R5B2SF$@_D@A|Y|6MAC^DVB(07%)AU#<
M$Y$BWX>^X@##^#2WNEEKZT^O=|54$6^UJM#^<H<(&T:CJR>JPO.=^C^382Y= M$H1L55;_RIA$Y30
^XS0R$|AB9>^&_U^HE3|ULM^M5N9&OTGK^7.%|>X$?C7_@N:S3<8<_MIF#0(1^T$AL=;)@>|J>4V%$I<1^S7WF6J|S)^3^#F>^$7O-5(1.FF%
^M10:9|2$A9IE&_ORL%*FVBM#F)^1^8Z=625>_=-|J9RX^+|A2%0=UQF6>=
MF^WMMD.S^AGT124_A9U>C6AP^1ZU(L_NUS|^%6_8@%$S3Z2ED77H|^R^=Y(*M^N>3^3J11PG150*(C)_JR^G300$91?
7_9E2|2|@^W@)_C31JQ4=C=V|RL>_<|6LT|@:SIAC_MMHOX%#@A|Z<_FOI5+^C5.S^N2K+_-2$/:,%F:7R@%1VATOC)^BA%_M@:#$A$|@2>
6HU3<^3R2_A$N$+^2D0IHZ=C=K_M11R_BAIR=&H_2)^<A^M^HAR%ZLW%#(N1^RZV^93VI@=^RZ%_1A=PI^=)^ZC^M^X81B_KDAI^N^V^2_7|
M4$6^DP9)MMY$4^38;JHN$B+JL_V&9H$O6J|V^2^*>^&+M$J8+^%00=9^G_MGI64>A&45_M)^1#0^LU+...RH^&ODLAZY4E0^F/U9^_JH+H&A?
M@<RXER@>U^Y_MV+41)U^YBWOUN^((SSP0A_9S)1^1^J^2B2XJ>^%K_Y6>_&W^K/4YHQ|T_M29)PQDS^*W%_&+P^%<8Q:6HE|^=H|^_-=?
<+O$|57R_>137+^S6C_TZ^CSE0_L^FC5IO^1^5^E(6JUY7^T_MC:9C^|E9V+|OKK+^B+61K53B7=L%Z^H4X3D7^OAB^|_|^1^2(1^H4X3D7
M11|@)%ZD_-$|=58_PJ|G+^=HU+|4K_/NJK^_VM2<^HJZ:@%_ZO<^#74Z:%6_M<1^NLC+GHF^2W7^F^2SQVSW:E14=Z^@W%|R1P|^|S@G0$DJN2CC
MD+BOQ^AP458Z_&C^JZQXK3>5ENR^Y#|J^K^T_2A_1^*+B98B$63>7|=N^N
M:X(O^NH>_NZLN^F6PNXN_PBCNB6(A_KF_J)^H@^WV^R^XU^1^CGEMDP|=19_ M2^N_R1N7^KAHK(UT&AU2WIV7N%J3_
JQX6E^63.F228I03=V=D.D|F^2GL_M4S|&0C_@G+^N^FPX05^=-.%>USNAI@0L^|YI%E|C_C4V|C^M5DGYTE0%|Y_M%=3R7G*
JF|^+W^_A:W3SA:AMQC:N<^QX|Y^ZBSJ_BO^B^1^E4LH7^YOK7^1L$=^W&N^SE$|A^M3X^U_H#^S>G1)^%_MU#>SOX+^M$EF7;77G@1^<5
MKD(DGN^E_F3H5DNYKNB+^&31^7H1^%<^<N^JED^HJG^F@E^D^2(A3K78_M)I^C^IZ1^T^TX5=)^L^
^WNJHJELHJZ^OP(HDEB|A|PCT_HD^>^JOD^%A$>_M|^B^E:X<^S^GE2X|^=H3P86|41@:B_T9^TYIGN^B6G70B^TZPL_Z:0=^WZ_MM^:#^28%4&_1H|
J^XN^<^FJU|^@HEJ^95D^SC79^KZ^#_4<^T:<^<Q62^HRH#^@B_M_+D|H=^%7_>@3(^Z|^O(2Y)^F^D12^|&M>^*U^J3$2^4_38E051QOOQ09D4EL
MP2Z%_9)^%4^W5^"%8>^(SE0%&_4TD)6GF^3^EXPDE^K^<(4K_#D0F|9HLM^Q@:OHB0HQBCCA3G^%_M^H6)2|J^X<2>=7L4=|V8D!HHQM1!
<@R1E^A|T2XRN^PB^A6^H|^=|^P^HYL^X(HX8Y)|@B^H^H^G^H^M7^A^M^%Q2AAZQM^+CU|V01HJ^JTHH^|HBFEXD+(6#^Y+JSP2H%W&H1
M9YN^R^K^M_JQ^#@11#^"$57LN^B^*IQZ|(S5?Q0F^K21^&W^1(51Q0@6LX^2X= M^|<4H(2+^M|^+71LPQS465+^(-2_D^?E&62Y|SRPD%$^H1D*
6^%>HJ|+8R8^+^B7HAQ_MF|^>GE^7^JH^E^0+3540C^&M$ZL|H<^FH^=M31Z6_QHB2KX_LB(D2_UW^C^M^F+^%N^R6+^2_0_P1A0_
31(UOPB^BAH99(M+T_=-U^MW8+D8H|=Y%JE^M^8MMZ^R^XU^1^66EH50_25P^F^V4^4UC>^DH^Q^M0%+^7AAW^R^R|JZO|3BCJ6^>D>6M^FK>@
M22^V^|L^F=^2/N0E^?^22^_UO2O_-FG=|D8940%=?Z=)^K2)5IED6G^V4_M|$(9$J4^T)8+^H^V$ODE/483FB^CYIP@96R_PNSYIC-%0/F57B7@BC^"UE
M$4@6^G7D^$W|02$K9Y7Z_|Y^<9^&THCY31>7^D^7P^V7^D6D0$Q^2B1>S^>^>^((S^D7^@F^F^>^<^7U4PYFN_X1&@&SNK9_FHMHY|O|&H8A&Q
M4_L7L_9^PWY^J^Q4D19J^X0$6<99Q3^@&M3SHU^|U^C^E|^TKE_Q914^<K^M51^G|9RIHW|S5G|H^3-N3^#R|J=XQ&O^NT_MUQ^2ZYR3$F(246POX
XC7^>7^*EO:U_V4I^MS(^_1^4$=2|O_MTC|4BR(NZR_IUO^LI^BCWUT10_JKJ^K|CR^J789(S_!&R^#0^VAD^|N@^M8&|^|^AX^P0TC^410HA?
6CXF|290)"242KLEA0;RFH|245|44>_3^>HQ6|74Z_MKC_-LA1GBW2=Y50V^"OR05)"A9RSG|8ZF&U2YD0|(HHD_E1^7G2N9XPHM^M^>5%>
<8DC^H|Z+A_CRA;$3^K_&|^2PB6_9Y&R^RR^RGB0;LUNOR|LJ32^O_M^C^G^E^F^G_U^W|09^E^%J^%*=^(+^VH8L>O@THQ^&02<A(K0&J^T^HEJ
MH4_M^@GSPJ2^LJ1^*RR|G9|ESF6=2R+EEC+^FD^#^C(4L_D2_3^*05IES:SP^M^MGCVB^611AR=-^7^WQ<6PMZ=&L^>@N^C_UJ^J^C|^<4L9D^|4&N3
M+^+1U+^N^S|<($7<_&^T(CK<^&DRR_2HD2^7^A8=MD^3ZOJR^<_<N^B$92_KD@_MA3CPD^E^%$=DN1<8^*HD2^7^AD>_N09Y_+ISH_J|L^FFWW^!^G)$
M^<(^I^S^H^L^X^T^HCK^"UE_9^G2Y=0G&=95)=4(NJ8_DJP^AX(M2^$PFQ+^9B589^EAD@5^$YAQ)^9C|^H+Q^|M^<KH$PI
844QM.KIDBBHH^LQGUINDKN^AW^#<JG^J^T^M^M^I^V2AREV:6A9|>G+@R^I=56=>E^J3KX^KE1QO+U^48+3JH^$1^T^F^H^M^Z|^F^H9XLJH|^UT^
E9T60|QH|E^JQ3L|=K^"7ACUYT^?^#_"U_7LS^HY^MX^F<41$>^>B54WU^M0W@^IYIC^AM^OU^C2|FQ27|Y^R|Z^
<^|LM2C^I^>+K<|SP|Z_X4P^|+^9^OXN$5K1^>+U^QO^3HZA^W>D^ETCHH^EEO^M^N^)$P0|3BBL^H^O^VDDBY^H_3|K+^>+9|)^F>0_8|YIJB|XMDIA
M^|6FZ^EGX1Y@>#7116&3721(^TVC^K71^ZZVX>7LZ+96%<X%CO=2D^|N^M^&DJ_X8|4EA^Y^|PN7H_PHDZUE^%|D^6/2<4<5$JC_2L^42.3G5^4_|TO|^F
M^A1^L$2B_|G|O8J^?>X0|&E|CS^|Q|^Y746Q+79>^FE2^H_|G(M_8Z^L4^IN)OQ&|R54">54ZSQ:GU2D^#|^Y^Y3B$GU^FY48
M09M^YU|^I=WE&|^F6;9^|H|^&6R7U|^HNF6<^&OD|G3P8WEF^%_E^M^W259|A^J3R=^73>9B)^@(<^P809<^<U8+2X^T^SV_CVL^MEQ_-75Y77%Y_
_NE2W|HYES<ARW_N^C|K^Z|N^O^S|^T4^MT4B|H8K^FQOB(D^BV^D2^?>^>^>^V^MAJL^C^MT5^L1^OU4E5
/6RTU@##+>L8)H6GIHN|^6L7>P$Q^VZ^_"_VUKKU_M2|FT^UT3-61AZT04A<_O+3H)|@JDD9(U@Q$OQXVGAEC7$>P9LQBPB4H8H5
M^/O9FDS^X_A|64A^F^>^E^H^CV^R+^>Q:S4N=^L42^9O^B50M30854DA
```

```
>=%@R:0720:GAU*!+IH$"? MM-1Q3R!6W^=IX^&R%WPPS|28?OA(S.VZKE64+9ECX? R1<+, $OMYS;ATX> M6>S^D3)#F0G!H#19CP.[!9!"CH9BT?
YY#2,M(NIG!)5I2RU"!@APC*K8Y MP *O MH4Q1RYE!=V%!MJFY4+9ECP/^R.#0K^)!L!9@)=
M/71G^!LXH4.2UD.DY%1Y^W&1>/((Q2PAR%S+HGB<_24@X3N!*WOWQP!RIRW> MBFDVC$(PIW-716RK1^0XA_9O,2V)B[!,:|= %W!L>H3+$T
F&RUWRJFM#WMMMLL&=:LIZ,F%HYV>DJN^>=D0E3RYE^O>? SYV31R2>!LO^$!7 H2VR M1^5^D2O9#!T@Y=ZQ731^H+,$3?
(YH^L"?O=CEx9L+YL2.W.JOD.%^MG0-WL<M_.$:1IMPLY06/$GHAO?]=E#DX @&$YR!H=S&JTRKO6Q1M-&MH^K5?-
X:N$H9HH.<A>R"*6&PICS9+L!2IKJPTe">.CH15AMSML$3&T@=(L=>!0QIK/J&PGV.*4$.G
M_X=P)>!!*A!IBXY_3=M!S!8<<"?ONC3ZMD..B9WKD@#:AQW:*P8?&5EH:0U M=19:E32(4%)NSAI_YF$K'!KD\!75_:5VVU^*8XH'$:$?#Y!ZP-VD/<
+D.MH!""?U"L.W.2U<#ICFT$953<$,<$VE\]=74/(P.Z7S>XIG3"N60^ M=13Z9>OP_5K5:OCP=@+59,'=TM7*B16@^H!>A/_==
HER6:_S=#1,5C=-M874PL_SU>=&9WMW>MB>_M48HWK6G_W\!T^>TAI-6NI,9WUG> >GUG@TZ'?ZMO2G.Y%,4#!7KZB#=
2@8@HP^*UD8>TGJOXHL@SM&WH!L@!8<!(PLM&&X_%Y:H)-NWAM-V9I4?>H+MLG?25#25(A$CM>)>U:4J5?TPU.D2^
M.VTUUK%AB&71H(B8f6XX"!^@UELEMD_@=R$FLEDO_OCI=(9W1UVY =MIH$:LH+*?O4+>2FX^NWK_L(OUN,Y)+RZ6HQ@WZ%.EP&
```

H5Z;2IO2=X?I6#02BCN(Z^G07<|4;:~|* M+E(RMZ?>0RY79#6P;HL_<P/9#7DFEFA@OZ;?==3\$;S7ISX*R=1 M-3>*4L"-|HZCE1
MR"3B80\$BYR.8*FU%|1WIG0IH;@<W*K&4W%);A/HIC06<.>000I7UNDGAI MP.R2-NN7YP+ 2>M88-T.9S3H_VOQ(ESDQ.*\$OV/ID>|=#=<7OI
MNKYU\$CX|K.\$5F@.I2RM'GHKPI?4VW;|>?Y7XB^6"?>CZOW"S(A*|&&|>/O"M^H_EL2?H>0V=S MUK%ZH*&X+C-CWIO|M..|&NFN"J.5>Z2-UWB7)
(X?Q\$>_HKO.*MPIAJ0.AJTLE|<=3R*Q+Q1.EEF5P_9FV0I5>G5^Q0I>.&|&C?Z8ZPEZYXNO|ZP@_MYI.L1DD\$F9;_M+0ZMB-DG.I48-Q>&|SW?
B=93A12>2.3N>S1F5MSJW.NEG1(=2VA6I>@QXP|>.)>OQCD6XJSI?|=GR" MZJEQ51%K=<GPN-\$NSH69.6Q|9HJ4Z-(H*+S3QB%)"N-
WG(I9CSLN5%L7V0 MS.&6RV+|2)@N.93P.@<N8N8?|>7%+5DBS68;*\$-0I)%B<4B<|SVI?=\$N.IAJVHYI&U8KNZWH&E|U.RG|.*I
M601'N0-IHV\$|P\$|@_ECR7+&Q1C-CF2+|=DICK7U%1-26\$2N1-8T|5.40/R4J4\$" M2;:
<|OVD'A:UNVZ3K_<OIG7)W"=|Q.4UI"YZCH3Z+PF/AAP<0?/T|8I MHE>?>M9..DS|UTONX;JBV(??"JF_'NYY|7XR 1)|2|B|<10WBD"2C^?;I*=>YI
M"GPI3U87+U+F#(3#(41GFW>0?9I'E(A:QR7M?52?K<0)O|O|U 1. M|PIZL 1A.L18O .ZGW^9I;|MH?>IAYMWL>PUK.N68;NO -I7..RIGAU5G
M'E5T) <|HJN1X5Y0D"P#IOL%(UDH\$ _L.H?>JNK35C|SC<_<N(KG;)M|1+ M@NY==<0MW3V"|"AEA*B4I3C.N5P@_+N\$U8J&X@|2?WJ0*
(I?>I4J|A|62 M-G1+&9_3GV;<ONHSSXD|8&0MS8FP8@B)42-(LRB<2|2I0-QN04\$B>LEVJ@_M%16@1PZ+2IPL+5BHN0S*SH_|
I:|AQ(IJ5GHIA)W^4IN_*KS 7I<_U0|1 MGC.AXCRIE7OP=P0'D9;9D44WY8Q;Q|I2\$ _HJD2XNM|O>_V +\$ M"2EKF1K-
&P\$<_<0K|>5X#?7BLU+H>P|C|S0F-BI\$EQ|M\$|@N+%"R|M"=Y0I M42ET\$&&JA600<9R31ZCQ|H7ZJF-8IN@L#U%|/!=@\$YI
M+|INK30%MV=I9>5(609LW-O)H23&NCGOJ0#F80X.C7N3MLB|<@BU|Z>= M(U9V|D<LCA2JEH2>3=ARKW5S65+0DW%H@1"YZ4R=)+-5)
(XXME1|B080.MN04#Y27RSCFD*E?KWJ9>?>@KXVA7B;2X-L%>+|I+Q+QR:2X-VIE.FF; ML|MO?_9JSUL#WZ;J?I2JEI0J7TMI;?7I2K4I;|= \$KN1_|
H7\$+459"OG*M-M+U^B1#Y|Y|R|A7L.BAO -|O<2@ Z"2)I8)/#R2.%;09F0^H\$&Q*|6LBKW&Y-M..DD0GN;5N=\$5<<6BM1*!^<G)C<3R?
K=6BVY+J12^X3J2B3>4QX-UD-MU&M_<|*?I#/@>7)DB9O|0>9T|42X|M8.)3A+VY9I9I#<(&L+ _ED;\$1.8>_QD?>ADPQ|696QJY+D|<U_/_Z/M2"
(H+@P%|DVE>>>E2A14TU<7|K|K|T M;|KJ12>M+>W-G|K|T|F|U|N|WAK.)K|Y-Y9W0F|<W9C|F7>|IR9+/_L5522#_-MZZ.N|@<GH\$W<1N%|A|V"?
1';JSG<K|S@<|@<J"PI K5|L>L)|L|572_L1"&Z M8-"H"8>D|XX/K8(8_O_3%|(F2?G\$|I2R&M|+|)E0J+?G|A|C|FR-K;DJB M1|JEVXW|7I%#0S0?>
YSIKE8\$FKE4T>6K|)%L\$<S MGR94|ISC|I7D_<D&I NQ4#<AL|A|H&E; F_>T^ _MB'BH_33WD MX X-GG\$5P\$<H"J25|T|1">?RI+5AZ2SP|HG\$6>
MM_RIB*2I@<H7>4P(E_V2>70.GI0#<+DR#<=946|F|N<+&X.VT|Y.W\$<L_O MNA(H'W'O<8^X"?&T|UPV|U|QQ@V1;I2&+G|H|(STO2U4Q?>
OSU)B|D>W5Z M|D4L_1%<^?C|H|H|B'E&(&>|XL#<AZ|>LAU%ISV_+W0|A6?>EC+>?S B-B<?6;\$?U(V)3I+UFI&PB(Z(5V?@<_UNU)I0?>
M9>2=..R.U8|ADZ5=MP|WY2L<E_8D%60EEDB_L|Q MZW-2%><5_972*OPIZ3D|<7D|J>\$Y*P3Z+|=I(W>=TPXA27L_<\$XG\$J46 MSA*FM<
<AEUB|BIV3&TP*U\$N?I?+N^?H408=2UA"=ZATS|H_<Z7^F9^<^ M_Z|JY-K|IGND<^<OY*08JF7E+*REDQ2D+6DK/OH|4>=HIK ME6|H|D-
>P|PNY|BGYR-O2G&R%R|<38M|O|D^<ZRI|YZ3&SAMU|I22B6(H_|D) M8|H+E;RX2KYM\$<_S\$OETDXA9_<S|TBX<D>O<?WOBL|L2|8N|Y86+ZCC932?
&0 M|(D_*>_8/6Q;P|X<_B(5|H>L_WU3>_M.W;H8X|77M2|I 0|A+<_O\$3ZRIY<|O|H*0D|T|Y?X\$4N(CK|T9)_M|Q=T M^N^I2"XQ0WC.EV|L1*(<@>
O?H|M_Q8@<PY|Y92I33RC-|E|<_7_F<|>)<G_ MAAO\$W\$WB|63 T\$|I)ONE|X+NC.9-(<301|8KYV"Z3>&Y_*5(|<D7>9_R&L M7\$5|Y@<^I.15%5(9;J|C_V<
|2KR>WA|<_X1+WB\$620|H|<22S2?I#<_JDO M>BAY B_1_?>L\$H\$<0|X%W\$4=YP@<L|U>N^2FHL|Q|AB|I|C@<I\$ M?>
KPGBYIE(C\$O4SCU<=BNQ..60TH>S;E5+Y|I<3B>&GWQYU_*I(M5FP_S|H|\$(Q0N=|<P3?5G740_S@<(B@<(Z7?F_Y|AB09 MS;<|<Z-
54LDI"Z4|OPS(C@25+34%&0C_U|V\$&+|UN|K(&=@4 M\$MOV|I_Z96+CE#*03@LG_L60_YI+)"|8_MB=FQQ|C|PRZ>I|N|Q|G|5|I|>"8M8'OMUI#;
M/>I%)1ZC|I1XC4UZ+R.EWDZ<=CXID%0X|BIV#)J>Z53V0I* MZNK>#P5N>R<7|H_8T1@<?I>T89156H;3_!WGW@<2<@%A#28@F=;T\$;*>^
M>^<U%_H|*R|J?%HX'1EPA@R3"R+|=8|I|N|Q|E3#D@<\$AX*TT &B|<F;T+MG3R M-%GOQBOX+O236#O.8%6QLO28#4 3_#Y-
+<Z.M<("Z%ZQ(GK|OLST)Y2|3 MKI?7L>?&X|L^2.C.C|E|H\$5CG_O|XLAB7Z?|<O|H@<#N_G_BZ0PE434A<|8|Q|MBW|+CH*K25|I|6J?BF?>
6|A|OHH|J6|H6W|GK1(I)|LMG" EY253_3|J@<M|H M|_<XXY\$O2|SXB|RO<2Z/O_<M+I#7P.MQG<N|H|6PTM"6G|H|N<(<5T4|3|8X*A?A6E_2|K MD
|E8J|21G8-M%<1P+<6WU|X=)H|<@<OZ|IGVB3P|BIV\$J-VG5>(<@WUQ=|OUW>6=I#CV_<6 MQ=2\$6^?>I D #^"E1>WP|?>
G|<Q+<0|R_<66Q|H<O#NU2?|M>|9\$|>_MD|TTR|7|O+BU8 WC<@W_A|G\$>3%RLKB|W5&|Q|N\$S^A0_4^>2V^MMI|271 MT_|D54(VA^TLZ4?>9
M*XB>S|_K%O_?44(ZWNF4X|_6EX+6|&AYNQ?4 M5|M9(G>E4UFID.HVT\$1%3N\$|_@|ZHY*3_-S+P+PY KC>#HQ|S|4JZWV3|C MAJPK7U2DP#5H
MN^I22|I|@#>C|H6<55;#=\$<B|R;D|T|E7A(ZBZ-|ED>? M|KX|T\$GR_1DV\$+B4E=CXC40LDP#X8_<7_S|T3\$ _M P=02P\$%>4_<|@<U9&D-H*^|E*0
"@ @<_M_97@<S_2TQ|<EAT;5|+<0(4 Q0<+V_#5F)_9|I@<_&I|J_*M"= _|E|>#_Q+3(N_<1M4\$|L|A0#%<@<O8_672GBMY#_M|O|!\$ H<|IG@|
&5X;S(M_2YH=&U02P\$=_4 M")@<U9_<E"ITH\$%G\$@<@<@<%)97@<S_BTR+FAT M;5|+<0(4 Q0<+V_#5G_5N|H|PX|_VT#_<7L8 M|F;W)M.3
M<2YH=&U02P\$=_4 M")@<U928K_YX<+ #80 \$0 M @<@<@<P\$>9V T_RTR#<T|<#8\$>_YX&UL4\$|L|A0#%<@<O8_62@S1)_<C'0|<4 M<|L\$S|
&C=&I.M.C.R_# V.S|29&5F+GAM;|<+<0(4 Q0<+V_M#5D_<^/Q\$|_%=P_5 "&UL4\$|L|@<_*H_90(<_?>0 \$!<end XML 45 form10-q.htm.xml|DEA;
XBRL DOCUMENT 0001506983 2024-01-01 2024-06-30 0001506983 2024-08-09 0001506983 2024-06-30 0001506983 2023-12-31 0001506983
2023-01-01 2023-06-30 0001506983 2024-04-01 2024-06-30 0001506983 2023-04-01 2023-06-30 0001506983 us-gaap:CommonStockMember
2022-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-12-31
0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001506983 us-gaap:RetainedEarningsMember 2022-12-31
0001506983 2022-12-31 0001506983 us-gaap:CommonStockMember 2023-03-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-03-31
0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-03-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-
03-31 0001506983 us-gaap:RetainedEarningsMember 2023-03-31 0001506983 2023-03-31 0001506983 us-gaap:CommonStockMember 2023-12-31
0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-12-31 0001506983
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001506983 us-gaap:RetainedEarningsMember 2023-12-31 0001506983 us-
gaap:CommonStockMember 2024-03-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001506983
GCTK:ReceiptsOnAccountOfSharesMember 2024-03-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31
0001506983 us-gaap:RetainedEarningsMember 2024-03-31 0001506983 2024-03-31 0001506983 us-gaap:CommonStockMember 2023-01-01 2023-
06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-
01-01 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001506983 us-
gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001506983 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001506983 us-
gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-04-01 2023-06-30
0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001506983 us-gaap:RetainedEarningsMember
2023-04-01 2023-06-30 0001506983 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember
2024-01-01 2024-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-01-01 2024-06-30 0001506983 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-01-01 2024-
06-30 0001506983 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-
06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-04-01 2024-06-30 0001506983 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-04-01 2024-
06-30 0001506983 us-gaap:CommonStockMember 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001506983
GCTK:ReceiptsOnAccountOfSharesMember 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30
0001506983 us-gaap:RetainedEarningsMember 2023-06-30 0001506983 2023-06-30 0001506983 us-gaap:CommonStockMember 2024-06-30
0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-06-30 0001506983
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-06-30 0001506983 us-
gaap:SubsequentEventMember 2024-08-14 0001506983 us-gaap:IPOMember 2023-01-01 2023-12-31 0001506983 us-
gaap:PrivatePlacementMember 2024-01-01 2024-06-30 0001506983 GCTK:NoteAndWarrantMember 2024-01-01 2024-06-30 0001506983 us-
gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2024-07-18 0001506983 GCTK:ConvertiblePromissoryNotesMember us-
gaap:SubsequentEventMember GCTK:WarrantsAgreementMember 2024-07-30 0001506983 GCTK:PrefundedWarrantsMember 2024-01-01 2024-
06-30 0001506983 GCTK:PrefundedWarrantsMember 2023-01-01 2023-06-30 0001506983 GCTK:PrefundedWarrantsMember 2024-04-01 2024-06-
30 0001506983 GCTK:PrefundedWarrantsMember 2023-04-01 2023-06-30 0001506983 GCTK:PerformanceMilestoneMember 2024-01-01 2024-06-
30 0001506983 GCTK:PerformanceMilestoneMember 2023-01-01 2023-06-30 0001506983 GCTK:PerformanceMilestoneMember 2024-04-01 2024-
06-30 0001506983 GCTK:PerformanceMilestoneMember 2023-04-01 2023-06-30 0001506983 GCTK:PrefundedWarrantsMember 2024-01-03 2024-
01-03 0001506983 us-gaap:CommonStockMember GCTK:ExchangeAgreementMember 2024-02-13 2024-02-13 0001506983 us-
gaap:WarrantMember GCTK:ExchangeAgreementMember 2024-02-13 2024-02-13 0001506983 GCTK:ExchangeAgreementMember 2024-02-13
2024-02-13 0001506983 GCTK:ExchangeAgreementMember 2024-02-13 0001506983 us-gaap:LeaseAgreementsMember 2024-02-19 2024-02-19
0001506983 us-gaap:LeaseAgreementsMember 2024-02-19 0001506983 us-gaap:PrivatePlacementMember 2024-04-22 2024-04-22 0001506983
us-gaap:PrivatePlacementMember 2024-04-22 0001506983 2024-04-30 2024-04-30 0001506983 GCTK:UnsecuredPromissoryNotesMember 2024-
06-27 0001506983 2024-06-27 0001506983 2024-06-27 2024-06-27 0001506983 GCTK:NoteAndWarrantMember 2024-06-27 2024-06-27
0001506983 GCTK:LessThanOneYearMember 2024-06-30 0001506983 GCTK:BetweenOneYearToTwoYearsMember 2024-06-30 0001506983
GCTK:MoreThanTwoYearsMember 2024-06-30 0001506983 GCTK:NotesMember 2024-06-30 0001506983 GCTK:WarrantsMember 2024-06-27
0001506983 GCTK:IsraeliInnovationAuthorityMember 2004-03-04 0001506983 srt:MinimumMember GCTK:IsraeliInnovationAuthorityMember
2004-03-03 2004-03-04 0001506983 srt:MaximumMember GCTK:IsraeliInnovationAuthorityMember 2004-03-03 2004-03-04 0001506983
GCTK:IsraeliInnovationAuthorityMember 2004-03-04 0001506983 GCTK:IsraeliInnovationAuthorityMember 2024-06-30 0001506983 us-
gaap:CommonStockMember GCTK:IntellectualPropertyPurchaseAgreementMember 2022-10-07 2022-10-07 0001506983 srt:MinimumMember us-
gaap:CommonStockMember GCTK:IntellectualPropertyPurchaseAgreementMember 2022-10-07 2022-10-07 0001506983 srt:MinimumMember us-
gaap:CommonStockMember GCTK:IntellectualPropertyPurchaseAgreementMember 2022-10-07 0001506983 srt:MinimumMember
GCTK:TrueupSharesMember us-gaap:CommonStockMember GCTK:IntellectualPropertyPurchaseAgreementMember 2022-10-07 0001506983 2023-
06-01 2023-06-20 0001506983 2024-05-01 2024-05-31 0001506983 GCTK:ConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember
GCTK:WarrantsAgreementMember 2024-07-30 2024-07-30 0001506983 GCTK:ConvertiblePromissoryNotesMember us-
gaap:SubsequentEventMember 2024-07-30 2024-07-30 0001506983 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember
2024-07-30 0001506983 us-gaap:SubsequentEventMember 2024-07-30 2024-07-30 0001506983 us-gaap:SubsequentEventMember 2024-07-30
0001506983 GCTK:FirstWarrantMember us-gaap:SubsequentEventMember 2024-07-30 2024-07-30 0001506983 GCTK:FirstWarrantMember us-
gaap:SubsequentEventMember 2024-07-30 0001506983 GCTK:SecondWarrantMember us-gaap:SubsequentEventMember 2024-07-30 2024-07-30

0001506983 GCTK:SecondWarrantMember us-gaap:SubsequentEventMember 2024-07-30 0001506983 GCTK:ThirdWarrantMember us-gaap:SubsequentEventMember 2024-07-30 0001506983 GCTK:ThirdWarrantMember us-gaap:SubsequentEventMember 2024-07-30
iso4217:USD shares iso4217:USD shares pure iso4217:ILS false Q2 -12-31 0001506983 P5Y 10-O true 2024-06-30 2024 false 001-41141
GLUCOTRACK INC. DE 98-0668934 301 Route 17 North Suite 800 Rutherford NJ 07070 (201) 842-7715 Common Stock CGTK NASDAQ Yes Yes
Non-accelerated Filer true false 5478436 0.001 159000 4492000 283000 376000 442000 4868000 71000 86000 27000 9000 10000 608000
4905000 2736000 839000 12000 25000 887000 673000 3660000 1512000 191000 196000 46000 3897000 1708000 0.001 0.001 100000000
100000000 5478436 5478436 4178274 4178274 5000 4000 5000 4000 113903000 112982000 50000 48000 22000 16000 117269000 109853000
3289000 3197000 608000 4905000 5737000 1269000 3589000 627000 170000 100000 1535000 1194000 802000 552000 7442000 2463000
4491000 1179000 7442000 2463000 4491000 1179000 26000 1000 2000 3000 7416000 2462000 4489000 1176000 6000 11000 6000
7410000 2451000 4489000 1170000 1.42 1.42 0.66 0.66 0.82 0.82 0.27 0.27 5234765 5234765 3706510 3706510 5475748 5475748 4312294
4312294 3099982 3000 103107000 4000 17000 101901000 1230000 2462000 2462000 11000 11000 229000 229000 855000 855000 1075294
1000 8729000 8730000 2998 9000 4000 5000 4178274 4000 112929000 28000 105218000 7743000 3100562 3000 103168000 5000 22000
103187000 11000 1176000 1176000 6000 172000 172000 855000 855000 1075294 1000 8729000 8730000 2418 5000 5000 4178274
4000 112929000 28000 105218000 7743000 4178274 4000 112982000 48000 16000 109853000 3197000 7416000 7416000 6000 6000 228000
228000 86861 126000 48000 78000 50000 50000 79366 50000 50000 20000 395294 718641 1000 1000 68000 68000 5478436 5000
113903000 50000 22000 117269000 3289000 5351110 5000 113050000 78000 22000 112780000 375000 5351110 5000 113050000 78000
22000 112780000 375000 4489000 4489000 207000 207000 47960 78000 78000 79366 500000 500000 50000 50000 68000 68000 5478436
5000 113903000 50000 22000 117269000 3289000 5478436 5000 113903000 50000 22000 117269000 3289000 7416000 2462000 12000
7000 228000 229000 128000 5000 5000 6000 93000 104000 1897000 173000 214000 121000 4849000 2267000 71000 71000 80000 8730000
500000 580000 8730000 6000 10000 4334000 6453000 4502000 2331000 168000 8784000 32000 855000 79000 <p id="xdx_804_eus-gaap-
OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock_zjnsBYpjZlI2" style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify;">NOTE 1 –GENERAL</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><table cellpadding="0" cellspacing="0" style="font:
10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-
align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in;"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">A.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">Glucotrack Inc. (the "Company") was incorporated on May 18, 2010 under the laws of the State of
Delaware. The Company is a medical device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons
with Type 1 diabetes and insulin-dependent Type 2 diabetes (the "Glucotrack CBGM Product").</td></tr><tr style="font: 10pt Times New
Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">B.
</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt">Liquidity and capital resources</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align:
top;"><td style="font: 10pt Times New Roman, Times, Serif">
</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">As of June 30, 2024, the Company has incurred accumulated deficit of \$<span id="xdx_907_eus-gaap-
RetainedEarningsAccumulatedDeficit_inJ_pn3n3_dI_c20240630_zNEvsNWjXOMI" title="Accumulated deficit">117,269. Furthermore, the
Company has generated operating losses and negative operating cash flow for all reported periods. As of June 30, 2024, the balance of cash and
cash equivalents amounted to \$<span id="xdx_907_eus-gaap-CashAndCashEquivalentsAtCarryingValue_II_pn3n3_c20240630_ztSgTrkrunDI"
title="Cash and cash equivalents">159, together with additional amounts raised subsequent to the balance sheet date amounted to \$<span
id="xdx_905_eus-gaap-CashAndCashEquivalentsAtCarryingValue_II_pn3n3_c20240814_us-gaap-SubsequentEventTypeAxis_us-gaap-
SubsequentEventMember_zrEdMiYQeW2" title="Cash and cash equivalents">4,360 thousand are insufficient for the Company to realize
its business plans for the twelve month period subsequent to the reporting period.</td></tr><tr style="font: 10pt Times New Roman,
Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times
New Roman, Times, Serif"></td><td style="font: 10pt Times
New Roman, Times, Serif"></td></tr><tr style="font: 10pt Times
New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company raised net proceeds of
\$&

[illegible]

Times, Times, Serif, margin: 0pt 0pt 0pt 0pt; text-align: center;">GLUCOTRACK INC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">(in thousands of US Dollars)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</p><p id="xdx_84D_eus-gaap-DerivativesPolicyTextBlock_ztLWQbQzEJXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">F.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">F.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">Warrants</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">G.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">Leases</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">Right of Use</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">Basic and diluted loss per share</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">Basic loss per share</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">Diluted loss per share</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">The Company applies ASC Topic 842, "Leases" ("ASC 842") under which the Company determines if an arrangement is a lease at inception. The Company's assessment is based on: (i) whether the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company's lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">Right of Use ("ROU") assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate ("IBR") based on the information available on the commencement date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, "Property, Plant, and Equipment – Overall", to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">GLUCOTRACK INC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">(in thousands of US Dollars)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">EarningsPerSharePolicyTextBlock_zxILzpfqgRK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">F.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">F.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">Basic and diluted loss per share</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">Basic loss per share</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">Diluted loss per share</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">The Company applies ASC Topic 842, "Leases" ("ASC 842") under which the Company determines if an arrangement is a lease at inception. The Company's assessment is based on: (i) whether the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company's lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">Right of Use ("ROU") assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate ("IBR") based on the information available on the commencement date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, "Property, Plant, and Equipment – Overall", to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options

[illegible]

xdx_90B_eus-gaap-WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401_20230630_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember_fkCOP_z5mknj5IZUjd" title="Ordinary shares used in computing diluted net loss per common stock">3,987,275</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 10pt">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">162,510</td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">325,019</td><td style="text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Shares of Common Stock to be issued upon achievement of second performance milestone</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,790</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,667</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left"></td><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td style="text-align: left"></td><td style="text-align: right">5,234,765</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td></td></td><td style="text-align: right">3,706,510</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">5,475,748</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">4,312,294</td><td style="text-align: left"></td><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">1.42</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom-EarningsPerShareBasicIncludingWarrantsAndPerformanceMilestones_pid_c20230101_20230630_z7

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)

(in thousands of US Dollars)

A.	Basis of Presentation
B.	Use of Estimates in the Preparation of Financial Statements
C.	Principles of Consolidation
D.	Cash and Cash Equivalents
E.	Modification of equity-classified contracts

The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company's consolidated financial statements and related notes included in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission ("SEC") on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

The preparation of the condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Management believes that there are no critical accounting estimates in these financial statements.

The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.

The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification,

accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

DerivativesPolicyTextBlock_ztLWQBQzEjXb

<p>Warrants</p>	<p>Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Company's own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital.</p>
-----------------	---

LesseeLeasesPolicyTextBlock_zRTVFVxUWfRe

Leases

A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company's lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases.

Right of Use (ROU) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate ("IBR") based on the information available on the commencement date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, "Property, Plant, and Equipment - Overall", to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

EarningsPerSharePolicyTextBlock_zxILzpfqgRKk

<p>Basic</p>	<p>Basic loss per share</p>
--------------	-----------------------------

Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of performance milestone during the period and upon exercise of pre-funded

In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the "treasury stock method", if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants.

Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify;">Shares to be issued upon exercise of all stock options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive.</p></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;">The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of six and three month ended June 30, 2024 and 2023, is as follows:</td></tr></table><p id="xdx_895_eus-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z23boqjCYcjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"><tr style="display: none; vertical-align: bottom; background-color: White"><td style="display: none; text-align: left; padding-left: 10pt"></td><td style="display: none"></td><td style="display: none; text-align: left"></td><td id="xdx_490_20240101_20240630_zk1EAREsYgzg" style="display: none; text-align: center"></td><td style="display: none; text-align: left"></td><td style="display: none"></td><td style="display: none; text-align: left"></td><td id="xdx_496_20230101_20230630_z1TYEgWgXjwI" style="display: none; text-align: center"></td><td style="display: none; text-align: left"></td><td style="display: none"></td><td style="display: none; text-align: left"></td><td id="xdx_495_20240401_20240630_z7OruMAXH95d" style="display: none; text-align: center"></td><td style="display: none; text-align: left"></td><td style="display: none"></td><td style="display: none; text-align: left"></td><td id="xdx_492_20230401_20230630_z4aA9t6SGZxe" style="display: none; text-align: center"></td><td style="display: none; text-align: left"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">Six-month period ended</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: center;">June 30,</p></td><td style="padding-bottom: 1.5pt"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three-month period ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr><td></td><td></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr><td></td><td></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr><td></td><td></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr><td></td><td></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr><td></td><td></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr><td></td><td></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border

style="text-align: right">5,460,081</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">3,987,275</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left; padding-left: 10pt">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">162,510</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td></td><td style="text-align: right">325,019</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Shares of Common Stock to be issued upon achievement of second performance milestone</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,790</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,667</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"></td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td></td><td style="text-align: left"></td><td style="text-align: right">5,234,765</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">3,706,510</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">5,475,748</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">4,312,294</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">1.42</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">0.89</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span

[illegible]

StatementEquityComponentsAxis_us-gaap-CommonStockMember_fKCop_zQ18KaKdxCO7" title="Ordinary shares used in computing basic net loss per common stock">3,544,000</td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td style="text-align: right;">5,460,081</td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td style="text-align: right;">3,987,275</td><td style="text-align: left;"></td><td></td><td style="vertical-align: bottom; background-color: White;"><td style="text-align: left; padding-left: 10pt">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td></td><td style="text-align: left;"></td><td style="text-align: right;"></td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td style="text-align: right;">162,510</td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td style="text-align: right;"></td><td style="text-align: left;"></td><td></td><td style="text-align: right;">325,019</td><td style="text-align: left;"></td><td></td><td style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Shares of Common Stock to be issued upon achievement of second performance milestone</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left;"></td><td style="border-bottom: Black 1.5pt solid; text-align: right;">7,790</td><td style="padding-bottom: 1.5pt; text-align: left;"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left;"></td><td style="border-bottom: Black 1.5pt solid; text-align: right;"></td><td style="padding-bottom: 1.5pt; text-align: left;"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left;"></td><td style="border-bottom: Black 1.5pt solid; text-align: right;">15,667</td><td style="padding-bottom: 1.5pt; text-align: left;"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left;"></td><td style="border-bottom: Black 1.5pt solid; text-align: right;"></td><td style="padding-bottom: 1.5pt; text-align: left;"></td><td></td><td style="vertical-align: bottom; background-color: White;"><td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td></td><td style="text-align: left;"></td><td style="text-align: right;">5,234,765</td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td></td><td style="text-align: right;">3,706,510</td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td style="text-align: right;">5,475,748</td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td></td><td style="text-align: left;"></td><td style="text-align: right;">4,312,294</td><td style="text-align: left;"></td><td></td><td style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left;"></td><td style="border-bottom: Black 2.5pt double; text-align: right;">1.42</td><td style="padding-bottom: 2.5pt; text-align: left;"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left;"></td><td style="border-bottom: Black 2.5pt double; text-align: right;"><span id="xdx_908_ecustom--EarningsPerShareBasicIncludingWarrantsAndPerformanceMilestones_pid_c20230101_20230630_z78lxbBEVGPd"

"Basic net loss per common stock">0.89</td><td style="padding-bottom: 2.5pt; text-align: left;"></td><td style="padding-bottom: 2.5pt"></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">\$</td><td style="border-bottom: Black 2.5pt double; text-align: right;">0.82</td><td style="padding-bottom: 2.5pt; text-align: left;"></td><td style="padding-bottom: 2.5pt"></td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">\$</td><td style="border-bottom: Black 2.5pt double; text-align: right;">0.47</td><td style="padding-bottom: 2.5pt; text-align: left;"></td></tr></table>-7416000_-2462000_-4489000_-1176000_-855000_-855000_-7416000_-3317000_-4489000_-2031000_5226975_5226975_3544000_3544000_5460081_5460081_3987275_3987275_162510_162510_325019_325019_7790_7790_15667_15667_5234765_5234765_3706510_3706510_5475748_5475748_4312294_4312294_1.42_1.42_0.89_0.89_0.82_0.82_0.47_0.47<p id="xdx_904_ecustom-SignificantTransactionsTextBlock_zSwVWw13Bkkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 3-SIGNIFICANT TRANSACTIONS</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">A.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercise of pre-funded warrants</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exchange Agreement</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 3, 2024, a number of395,294</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the "Holders"), pursuant to which the Company and the Holders agreed to exchange (the "Exchange") warrants with down round protection feature exercisable to common shares (the "Warrants") owned by the Holders for shares of Common Stock to be issued by the Company.</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 13, 2024, the Company closed the Exchange and issued to the Holders on February 15, 2024 an aggregate of718,641</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 15, 2024, the Company closed the Exchange and issued to the Holders on February 15, 2024 an aggregate of876,391</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">It was also agreed that the Holders will not, during the period ("Lock-Up Period") (i) offer, pledge, announce the intention to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction specific in clause (i), (ii) or (iii) above, provided however that the Holder, during the Lock-Up Period, may(a) sell or contract to sell Shares at a price higher than \$0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than \$0.80 per Share on any trading day with no limitation on volume.</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above \$1.00</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument was estimated as less than the fair value of the replaced equity instrument, deemed dividend was not recorded.</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 19, 2024, the Company entered into Lease Agreement (the "Agreement") with Tapsak Enterprises LLC dba Virginia Analytical (the "Landlord") under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of \$<span id="xdx_900_ecustom-LeaseAgreementMember_zmLfz

[illegible]

[illegible]

(in thousands of US Dollars)

NOTE 3 – SIGNIFICANT TRANSACTIONS (CONT.)

E.

Adoption of 2024 Equity Incentive Plan and Reverse Share Split

F.

Note and Warrant Purchase Agreements

Note and Warrant Purchase Agreements

Notes payable description

The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of:

(i) twelve months from the date of the Note; or

(ii) the date the Company raises third-party equity capital in an amount equal to or in excess of \$1,000 (the "Maturity Date"). The Company may prepay the Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash.

Warrants exercise price

Warrants term

Schedule of Fair Value of Identified Components

Component	Fair Value
Notes	\$43.3
Warrants	\$68.0
Total	\$111.3

Fair value at Closing Date

Component	Fair Value
Notes	\$43.3
Warrants	\$68.0
Total	\$111.3

[illegible]

[illegible]

Roman, Times, Serif")>(1)</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">The fair value of the Notes was determined based on rating model using a discount rate of 12% which represented the Company's applicable rate of risk, as determined by management.</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td><td style="font: bold 10pt Times New Roman, Times, Serif"></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td><td style="font: bold 10pt Times New Roman, Times, Serif">(2)</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">The fair value of the Warrants determined by management based on Black-Scholes pricing model taking into account expected stock price volatility of 245% and risk-free interest rate of 4.52%</td></tr></table> 12000 68000 80000 0.12 2.45 0.0452 <p id="xdx_807_eus-gaap-CommitmentsAndContingenciesDisclosureTextBlock_zTQq9k4sb1o7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4COMMITMENTS AND CONTINGENT LIABILITIES</p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 0.5in">A.</td><td style="text-align: justify">On March 4, 2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately \$93 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the "Development Plan"). Integrity Israel is required to pay royalties to the IIA at a rate ranging between 35% of the proceeds from the sale of the Company's products arising from the Development Plan up to an amount equal to \$93, plus interest at LIBOR from the date of grant. As to the replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of June 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately \$73, excluding interest. Such contingent obligation has no expiration date.</td></tr><tr style="vertical-align: top"><td></td><td style="text-align: justify"></td></tr><tr style="vertical-align: top"><td>B.</td><td style="text-align: justify">On October 7, 2022 ("the Closing Date"), the Company entered into Intellectual Property Purchase Agreement (the "Agreement") with Paul Goode, which is the Company's Chief Executive Officer (the "Seller"), under which it was agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller shall sell, assign, transfer, convey and deliver to the Company, all of Seller's right, title and interest in and to the following assets, properties and rights (collectively, the "Purchased Assets");</td></tr></table><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 0.5in">(a)</td><td style="text-align: justify">All rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the "Conveyed Intellectual Property"); and</td></tr><tr style="vertical-align: top"><td>(b)</td><td style="text-align: justify">All the goodwill relating to the Purchased Assets.</td></tr></table><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 0.5in"></td><td style="text-align: justify">In consideration for the sale by Seller of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated to issue up to 200,000 shares of Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the "Purchase Price"). In addition, if upon the final issuance, the aggregate 200,000 shares represent less than 1.5% of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5% of the outstanding shares (the "True-Up Shares"). All shares of Common Stock of the company that will be issued under this agreement shall be (i) restricted over a limited period as defined in the Agreement and issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and (ii) subject to the lockup provisions.</p><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted for as asset acquisition and no goodwill is

[illegible]

Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(in thousands of US Dollars)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 5- SUBSEQUENT EVENTS (Cont.)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 0.5in">B.</td><td style="text-align: justify">On July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the "Warrants") with an existing investor (the "Holder"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of \$4,000 (the "Note"). The Note is not convertible until and unless approved at a meeting of the Company's stockholders (the "Stockholder Approval"). The Company has agreed to hold such a meeting to seek Stockholder Approval within 90 days.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Note bears simple interest at the rate of8% per annum and is due and payable in cash on the earlier of:(i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (defined below) (the "Maturity Date"). The Note is secured by a first priority security interest on all Company assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Except with regard to conversion of the Note a or a Sale Transaction as discussed below, the Company may not prepay the Note without the written consent of the Holder. If Stockholder Approval is obtained, the Note(i) is convertible at the discretion of the Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price ("VWAP") of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">In the event of a Sale Transaction on or prior to the Maturity Date, the Company will repay the Holder, at the Holder's election, as follows:(i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the Note was converted pursuant to an optional conversion. "Sale Transaction" means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the assets of the Company, or any other transaction or series of related transactions in which the Company's stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Upon the occurrence of an Event of Default (defined below), a Holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the Note balance. An "Event of Default" means(i) failure by the Company to pay the Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the Holder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Each Warrant becomes exercisable 12 months after its issuance and has term of10 years. The Warrants are exercisable for cash only and have no price-based antidilution. The first Warrant is for2,133,334 shares at \$1.875 per share. The second Warrant is for1,523,810 shares at \$2.625 per share. The third Warrant is for1,185,186 shares at \$3.375 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"></p><p>360000 0.08 500000 1.56 4000000 0.08 (i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (defined below) (the "Maturity Date") (i) is convertible at the discretion of the Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price ("VWAP") of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction), 5.00 (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the Note was converted pursuant to an optional conversion. "Sale Transaction" means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the assets of the Company, or any other transaction or series of related transactions in which the Company's stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent (i) failure by the Company to pay the Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the Holder. 50000000 P10Y 2133334 1.875 1523810 2.625 1185186 3.375 Represents amount lower than \$1. The fair value of the Notes was determined based on rating model using a discount rate of the fair value of the Warrants determined by management based on Black-Scholes pricing model taking into account expected stock price volatility of 245% and risk-free interest rate of 4.52%,